<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">80168</article-id><article-id pub-id-type="doi">10.7554/eLife.80168</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Tools and Resources</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group><subj-group subj-group-type="heading"><subject>Stem Cells and Regenerative Medicine</subject></subj-group></article-categories><title-group><article-title>High-content synaptic phenotyping in human cellular models reveals a role for BET proteins in synapse assembly</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-166700"><name><surname>Berryer</surname><given-names>Martin H</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-280237"><name><surname>Rizki</surname><given-names>Gizem</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-280242"><name><surname>Nathanson</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-310643"><name><surname>Klein</surname><given-names>Jenny A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-280241"><name><surname>Trendafilova</surname><given-names>Darina</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-280238"><name><surname>Susco</surname><given-names>Sara G</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-280239"><name><surname>Lam</surname><given-names>Daisy</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-280240"><name><surname>Messana</surname><given-names>Angelica</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-160719"><name><surname>Holton</surname><given-names>Kristina M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-250914"><name><surname>Karhohs</surname><given-names>Kyle W</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-176742"><name><surname>Cimini</surname><given-names>Beth A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9640-9318</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-280243"><name><surname>Pfaff</surname><given-names>Kathleen</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-76519"><name><surname>Carpenter</surname><given-names>Anne E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1555-8261</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-7036"><name><surname>Rubin</surname><given-names>Lee L</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8658-841X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-123252"><name><surname>Barrett</surname><given-names>Lindy E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3229-4774</contrib-id><email>lbarrett@broadinstitute.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05a0ya142</institution-id><institution>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03vek6s52</institution-id><institution>Department of Stem Cell and Regenerative Biology, Harvard University</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05a0ya142</institution-id><institution>Imaging Platform, Broad Institute of MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Goda</surname><given-names>Yukiko</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02qg15b79</institution-id><institution>Okinawa Institute of Science and Technology</institution></institution-wrap><country>Japan</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Chen</surname><given-names>Lu</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00f54p054</institution-id><institution>Stanford University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>21</day><month>04</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e80168</elocation-id><history><date date-type="received" iso-8601-date="2022-05-11"><day>11</day><month>05</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-04-10"><day>10</day><month>04</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-05-17"><day>17</day><month>05</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.05.17.492322"/></event></pub-history><permissions><copyright-statement>© 2023, Berryer et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Berryer et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-80168-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-80168-figures-v1.pdf"/><abstract><p>Resolving fundamental molecular and functional processes underlying human synaptic development is crucial for understanding normal brain function as well as dysfunction in disease. Based upon increasing evidence of species-divergent features of brain cell types, coupled with emerging studies of complex human disease genetics, we developed the first automated and quantitative high-content synaptic phenotyping platform using human neurons and astrocytes. To establish the robustness of our platform, we screened the effects of 376 small molecules on presynaptic density, neurite outgrowth, and cell viability, validating six small molecules that specifically enhanced human presynaptic density in vitro. Astrocytes were essential for mediating the effects of all six small molecules, underscoring the relevance of non-cell-autonomous factors in synapse assembly and their importance in synaptic screening applications. Bromodomain and extraterminal (BET) inhibitors emerged as the most prominent hit class and global transcriptional analyses using multiple BET inhibitors confirmed upregulation of synaptic gene expression. Through these analyses, we demonstrate the robustness of our automated screening platform for identifying potent synaptic modulators, which can be further leveraged for scaled analyses of human synaptic mechanisms and drug discovery efforts.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>human</kwd><kwd>iPSC</kwd><kwd>synapse</kwd><kwd>screening platform</kwd><kwd>neurons</kwd><kwd>astrocytes</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100013113</institution-id><institution>Stanley Center for Psychiatric Research at the Broad Institute</institution></institution-wrap></funding-source><award-id>Broadnext10</award-id><principal-award-recipient><name><surname>Rubin</surname><given-names>Lee L</given-names></name><name><surname>Barrett</surname><given-names>Lindy E</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R35 GM122547</award-id><principal-award-recipient><name><surname>Carpenter</surname><given-names>Anne E</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>An automated synaptic phenotyping platform combined with small molecule screening reveals modulators of human neuron synapse formation.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Synapses are intercellular junctions between neurons crucial for information processing. Seminal studies using the frog neuromuscular junction (<xref ref-type="bibr" rid="bib24">del Castillo and Katz, 1954</xref>) or giant squid synapse (<xref ref-type="bibr" rid="bib12">Bullock and Hagiwara, 1957</xref>) established fundamental principles of chemical transmission. Subsequent genetic and neurobiological studies have further illuminated our understanding of the mammalian central nervous system and have implicated synaptic alterations in brain disorders, including autism spectrum disorder (<xref ref-type="bibr" rid="bib10">Bourgeron, 2015</xref>; <xref ref-type="bibr" rid="bib23">De Rubeis et al., 2014</xref>), schizophrenia (<xref ref-type="bibr" rid="bib31">Fromer et al., 2014</xref>; <xref ref-type="bibr" rid="bib47">Kirov et al., 2012</xref>; <xref ref-type="bibr" rid="bib76">Purcell et al., 2014</xref>), and Alzheimer’s disease (<xref ref-type="bibr" rid="bib53">Kunkle et al., 2019</xref>; <xref ref-type="bibr" rid="bib87">Spires-Jones and Hyman, 2014</xref>). Thus, insights into synaptic development and function are critical for our understanding of normal brain function as well as dysfunction in disease. Diverse genes such as neuroligins and neurexins (<xref ref-type="bibr" rid="bib33">Graf et al., 2004</xref>; <xref ref-type="bibr" rid="bib100">Varoqueaux et al., 2006</xref>), neurotrophic receptors (<xref ref-type="bibr" rid="bib28">Elmariah et al., 2004</xref>), EphrinB and EphrinB receptors (<xref ref-type="bibr" rid="bib39">Henderson and Dalva, 2018</xref>), and cadherins, protocadherins, and catenins (<xref ref-type="bibr" rid="bib3">Arikkath and Reichardt, 2008</xref>; <xref ref-type="bibr" rid="bib110">Weiner et al., 2005</xref>; <xref ref-type="bibr" rid="bib112">Yamagata et al., 2018</xref>) have been implicated in synaptic biology, although given the complex nature of mammalian brain development and function, molecular programs underlying neuronal connectivity have yet to be fully resolved.</p><p>Notably, most synaptic studies in mammals use rodent primary neuronal cultures (<xref ref-type="bibr" rid="bib57">Linhoff et al., 2009</xref>; <xref ref-type="bibr" rid="bib67">Nieland et al., 2014</xref>; <xref ref-type="bibr" rid="bib84">Sharma et al., 2013</xref>; <xref ref-type="bibr" rid="bib83">Sharma et al., 2012</xref>; <xref ref-type="bibr" rid="bib103">Verstraelen et al., 2014</xref>). While the general principles of neuronal and synaptic development are thought to be conserved across species (<xref ref-type="bibr" rid="bib22">DeFelipe, 2011</xref>), increasing evidence suggests that species-divergent features influence signal processing in dendrites and axons, which in turn may contribute to differences in cognition and function across organisms (<xref ref-type="bibr" rid="bib29">Eyal et al., 2016</xref>; <xref ref-type="bibr" rid="bib64">Molnár et al., 2016</xref>). Indeed, it is possible that human-specific aspects of synapse biology contribute to higher order cognition and function and may be perturbed in disease, underscoring the importance of utilizing both highly tractable, well-studied animal models as well as emerging human cellular in vitro models to identify and analyze convergent and divergent principles. In this regard, studies comparing human and rodent cortical neurons have revealed differences in membrane capacitance (<xref ref-type="bibr" rid="bib29">Eyal et al., 2016</xref>), epigenetic signatures (<xref ref-type="bibr" rid="bib59">Luo et al., 2017</xref>), gene expression and transcriptional regulatory mechanisms (<xref ref-type="bibr" rid="bib4">Bakken et al., 2016</xref>; <xref ref-type="bibr" rid="bib41">Hodge et al., 2019</xref>; <xref ref-type="bibr" rid="bib115">Zeng et al., 2012</xref>), as well as changes in activity-dependent gene expression (<xref ref-type="bibr" rid="bib75">Pruunsild et al., 2017</xref>) associated with distinct somatic, axonal, dendritic, and spine morphologies (<xref ref-type="bibr" rid="bib5">Beaulieu-Laroche et al., 2018</xref>; <xref ref-type="bibr" rid="bib6">Benavides-Piccione et al., 2002</xref>; <xref ref-type="bibr" rid="bib63">Mohan et al., 2015</xref>), which correlate with differences in synaptic plasticity (<xref ref-type="bibr" rid="bib92">Szegedi et al., 2016</xref>; <xref ref-type="bibr" rid="bib102">Verhoog et al., 2013</xref>) and likely contribute to the differences observed in the integrative properties of the neuron (<xref ref-type="bibr" rid="bib64">Molnár et al., 2016</xref>; <xref ref-type="bibr" rid="bib92">Szegedi et al., 2016</xref>; <xref ref-type="bibr" rid="bib102">Verhoog et al., 2013</xref>). For example, electrophysiological analyses have revealed key differences in spike timing-dependent plasticity in the human cortex compared with rodent, including the ability of human synapses to change strength bidirectionally in response to spike timing (<xref ref-type="bibr" rid="bib102">Verhoog et al., 2013</xref>). A study of connections between human pyramidal neurons and fast-spiking GABAergic interneurons reported four times more functional presynaptic release sites in humans compared with rodents (<xref ref-type="bibr" rid="bib64">Molnár et al., 2016</xref>). Paralleling functional differences, dendritic spines from pyramidal neurons in the human brain were reported to be larger, longer, and more densely packed compared with their rodent counterparts (<xref ref-type="bibr" rid="bib6">Benavides-Piccione et al., 2002</xref>). Moreover, astrocytes are known to play critical roles in synapse development, maintenance, and function (<xref ref-type="bibr" rid="bib1">Allen et al., 2012</xref>; <xref ref-type="bibr" rid="bib2">Allen and Eroglu, 2017</xref>; <xref ref-type="bibr" rid="bib7">Bernardinelli et al., 2014</xref>; <xref ref-type="bibr" rid="bib26">Di Castro et al., 2011</xref>; <xref ref-type="bibr" rid="bib51">Krencik et al., 2017</xref>; <xref ref-type="bibr" rid="bib70">Panatier et al., 2011</xref>; <xref ref-type="bibr" rid="bib98">Ullian et al., 2001</xref>), and human astrocytes exhibit transcriptomic profiles as well as functional and structural properties that diverge from rodent astrocytes (<xref ref-type="bibr" rid="bib35">Hawrylycz et al., 2012</xref>; <xref ref-type="bibr" rid="bib68">Oberheim et al., 2009</xref>). Thus, human and rodent astrocytes likely differ in their contributions to synaptic and neuronal function (<xref ref-type="bibr" rid="bib68">Oberheim et al., 2009</xref>; <xref ref-type="bibr" rid="bib118">Zhang et al., 2016</xref>). The above species-specific features highlight the importance of studying human neurons and human astrocytes to decode human nervous system function, which critically depends on networked neural activity involving both cell types.</p><p>Recent advances in human pluripotent stem cell (hPSC) biology and differentiation now allow for the generation of multiple human brain cell types in vitro including glutamatergic neurons (<xref ref-type="bibr" rid="bib13">Busskamp et al., 2014</xref>; <xref ref-type="bibr" rid="bib16">Chambers et al., 2009</xref>; <xref ref-type="bibr" rid="bib117">Zhang et al., 2013</xref>). This has provided key insights into molecular mechanisms underlying normal synaptic development (<xref ref-type="bibr" rid="bib71">Patzke et al., 2019</xref>), as well as alterations in human neurodevelopmental and neurological disorders such as autism (<xref ref-type="bibr" rid="bib52">Krey et al., 2013</xref>; <xref ref-type="bibr" rid="bib60">Marchetto et al., 2017</xref>; <xref ref-type="bibr" rid="bib113">Yi et al., 2016</xref>), schizophrenia (<xref ref-type="bibr" rid="bib69">Pak et al., 2015</xref>; <xref ref-type="bibr" rid="bib114">Yoon et al., 2014</xref>)<italic>,</italic> Alzheimer’s disease (<xref ref-type="bibr" rid="bib42">Israel et al., 2012</xref>; <xref ref-type="bibr" rid="bib55">Lin et al., 2010</xref>), and Parkinson’s disease (<xref ref-type="bibr" rid="bib80">Sánchez-Danés et al., 2012</xref>; <xref ref-type="bibr" rid="bib101">Vera et al., 2016</xref>). Advances in differentiation technologies have also facilitated the scalable production of hPSC-derived neurons to allow for phenotypic cell-based screening assays. Both genetic and pharmacological drug screening strategies using hPSC-derived neurons have been employed to study pathways regulating Tau and β-amyloid production in Alzheimer’s disease (<xref ref-type="bibr" rid="bib11">Brownjohn et al., 2017</xref>; <xref ref-type="bibr" rid="bib48">Kondo et al., 2017</xref>; <xref ref-type="bibr" rid="bib99">van der Kant et al., 2019</xref>; <xref ref-type="bibr" rid="bib105">Wang et al., 2017</xref>). Other studies have used hPSC-derived neurons to measure neurotoxicity (<xref ref-type="bibr" rid="bib79">Ryan et al., 2016</xref>), neurite outgrowth (<xref ref-type="bibr" rid="bib85">Sherman and Bang, 2018</xref>), and gene function using CRISPR interference and activation (<xref ref-type="bibr" rid="bib96">Tian et al., 2021</xref>; <xref ref-type="bibr" rid="bib95">Tian et al., 2019</xref>), further supporting the utility of such models for high-throughput screens. However, despite their unprecedented potential, scaled analyses of synaptic mechanisms using human cellular systems have not yet been achieved, in part due to the technical challenges associated with generating and analyzing reproducible culture preparations essential for these analyses. Indeed, while studies using human neurons have quantified the effects of candidate small molecules on synaptic density (<xref ref-type="bibr" rid="bib34">Green et al., 2019</xref>; <xref ref-type="bibr" rid="bib71">Patzke et al., 2019</xref>; <xref ref-type="bibr" rid="bib97">Trujillo et al., 2021</xref>), to date we are not aware of any automated systems for their unbiased interrogation. This will become increasingly relevant for the study of basic synaptic mechanisms as additional species divergent features of brain cell types are identified and for the study of complex human diseases that impact synaptic function.</p><p>We therefore devised a fully automated and quantitative high-content synaptic phenotyping platform using in vitro-derived human glutamatergic neurons and primary human astrocytes. To demonstrate the utility of our platform, we screened effects of 376 small molecules on presynaptic density, neurite outgrowth, and cell viability. These analyses identified six small molecules that specifically enhanced presynaptic density. We then probed the most prominent hit class, bromodomain and extraterminal (BET) inhibitors, through global transcriptional analyses. While BET inhibitors have been associated with decreased synaptic gene expression in rodent models (<xref ref-type="bibr" rid="bib50">Korb et al., 2015</xref>; <xref ref-type="bibr" rid="bib89">Sullivan et al., 2015</xref>), we confirmed upregulation of synaptic gene expression in human cellular models, supporting the results of our synaptic assay. Taken together, we have established a novel human synaptic phenotyping platform that effectively identifies synaptic modulators in vitro. This platform can now be leveraged for further interrogation of human synaptic mechanisms and drug discovery efforts.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Generation of robust human neuronal cultures for synaptic screening applications</title><p>To reproducibly generate large batches of human-induced neurons (hNs) from hPSCs, we used a well-described in vitro differentiation protocol based on ectopic expression of Neurogenin 2 (NGN2) combined with developmental patterning using small molecules (<xref ref-type="bibr" rid="bib66">Nehme et al., 2018</xref>; <xref ref-type="bibr" rid="bib117">Zhang et al., 2013</xref>). We selected this protocol based on extensive molecular and physiological characterization of these hNs alongside their use in multiple studies of disease-associated genes (<xref ref-type="bibr" rid="bib13">Busskamp et al., 2014</xref>; <xref ref-type="bibr" rid="bib25">Deneault et al., 2018</xref>; <xref ref-type="bibr" rid="bib56">Lin et al., 2018</xref>; <xref ref-type="bibr" rid="bib61">Meijer et al., 2019</xref>; <xref ref-type="bibr" rid="bib66">Nehme et al., 2018</xref>; <xref ref-type="bibr" rid="bib69">Pak et al., 2015</xref>; <xref ref-type="bibr" rid="bib113">Yi et al., 2016</xref>; <xref ref-type="bibr" rid="bib117">Zhang et al., 2013</xref>; <xref ref-type="bibr" rid="bib119">Zhang et al., 2018</xref>) and in the only published genome-wide CRISPRi/CRISPRa screens of in vitro-derived human neurons to date (<xref ref-type="bibr" rid="bib96">Tian et al., 2021</xref>; <xref ref-type="bibr" rid="bib95">Tian et al., 2019</xref>). Importantly, studies using these hNs have identified physiological and/or morphological phenotypes upon perturbation of synaptic genes (e.g., <italic>NRXN1</italic>, <italic>SHANK3</italic>), which have then been recapitulated using other differentiation paradigms<italic>,</italic> further validating the accuracy of synaptic phenotypes detected in hNs generated with this protocol (<xref ref-type="bibr" rid="bib69">Pak et al., 2015</xref>; <xref ref-type="bibr" rid="bib113">Yi et al., 2016</xref>). Moreover, most neuronal differentiation paradigms in vitro generate heterogeneous cell types at lower throughput (<xref ref-type="bibr" rid="bib16">Chambers et al., 2009</xref>) however, this protocol produces relatively homogeneous populations of glutamatergic neurons at large scale, making it uniquely suited for screening applications (<xref ref-type="bibr" rid="bib66">Nehme et al., 2018</xref>; <xref ref-type="bibr" rid="bib96">Tian et al., 2021</xref>; <xref ref-type="bibr" rid="bib95">Tian et al., 2019</xref>). Data from our laboratory and others confirm that hNs begin to show electrophysiological activity around day 21 in vitro displaying spontaneous excitatory post-synaptic currents (sEPSCs) and NMDAR-mediated currents (<xref ref-type="bibr" rid="bib61">Meijer et al., 2019</xref>; <xref ref-type="bibr" rid="bib66">Nehme et al., 2018</xref>; <xref ref-type="bibr" rid="bib90">Susco et al., 2020</xref>). However, it is important to note that at this timepoint synapses and synaptic network are still maturing.</p><p>To overcome the limitations of lentiviral titer used to transduce NGN2 and to enhance differentiation efficiency, we used a pair of TALENs to stably introduce a doxycycline-inducible NGN2 cassette (<xref ref-type="bibr" rid="bib117">Zhang et al., 2013</xref>) into the AAVS1 safe harbor locus of the hPSC line H1 to generate a zeocin-resistant doxycycline-inducible NGN2 hPSC line, referred to as iNGN2-hPSC (<xref ref-type="fig" rid="fig1">Figure 1a</xref>), similar to the approach used by <xref ref-type="bibr" rid="bib61">Meijer et al., 2019</xref>. Upon transfection, cells were selected for geneticin resistance and individual clones were isolated, expanded, re-plated for genomic DNA extraction and PCR analysis of the transgene integration, and further analyzed by G-band karyotyping (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). To generate large-scale neuronal preparations essential for screening applications, we then differentiated the iNGN2-hPSCs into hNs as described (<xref ref-type="bibr" rid="bib66">Nehme et al., 2018</xref>; <xref ref-type="fig" rid="fig1">Figure 1b</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Development of an automated, high-content human synaptic phenotyping platform.</title><p>(<bold>a</bold>) Schematic of stable integration of a doxycycline-responsive NGN2 (iNGN2) cassette into human pluripotent stem cells (hPSCs). TALENs were used to insert iNGN2 into the AAVS1 safe harbor locus of the <italic>PPP1R12C</italic> gene. (<bold>b</bold>) Summary of human-induced neuron (hN) protocol. hPSCs are differentiated into neural progenitor like cells using extrinsic inhibition of BMP, SMAD, and Wnt in combination with doxycycline-driven transient ectopic NGN2 expression. Zeocin is used as a selective agent. Neural progenitor-like cells were then incubated with neurotrophins in addition to the anti-mitotic agent floxuridine. hNs are then maintained in neurobasal medium and neurotrophins. (<bold>c</bold>) Flowchart of the high-content synaptic screening platform. One day after automated seeding of hNs and hpAs (using a liquid handler, day 5 of hN differentiation), a random plate is selected for assessing plating consistency (Columbus script). On day 18, treatments (shown here as small molecules at 3 µM) are administered in triplicate for 72 hr using a liquid handler; two plates are used as sentinel or reference. On day 21, co-cultures are then stained for synaptic markers using the liquid handler and high-content images are acquired using the Opera Phenix (Perkin Elmer). Data are then processed through CellProfiler and Screener to quantify the number and area of SYNAPSIN1 puncta on MAP2-expressing neurites, the area of MAP2-positive neurites, the number of DAPI-positive nuclei, and the density of SYNAPSIN1 puncta on MAP2-expressing neurites (Z-score). (<bold>d</bold>) Representative images of hNs co-cultured with hpAs and stained for SYNAPSIN1 (red) and MAP2 (green). Cells are counterstained with DAPI (blue). Scale: 100 pixels. Insets: arrows show SYNAPSIN1 puncta localized on MAP2-positive neurites. (<bold>e, f</bold>) Acceptance criteria for plating consistency. Plating consistency for each batch is determined using a Columbus script by quantifying detected hN nuclei per well (<bold>e</bold>) as well as the intra-plate covariance (<bold>f</bold>) of the randomly selected plate on day 6 after hN differentiation. Circles represented the number of neuronal nuclei detected per well from the plates randomly selected on day 6 (one day after seeding the co-culture). Thresholds for inclusion (red dashed lines) are set as above 4000 detected hN nuclei per well and below 12,000 detected hN nuclei per well (<bold>e</bold>) and a covariance below 8% across the plate (<bold>f</bold>). n = 1 x 96 well-plate per Batch which corresponds to 60 wells per 96-well plate per Batch. Error bars are shown as mean +/- SEM. (<bold>g</bold>) Quantification of the density of SYNAPSIN1 puncta on MAP2 neurites after incubation with SYNAPSIN siRNA versus control conditions. n = 6 wells for each condition; ***p&lt;0.0001, ANOVA with Dunnett’s post hoc test. Error bars are shown as SEM.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80168-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Validation of stably integrated iNGN2 cassette in human pluripotent stem cells (hPSCs) and additional synaptic markers.</title><p>(<bold>a</bold>) Design of the PCR genotyping strategy for validation of stable integration of the iNGN2 cassette in the AAVS1 safe harbor locus of the H1 genome. (<bold>b</bold>) Cytogenetic analysis performed by Cell Line Genetics on iNGN2-hPSCs demonstrating an apparently normal karyotype 46,XY. (<bold>c</bold>) Example images (left) and quantification (right) of SYNAPSIN1 on MAP2 co-localized with the presynaptic marker synaptophysin (n = 3 wells, 28 fields). (<bold>d</bold>) Example images (left) and quantification (right) of SYNAPSIN1 on MAP2 co-localized with the postsynaptic marker PSD-95 (n = 3 wells, 16 fields, &gt;10 puncta/field threshold).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80168-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Columbus script to evaluate acceptance criteria for each batch of cultures.</title><p>(<bold>a</bold>) One day after seeding cells, a random plate among the batch is selected, stained against MAP2, and counterstained with DAPI. Images are acquired through ImageXpress (Molecular Devices) and uploaded to Columbus (PerkinElmer). DAPI projected images are filtered and the hN nuclei identified based on the intensity, morphology, contrast, area, roundness, and MAP2-positive soma. hN nuclei are then counted and the intra-plate covariance is calculated. Acceptance criteria for inclusion of each batch of human co-cultures are set above 4000 hN nuclei detected, and a covariance below 8% as depicted by the gray dashed lines (also shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>). (<bold>b</bold>) Columbus script for assessment of the number of neuronal DAPI-positive nuclei.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80168-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Overview of automated layered profiling and quantitative analysis of SYNAPSIN1 puncta on MAP2 neurites (ALPAQAS).</title><p>For each acquired field, 5–8 stacks of MAP2, SYNAPSIN1, and DAPI channels are projected in a single plane before segmentation. A colocalization module then assigns the relationship between the identified SYNAPSIN1 puncta contained within or partly touching the MAP2 neurite objects. The area covered by MAP2 neurites and the number of SYNAPSIN1 puncta on MAP2 neurites from each field are then exported to a *.csv spreadsheet.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80168-fig1-figsupp3-v1.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>ALPAQAS detects SYNAPSIN1 knock-down.</title><p>(<bold>a</bold>) Schematic of siRNA delivery. hN + hpA co-cultures were untreated or incubated on day 18 with SYNAPSIN1 or control siRNA (1 µM) for 72 hr, stained and processed through the synaptic assay. Scale bar = 100 pixel. (<bold>b</bold>) Examples of output from CellProfiler showing overlay of SYNAPSIN1 puncta (red) on MAP2-expressing neurites (green) from untreated and SYNAPSIN1 siRNA-treated conditions. (<bold>c</bold>) Histograms showing the MAP2-positive neurite coverage and the number of DAPI-positive nuclei after incubation with SYNAPSIN1 siRNA versus control conditions. n = 6 wells for each condition; *p&lt;0.05, ANOVA with Dunnett’s post hoc test. (<bold>d</bold>) Cumulative distribution of the diameter of SYNAPSIN1 puncta.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80168-fig1-figsupp4-v1.tif"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 5.</label><caption><title>Workflow supported by Genedata.</title><p>CellProfiler *.csv files (field level) are uploaded with a Genedata parser and filtered through three quality control steps: (i) for each individual field (cross) the area covered by MAP2 must fall within ± 1 standard deviation (σ) to the intra-batch mean (µ) MAP2 coverage (blue crosses represent accepted fields shown within red dashed lines; gray crosses indicated fields that are rejected), (ii) exclusion of the well if ≤4 fields remain following the first quality control step; (iii) exclusion of conditions with one well remaining following the well-level quality control. Data are then imported into Genedata Screener and pattern correction algorithms are leveraged for calculation of Z-score values of the density of SYNAPSIN1 puncta on MAP2 neurites for each condition tested.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80168-fig1-figsupp5-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Establishment of automated pipelines for high-content human presynaptic phenotyping</title><p>We next developed a novel and scalable platform for automated quantification of presynaptic puncta in hNs co-cultured with human primary astrocytes (hpAs, ScienCell) (<xref ref-type="fig" rid="fig1">Figure 1c</xref>). First, because the number and distribution of synapses in a network is critically dependent upon neuronal density (<xref ref-type="bibr" rid="bib20">Cullen et al., 2010</xref>), we used an automated liquid handling system (Personal Pipettor, Apricot Designs) to maximize pipetting precision and accuracy and reliably dispense batches of post-mitotic hNs and hpAs across the 60 inner wells of each 96-well plate. Upon hN co-culture with hpAs, we observed a dense synaptic network (<xref ref-type="fig" rid="fig1">Figure 1d</xref>). We specifically focused on the presynaptic marker SYNAPSIN1, which is crucial for maintenance, translocation, and exocytosis of synaptic vesicle pools, and the cytoskeletal protein MAP2 (microtubule-associated protein 2), which is primarily enriched in perikarya and dendrites (<xref ref-type="bibr" rid="bib14">Caceres et al., 1984</xref>) in addition to DAPI-expressing nuclei. We then quantified presynaptic puncta, defined as SYNAPSIN1 puncta assembled on MAP2-expressing neuronal dendrites, which are (1) robustly captured in our human cellular models; (2) essential for normal neuronal development with perturbations implicated in disease (<xref ref-type="bibr" rid="bib88">Südhof, 2017</xref>; <xref ref-type="bibr" rid="bib104">Waites and Garner, 2011</xref>); (3) a prerequisite for the assembly of postsynaptic machinery (<xref ref-type="bibr" rid="bib30">Friedman et al., 2000</xref>; <xref ref-type="bibr" rid="bib78">Rohrbough et al., 2007</xref>; <xref ref-type="bibr" rid="bib81">Sanes and Lichtman, 2001</xref>); and (4) successfully measured in multiple synaptic screens performed in mouse (<xref ref-type="bibr" rid="bib38">Hempel et al., 2011</xref>; <xref ref-type="bibr" rid="bib86">Spicer et al., 2018</xref>), as well as in small-scale synaptic measurements performed using human cellular systems (<xref ref-type="bibr" rid="bib17">Chanda et al., 2019</xref>; <xref ref-type="bibr" rid="bib69">Pak et al., 2015</xref>; <xref ref-type="bibr" rid="bib113">Yi et al., 2016</xref>). SYNAPSIN1 appeared in a discrete punctate staining pattern localized on and along the clearly defined MAP2-expressing neurites (<xref ref-type="fig" rid="fig1">Figure 1d</xref>). To enhance the resolution of presynaptic puncta and reduce nonspecific background for high-content imaging, we included glycine and TrueBlack Lipofuscin, key reagents for unmasking epitopes and quenching autofluorescence in our immunocytochemistry protocol.</p><p>In addition to quantifying SYNAPSIN1 on MAP2, we also assessed the possibility of incorporating an additional synaptic marker into our assay, testing conditions for labeling two additional presynaptic proteins: synaptophysin, SV2A, and four additional postsynaptic proteins: PSD-95, NLGN4, BAIAP2, and Homer1 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> and data not shown). Among the tested antibodies, we were able to quantify signal for synaptophysin, involved in synaptic vesicle endocytosis, and PSD-95, a key postsynaptic scaffolding protein (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Roughly half of the SYNAPSIN1 signal on MAP2 colocalized with synaptophysin and vice versa (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Interestingly, studies in rodent cortex report that SYNAPSIN1 expression occurs prior to synaptophysin, potentially reflecting maturation of vesicle exocytosis mechanisms prior to endocytosis mechanisms (<xref ref-type="bibr" rid="bib73">Pinto et al., 2013</xref>), which may contribute to the partial overlap in our assay. In general, SYNAPSIN1 is reported to be a more robust and specific marker for presynaptic terminals, with reports of synaptophysin also expressed at extrasynaptic sites (<xref ref-type="bibr" rid="bib62">Micheva et al., 2010</xref>; <xref ref-type="bibr" rid="bib73">Pinto et al., 2013</xref>). Indeed, the signal we obtained for synaptophysin was weak compared with the signal we obtained for SYNAPSIN1 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). We observed moderate colocalization of PSD-95 with SYNAPSIN1; of the PSD-95 puncta on MAP2, 43.1% also colocalized with SYNAPSIN1 and of the SYNAPSIN1 puncta on MAP2, 28.8% colocalized with PSD-95 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). This may indicate presynaptic assembly occurring prior to postsynaptic assembly (<xref ref-type="bibr" rid="bib30">Friedman et al., 2000</xref>; <xref ref-type="bibr" rid="bib78">Rohrbough et al., 2007</xref>; <xref ref-type="bibr" rid="bib81">Sanes and Lichtman, 2001</xref>) at this early stage of neuronal development. Again, at this developmental timepoint, the signal obtained for PSD-95 was weak and of insufficient quality as well as consistency for screening applications (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). It was therefore not feasible to incorporate these additional synaptic markers into our high-content assay; thus, we focused on SYNAPSIN1 puncta assembled on MAP2-expressing neurites.</p><p>To rigorously confirm hN plating consistency (1 d after co-culture, which corresponds to 6 d after the start of hN differentiation), we developed an in silico script using Columbus Acapella software (PerkinElmer; <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>), quantified DAPI-expressing hN nuclei in the co-culture and established key thresholding criteria (i.e<italic>.,</italic> the minimum number of detected hN nuclei per well and the related intra-plate covariance) for each batch of plates (<xref ref-type="fig" rid="fig1">Figure 1e and f</xref>). Of note, while several synaptic screens using mouse primary neurons report plating a range of 10,000–20,000 neurons per well in 96-well plates (<xref ref-type="bibr" rid="bib67">Nieland et al., 2014</xref>; <xref ref-type="bibr" rid="bib83">Sharma et al., 2012</xref>), we validated the number of hNs from a randomly selected plate 1 d after co-culture and found that 4000 surviving hNs per well was a minimum to establish a synaptic network and 12,000 surviving hNs per well was the maximum to circumvent hN clumping as well as reliably discriminate distinct SYNAPSIN1 puncta and track MAP2-expressing neurites for image processing (<xref ref-type="fig" rid="fig1">Figure 1e</xref>). Importantly, consistency of plating was high within batches, with an 8% covariance threshold (<xref ref-type="fig" rid="fig1">Figure 1f</xref>). Each treatment condition was compared to intra-plate/intra-batch controls and independent batches of plates were used as experimental replicates where treatment conditions were again compared to intra-plate/intra-batch controls.</p><p>Second, we developed an automated synaptic quantification pipeline called ALPAQAS (Automated Layered Profiling And Quantitative Analysis of Synaptogenesis) based on image analysis algorithms from the open-source software CellProfiler (<xref ref-type="bibr" rid="bib15">Carpenter et al., 2006</xref>) to analyze our hN/hpA co-cultures after 21 d in vitro. We selected day 21 in vitro to study the developing synapse rather than a more mature synaptic network, which is not established in hNs at this timepoint. This decision was based in part on technical limitations associated with prolonged culturing of cells for screening applications, combined with the recognition that with current protocols, in vitro-derived neurons are unlikely to achieve a fully mature synaptic state regardless of time in culture. After immunostaining our co-cultures, image fields were acquired with a ×20 objective with the Opera Phenix high-content screening system (PerkinElmer), taking 12 fields per well and 5–8 stacks per field at 0.3 µm distance (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). We then used ALPAQAS pipelines to quantify MAP2-positive neurites and SYNAPSIN1 puncta parameters based on staining intensity and morphological thresholding (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). The first ALPAQAS pipeline was designed to merge in a single plane (maximum projection) the 5–8 stacks of each channel for each acquired field of a well. The generated output files were the inputs for a second pipeline, which corrected for potential illumination variations and translational misalignments, performed morphological reconstruction and de-clustering, and generated a *.csv file reporting at a field level: (1) the area covered by MAP2-positive neurites; (2) the number of SYNAPSIN1 puncta localized on MAP2-positive neurites; (3) the number of DAPI-positive nuclei; and (4) the area covered by SYNAPSIN1 puncta (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). To validate the specificity of synaptic detection in vitro, we assessed presynaptic density (i.e<italic>.,</italic> the number of SYNAPSIN1 puncta localized on the MAP2-positive neurites divided by the area covered by MAP2-positive neurites) using ALPAQAS following small interfering RNA (siRNA) perturbation of SYNAPSIN1 (<italic>SYN1</italic>; Accell Dharmacon). Although siRNA-mediated knockdown is heterogeneous, incubating human co-cultures with <italic>SYN1</italic> targeting siRNA for 72 hr significantly reduced presynaptic density compared to <italic>GAPD</italic> and non-targeting siRNA controls, with no or minimal impact on the area covered by MAP2-positive neurites or the total number of DAPI-positive neurites in any condition (<xref ref-type="fig" rid="fig1">Figure 1g</xref>; <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>). SYNAPSIN1 puncta with diameters between 1 and 6 pixels were selected based on analyses of their cumulative distribution (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>), a setting which can be customized in our platform. Indeed, estimates of SYNAPSIN1 puncta diameter vary; some studies have used diameters of 0.4–1.6 µm<sup>2</sup> (<xref ref-type="bibr" rid="bib113">Yi et al., 2016</xref>; <xref ref-type="bibr" rid="bib71">Patzke et al., 2019</xref>), which would correspond to roughly 1–3 pixels in our assay (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>).</p><p>Third, to convert the field-level analysis generated by ALPAQAS to well- or condition-level analyses, and to control for potential intra-plate edge and drift effects, we used Genedata Screener software (Genedata). Specifically, the *.csv data file generated from ALPAQAS was imported into Genedata through a high-content parser containing three additional quality control steps: (1) data were selected according to their MAP2 field area coverage in comparison to the intra-batch mean MAP2 field area coverage; (2) data from wells of poor quality (fewer than five fields persisting after the first quality control step) were discarded from the analysis; and (3) a minimum of two out of three wells per condition (e.g., genotype, treatment) was required by the parser for use in Genedata Screener to aggregate the data from a well-level to a condition-level (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref>). To control for potential intra-plate edge effects, we included two columns of control wells (0.1% DMSO treated) in each plate. In addition, two plates were assigned as sentinel or reference in each batch of human co-cultures to evaluate and correct eventual anomalies due to intra-batch drift effects. We then leveraged pattern correction algorithms in Genedata Screener to potentially rectify values across plates prior to performing Z-score calculations (<xref ref-type="bibr" rid="bib85">Sherman and Bang, 2018</xref>; <xref ref-type="bibr" rid="bib99">van der Kant et al., 2019</xref>; <xref ref-type="bibr" rid="bib116">Zhang et al., 1999</xref>) for synaptic density (<xref ref-type="fig" rid="fig1">Figure 1c</xref>; <xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref>).</p><p>Collectively, these customized protocols and analysis pipelines establish a novel platform for automated quantification of presynaptic density of hN + hpA co-cultures.</p></sec><sec id="s2-3"><title>Primary screening results for 376 small molecules followed by secondary validation reveal six potent small molecules increasing presynaptic density</title><p>To validate the robustness of our platform and uncover modulators of human synaptogenesis, we next assessed the impact of 376 small molecules from a highly selective inhibitor library (SelleckChem, L3500, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Here, small molecules were not selected based on known roles in neuronal or synaptic development, but instead from structurally diverse classes of inhibitors targeting kinases, chromatin modifiers, and cytoskeletal signaling pathways, among others (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Human co-cultures (hNs + hpAs) were treated with small molecules at a concentration of 3 µM in triplicate for 72 hr starting on day 18 of hN differentiation (<xref ref-type="fig" rid="fig2">Figure 2a</xref>). Importantly, 92.94% of the control and treated wells had a Z-score for synaptic density between –2 and +2, underscoring the reliability and robustness of our automated high-content synaptic screening platform (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Thirteen small molecules (3.46% of the library) did not meet the above quality control requirements and seven (1.86% of the library) reduced the density of SYNAPSIN1 puncta on MAP2 neurites by a Z-score ≤–3 and reduced the area covered by MAP2-positive neurites by a Z-score ≤ –2 (<xref ref-type="fig" rid="fig2">Figure 2a</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>); as expected, these small molecules were known to induce apoptosis or catalytic process of autophagy (<xref ref-type="bibr" rid="bib9">Boccadoro et al., 2005</xref>; <xref ref-type="bibr" rid="bib74">Piva et al., 2008</xref>; <xref ref-type="bibr" rid="bib77">Reddy et al., 2011</xref>). Representative examples of the effects of individual small molecules on presynaptic density are shown in <xref ref-type="fig" rid="fig2">Figure 2b</xref>.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Primary screening results for 376 small molecules.</title><p>(<bold>a</bold>) Z-score values for the density of SYNAPSIN1 on MAP2-expressing neurites for hN + hpA co-cultures incubated with small molecules in triplicate at 3 µM for 72 hr starting on day 18 of neuronal differentiation (each circle represents the small molecule level aggregate of the replicates). The effects of each individual small molecule were assessed using our in silico pipelines. Small molecules that increased presynaptic density and were selected for further validation are indicated by colored circles. Those in purple are anticarcinogens that reduced presynaptic density and were not selected for further validation. (<bold>b</bold>) Representative immunofluorescence images and CellProfiler output images (field-level) of human co-cultures treated with either 0.1% DMSO, (+)-JQ1, BI-D1870, I-BET151, Rigosertib, or GSK J4 HCl. Scale bar = 1 µm. Note the increase in SYNAPSIN1 puncta on MAP2-expressing neurites following (+)-JQ1, BI-D1870, and I-BET151 compared to 0.1% DMSO control, and the decrease in SYNPASIN1 puncta following treatment with Rigosertib and GSK J4 HCl.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80168-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Small molecules used in the primary screen.</title><p>(<bold>a</bold>) Number of small molecules per pathway used in the primary screen. (<bold>b, c</bold>) Small molecules were screened at 3 µM in triplicate for 72 hr. 13 small molecules did not meet quality control requirements. 92.94% of the control and treated wells had a Z-score for synaptic density between –2 and +2 as depicted by the red dashed lines (<bold>b</bold>). Values are presented as Z-score of the density of SYNAPSIN1 puncta on MAP2-positive neurites (<bold>b</bold>, each circle represents either a DMSO or a small molecule treated well) or the area covered by MAP2-expressing neurites (<bold>c</bold>, each circle represents the aggregate value of the triplicate). Small molecules decreasing the area covered by MAP2-positive neurites are indicated by circles filled in red, and one small molecule increasing the area covered by MAP2-positive neurites is indicated by circle filled in green.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80168-fig2-figsupp1-v1.tif"/></fig></fig-group><p>To further validate the top hit classes that increased presynaptic density in our primary screen, we executed secondary dose–response assays with newly purchased reagents. Specifically, we selected three heat-shock protein 90 inhibitors (Luminespib, Ganestespib, and Tanespimycin), three BET inhibitors (I-BET151 and (+)-JQ1 included in the primary screen in addition to Birabresib, which was added to expand the number of independent BET inhibitors queried), two phosphoinositide 3-kinase inhibitors (VS-5584 and TG100-15), two histone deacetylase inhibitors (Tubacin and Belinostat), two HMG CoA reductase inhibitors (Fluvastatin and Lovastatin), an S6 ribosome inhibitor and a ROCK1/ROCK2 inhibitor (BI-D1870 and GSK429286A, respectively), a histamine H1 and an opioid receptor antagonist (Loratadine and Naltrexone, respectively), and a ligand of ubiquitin E3 (Lenalidomide) (<xref ref-type="fig" rid="fig2">Figure 2a and b</xref>), for a total of 17 small molecules. We then performed dose–response assays in hN + hpA co-cultures using the automated HP D300e Digital Dispenser (HP, FOL57A) to reliably and randomly dispense at increasing concentrations, nanoliters or microliters of the freshly dissolved small molecules across the 60 inner wells of each 96-well plate, and subsequently quantified synaptic density using our previously described ALPAQAS pipelines (<xref ref-type="fig" rid="fig3">Figure 3a</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Secondary validation reveals potent small molecules increasing presynaptic density.</title><p>(<bold>a</bold>) Workflow for the dose–response assay. hN + hpA co-cultures were treated on day 18 with selected small molecules at various concentrations or 0.1% DMSO for 72 hr, stained and processed through the synaptic assay on day 21. Scale bar = 100 pixel. (<bold>b–d</bold>) Concentration responses for three small molecules (two BET inhibitors [(+)-JQ1, Birabresib] and VS-5584) increasing human presynaptic density (left). The impact on the area covered by MAP2-positive neurites (middle) and toxicity (number of DAPI-positive nuclei; right) are also shown. Data are quantified by percentage of intra-plate control (0.1% DMSO) represented as mean values ± SEM, n = 3 biological replicates, n = 3 technical replicates. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001; one-way ANOVA with Dunnett’s multiple comparisons test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80168-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Dose–response curves for the impact of 17 selected small molecules on human presynaptic density.</title><p>Human co-cultures were treated on day 18 with 0.1% DMSO or the 17 selected small molecules at various concentrations for 72 hr, stained and processed through the synaptic assay. Dose–response curves show the density of SYNAPSIN1 puncta on MAP2-expressing neurites (same data in histogram format shown in <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). Green dots represent the optimal concentration of the chosen small molecules. EC(50) and curves were calculated and drawn using PRISM software. Data are quantified by percentage of intra-plate control (0.1% DMSO) represented as mean values ± SEM, n = 3 biological replicates, n = 3 technical replicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80168-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Histograms for the impact of 17 selected small molecules on human presynaptic density.</title><p>Human co-cultures were treated on day 18 with 0.1% DMSO or the 17 selected small molecules at various concentrations for 72 hr, stained and processed through the synaptic assay. Histograms show the density of SYNAPSIN1 puncta on MAP2-expressing neurites (same data in dose–response curve format shown in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref> and for (+)-JQ1, Birabresib, and VS-5584 in <xref ref-type="fig" rid="fig3">Figure 3</xref>; all data are included together here for comparison). Data are quantified by percentage of intra-plate control (0.1% DMSO) represented as mean values ± SEM, n = 3 biological replicates, n = 3 technical replicates. *p&lt;0.05; **p&lt;0.01, ***p&lt;0.001; one-way ANOVA with Dunnett’s multiple comparisons test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80168-fig3-figsupp2-v1.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Histograms for the impact of 17 selected small molecules on the area covered by MAP2.</title><p>Human co-cultures were treated on day 18 with 0.1% DMSO or the 17 selected small molecules at various concentrations for 72 hr, stained and processed through the synaptic assay. Histograms show the area covered by MAP2 (same data for (+)-JQ1, Birabresib, and VS-5584 shown in <xref ref-type="fig" rid="fig3">Figure 3</xref>; all data are included together here for comparison). Each circle represents the value of one replicate. Data are quantified by percentage of intra-plate control (0.1% DMSO) represented as mean values ± SEM, n = 3 biological replicates, n = 3 technical replicates. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001; one-way ANOVA with Dunnett’s multiple comparisons test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80168-fig3-figsupp3-v1.tif"/></fig><fig id="fig3s4" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 4.</label><caption><title>Histograms for the impact of 17 selected small molecules on the number of DAPI-positive nuclei.</title><p>Human co-cultures were treated on day 18 with 0.1% DMSO or the 17 selected small molecules at various concentrations for 72 hours, stained and processed through the synaptic assay. Histograms show the number of DAPI-positive nuclei (same data for (+)-JQ1, Birabresib, and VS-5584 shown in <xref ref-type="fig" rid="fig3">Figure 3</xref>; all data are included together here for comparison). Each circle represents the value of one replicate. Data are quantified by percentage of intra-plate control (0.1% DMSO) represented as mean values ± SEM, n = 3 biological replicates, n = 3 technical replicates. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001; one-way ANOVA with Dunnett’s multiple comparisons test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80168-fig3-figsupp4-v1.tif"/></fig><fig id="fig3s5" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 5.</label><caption><title>The effect of BET inhibition on presynaptic density is reproducible across cell lines.</title><p>hNs were generated using an independent cell line (iNgn2-DS2U human iPSCs), co-cultured with hpAs, treated on day 18 with 0.1% DMSO or selected small molecules at the optimal concentrations for 72 hr, stained and processed through the synaptic assay. Histograms show the density of SYNAPSIN1 puncta on MAP2-positive neurons (left), the area covered by MAP2-expressing neurites (middle), and the number of DAPI-positive nuclei (right). Data are quantified by percentage of intra-plate control (0.1% DMSO) represented as mean values ± SEM, n = 2 biological replicates, n = 8 technical replicates. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001; one-way ANOVA with Dunnett’s multiple comparisons test. Scale bar = 100 pixel.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80168-fig3-figsupp5-v1.tif"/></fig></fig-group><p>We found that 6 out of 17 small molecules tested exhibited a significant dose-dependent increase in presynaptic density compared to DMSO-treated controls (<xref ref-type="fig" rid="fig3">Figure 3</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplements 1</xref> and <xref ref-type="fig" rid="fig3s2">2</xref>). Notably, all three BET inhibitors ((+)-JQ1, Birabresib, and I-BET151) increased presynaptic density with similar magnitudes of effect (<xref ref-type="fig" rid="fig3">Figure 3b and c</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplements 1</xref> and <xref ref-type="fig" rid="fig3s2">2</xref>). BI-D1870 and GSK429286A also elicited a significant dose–response, indicating that the synaptic connectivity in hNs is modulated through multiple intracellular pathways (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplements 1</xref> and <xref ref-type="fig" rid="fig3s2">2</xref>). Indeed, previous studies have shown that ROCK1/ROCK2 inhibition can enhance synapse formation in rodent models (<xref ref-type="bibr" rid="bib91">Swanger et al., 2015</xref>), consistent with our results from GSK429286A treatment of hN + hpA co-cultures. Finally, VS-5584, an ATP-competitive Pi3K inhibitor with equivalent potency against all human isoforms (α, β, γ, and δ), drove a concentration-dependent increase in presynaptic density compared to the DMSO-treated wells, but not TG100-15, a selective inhibitor of the γ and δ isoforms (<xref ref-type="fig" rid="fig3">Figure 3d</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>), consistent with the preferential immune-cell expression of Pi3Kγ and δ versus the ubiquitous expression patterns of Pi3Kα and β (<xref ref-type="bibr" rid="bib111">Winkler et al., 2013</xref>). The six validated small molecules showed minimal to no toxicity or effect on neurite outgrowth at lower doses, as assessed by the number of DAPI-positive nuclei detected and the area covered by MAP2-positive neurites (<xref ref-type="fig" rid="fig3">Figure 3b–d</xref> and <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplements 3</xref> and <xref ref-type="fig" rid="fig3s4">4</xref>).</p><p>For subsequent experiments, we determined the optimal dosage of each small molecule in hN + hpA co-cultures based upon (1) a significant increase in synaptic connectivity compared to the DMSO-treated wells; (2) a concentration higher than the EC (50); (3) minimal impact on the area covered by MAP2-positive neurites; and (4) minimal or no toxicity (<xref ref-type="fig" rid="fig3">Figure 3</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplements 1</xref>–<xref ref-type="fig" rid="fig3s4">4</xref>). We selected 0.5 µM for (+)-JQ1, 1 µM for Birabresib, 3 µM for I-BET151, VS-5584, and BI-D1870, and 5 µM for GSK429286A as effective concentrations to increase human presynaptic density in hN + hpA co-cultures. We then derived hNs from an independent hPSC line with the same stable, inducible AAVS1 NGN2 integration strategy described above, and confirmed that four out of six small molecules, including all three BET inhibitors, increased presynaptic density in hN + hpA co-cultures at these specific concentrations (<xref ref-type="fig" rid="fig3s5">Figure 3—figure supplement 5</xref>), further validating our previous findings and indicating that the effects of the selected small molecules were generally reproducible across cell lines. Collectively, these analyses highlight the robustness and the sensitivity of our platform to detect modulators of human synaptogenesis.</p></sec><sec id="s2-4"><title>Astrocytes are key regulators of human synapse assembly in vitro and response to small molecules</title><p>Astrocytes are known to play critical roles in the regulation of neuronal network development (<xref ref-type="bibr" rid="bib18">Chung et al., 2015</xref>; <xref ref-type="bibr" rid="bib72">Perez-Catalan et al., 2021</xref>), including the enhancement of presynaptic function (<xref ref-type="bibr" rid="bib98">Ullian et al., 2001</xref>), and we therefore assessed the necessity of hpAs in mediating the effects of the identified small molecules. This was particularly relevant to assess, given that astrocytes are not standardly included in hN screening strategies. Specifically, we tested the impact of the six validated small molecules described above on presynaptic density in the absence of hpAs. hN monocultures were plated, treated, and analyzed using our established pipelines (<xref ref-type="fig" rid="fig4">Figure 4a</xref>). While hN monocultures passed all quality control and thresholding criteria (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>), none of the six small molecules elicited a significant increase in presynaptic density in this condition (<xref ref-type="fig" rid="fig4">Figure 4b</xref>). As expected, the area covered by MAP2-positive neurites and the number of DAPI-positive nuclei remained unchanged by small molecule treatment (<xref ref-type="fig" rid="fig4">Figure 4c and d</xref>), paralleling the hN + hpA co-culture condition (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Importantly, we performed experiments with and without hpAs in parallel using experiments with hpAs as a positive control for experiments performed without hpAs. Small molecule treatment also did not significantly affect the level of SYNAPSIN1 protein expression in either the hN monoculture or hN + hpA co-culture conditions as assessed by western blot analysis (<xref ref-type="fig" rid="fig4">Figure 4e and f</xref>), indicating that the differences observed between hN monocultures and hN + hpA co-cultures after small molecule addition were more likely due to changes in SYNAPSIN1 protein localization as opposed to overall protein abundance.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Astrocytes play a critical role in mediating response to small molecules.</title><p>(<bold>a</bold>) Workflow for small molecule validation in the absence of hpAs. Scale bar = 100 pixel. (<bold>b–d</bold>) In the absence of hpAs, none of the selected small molecules affected SYNAPSIN1 density of hNs, in contrast to the co-culture condition analyzed in parallel. The area covered by MAP2-positive neurites and cell viability was also not impacted as compared to intra-plate DMSO controls. Error bars are shown as mean +/- SEM. (<bold>e</bold>) Schematic of the preparation of the immunoblot samples. (<bold>f</bold>) Representative images of immunoblots and quantification of SYNAPSIN1 normalized to GAPDH and presented as a percentage of DMSO control in both hN alone and hN + hpA co-culture conditions. Note that SYNAPSIN1 protein expression levels were not impacted in any condition. n = 3 biological replicates (<bold>f</bold>). Error bars are shown as mean +/- SEM.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Source of western blots for SYNAPSIN1 as well as GAPDH loading control following small molecule treatment versus DMSO control.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80168-fig4-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80168-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Acceptance criteria of all batches.</title><p>(<bold>a</bold>) Representative image of hN + hpA co-culture and hN alone culture fixed 1 d after plating, stained for MAP2 and counterstained with DAPI. In red, hN DAPI-positive nuclei selected through the Columbus script. Scale = 50 µm. (<bold>b</bold>) Number of DAPI-positive hN nuclei detected per well and intra-plate covariance for each batch used for the dose–response assays, the small molecule validation, and the hN alone experiments. Acceptance criteria for inclusion of each batch of human co-cultures are set above 4000 hN nuclei detected, and a covariance below 8% as depicted by the gray dashed lines. n = 1 x 96 well-plate per Batch which corresponds to 60 wells per 96-well plate per Batch. Error bars are shown as mean +/- SEM.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80168-fig4-figsupp1-v1.tif"/></fig></fig-group><p>The addition of hpAs also had a significant effect on synapse development in the absence of small molecules, including a significant increase in SYNAPSIN1 presynaptic density as well as in the size of individual SYNAPSIN1 puncta with a modest reduction in the area covered by MAP2-positive neurites (<xref ref-type="fig" rid="fig5">Figure 5a–e</xref>). Indeed, the addition of hpAs roughly doubled both the density and size of SYNAPSIN1 puncta on MAP2-positive neurites compared with hNs alone (<xref ref-type="fig" rid="fig5">Figure 5c and d</xref>). Collectively, our results indicate that hNs can form quantifiable presynaptic puncta that can be reliably captured by our platform in the absence of astrocytes. However, hpAs contributed to the assembly or localization of presynaptic machinery, underscoring the relevance of astrocytes in human synaptic screening applications. hpAs were therefore included in all subsequent experiments.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Astrocytes are key regulators of human synapse assembly in vitro.</title><p>(<bold>a, b</bold>) Representative immunofluorescence and CellProfiler output images (field-level) of hN monocultures (<bold>a</bold>) and hN + hpA co-cultures (<bold>b</bold>). Scale bar = 1 µm. (<bold>c–e</bold>) Measurements comparing the density of SYNAPSIN1 puncta on MAP2-positive neurites (<bold>c</bold>), the area covered by individual SYNAPSIN1 puncta (<bold>d</bold>) and the area covered by MAP2-positive neurites (<bold>e</bold>) between hN monocultures and hN + hpA co-cultures. Data are represented as mean values ± SEM, n = 3 biological replicates, n = 8 technical replicates (<bold>c–e</bold>); n &gt; 1000 fields and n &gt; 50,000 SYNAPSIN1 puncta for each condition (<bold>c–e</bold>). ***p&lt;0.001; Kolmogorov–Smirnov unpaired <italic>t</italic>-test. (<bold>f, g</bold>) Power calculations for hN + hPA co-culture (<bold>f</bold>) and hN monoculture (<bold>g</bold>) validation experiments at the well level for the hypothesis ‘greater than.’ Cohen’s d and the number of wells analyzed for each experiment following 0.5 uM (+)-JQ1, 3 uM I-BET151, and 1 uM Birabresib treatment are indicated by the dotted lines.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80168-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Power calculations for the primary screen and validation experiments.</title><p>(<bold>a–d</bold>) Graphs showing Cohen’s d on the x-axis and different sample sizes on the y-axis, for the primary screen with a hypothesis of ‘greater than’ (<bold>a</bold>), the primary screen with a hypothesis of ‘less than’ (<bold>b</bold>), hN + hpA co-cultures at the field level with the hypothesis ‘greater than’ (<bold>c</bold>), and hN monocultures at the field level with the hypothesis ‘greater than’ (<bold>d</bold>). Cohen’s d and the number of samples analyzed for each experiment following 0.5 uM (+)-JQ1, 3 uM I-BET151 and 1 uM Birabresib treatment are indicated by the dotted lines.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80168-fig5-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-5"><title>Power calculations inform on study design</title><p>To more precisely define the power of our assay and gain additional insight into study design, we calculated effect size (Cohen’s d) for our primary screen overall as well as for each small molecule tested, for our hN + hpA co-culture validation experiments, and for our hN monoculture validation experiments (<xref ref-type="fig" rid="fig5">Figure 5f and g</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). For the primary screen, we obtained a Cohen’s d of –0.18, as individual small molecules increased as well as decreased presynaptic density (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Data for each small molecule included in the primary screen is shown in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>. Notably, both (+)-JQ1 and I-BET151 had very large effect sizes in the primary screen, with a Cohen’s d of 2.914 for (+)-JQ1 and 3.710 for I-BET151 (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Consistent with the results of the primary screen, we also noted large effect sizes for each BETi tested in our hN + hpA co-culture validation experiments (<xref ref-type="fig" rid="fig5">Figure 5f and g</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Here, effect sizes were sufficiently large that the number of replicate fields (n = 47–80) and wells (n = 6–9) analyzed per small molecule could be scaled down in future experiments (<xref ref-type="fig" rid="fig5">Figure 5f and g</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). For our hN monoculture validation experiments, we noted effect sizes in the small to medium range (<xref ref-type="fig" rid="fig5">Figure 5f and g</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Here, we scaled up the number of fields (n = 404–417) and wells (n = 52) analyzed per small molecule, which was sufficient to achieve 95% power for detecting the small and medium effect sizes of Birabresib and I-BET151 (one-sided power = greater; <xref ref-type="fig" rid="fig5">Figure 5f and g</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). These analyses confirmed that we were well powered to detect the impacts of BETi in both the hN co-culture and monoculture assays; however, the hN monoculture condition required substantially greater scale given the reduced effect sizes. Overall, in order to achieve 95% power (one-sided) to detect small effect sizes (Cohen’s d = 0.2), experiments would require around n = 270 replicates, while medium effect sizes (Cohen’s d = 0.5) would require around n = 43 replicates, and large effect sizes (Cohen’s d = 0.8) would require around n = 17 replicates. In future experiments, small molecules with effect sizes similar to those of the BET inhibitors in the co-culture condition could be readily detected with modest experimental scale as noted above; in order to detect small effect sizes, experiments may require hundreds of replicates.</p></sec><sec id="s2-6"><title>Multiple BET inhibitors enhance synaptic gene expression</title><p>Given that BET inhibitors were the most prominent hit class identified in our small molecule screen, with three independent BET inhibitors increasing presynaptic density in two independent hPSC lines, we sought to confirm a role for BET proteins in human synaptic development and further validate the results of our synaptic assay. The BET family of chromatin readers, which includes BRD2, BRD3, BRD4, and BRDT, bind acetylated lysine residues on histone proteins as well as transcription factors to mediate gene expression. Through unbiased screening, (+)-JQ1 was identified as a positive modulator of human neurogenesis (<xref ref-type="bibr" rid="bib54">Li et al., 2016</xref>). However, in adult mice, BET inhibition through (+)-JQ1 was shown to reduce synaptic gene expression and impair memory consolidation (<xref ref-type="bibr" rid="bib50">Korb et al., 2015</xref>), while BET inhibition through I-BET858 in mouse primary neurons reportedly led to decreased expression of neuronal differentiation and synaptic genes (<xref ref-type="bibr" rid="bib89">Sullivan et al., 2015</xref>). Importantly, region-specific differences in response to (+)-JQ1 have been identified in the rodent brain, particularly in the context of dendritic spine density, suggesting that brain cell type may be a major determining factor in the expression of these phenotypes (<xref ref-type="bibr" rid="bib108">Wang et al., 2021b</xref>). Moreover, a recent study found sex divergent effects of Brd4 on cellular and transcriptional phenotypes in both human and mouse (<xref ref-type="bibr" rid="bib45">Kfoury et al., 2021</xref>), further supporting the hypothesis that the impacts of BET inhibition are highly context dependent.</p><p>We therefore performed global transcriptional analyses on both (+)-JQ1 and Birabresib-treated hN + hpA co-cultures compared with DMSO-treated controls (<xref ref-type="fig" rid="fig6">Figure 6a</xref>) to independently assess their roles in synaptic development. (+)-JQ1, Birabresib, or DMSO was added on day 18 in vitro for 72 hr, paralleling the approach used in our small molecule screen. Applying an adjusted p-value cut-off of 0.05 and log<sub>2</sub> fold change cut-offs of ≤–1 and ≥ 1, we identified a comparable number of significantly differentially expressed genes (DEGs) after (+)-JQ1 and Birabresib treatment compared to DMSO control (<xref ref-type="fig" rid="fig6">Figure 6b and c</xref>, <xref ref-type="supplementary-material" rid="supp3 supp4">Supplementary files 3 and 4</xref>). A majority of DEGs were downregulated after BET inhibition (<xref ref-type="fig" rid="fig6">Figure 6b and c</xref>), consistent with the known roles of BET proteins in transcriptional activation, and were also shared between the (+)-JQ1 and Birabresib treatment conditions (n = 2368; <xref ref-type="fig" rid="fig6">Figure 6d</xref>). We also observed strong positive correlation in the magnitudes of effect of (+)-JQ1 and Birabresib treatment as attested by the Pearson’s r score of 0.9404 (<xref ref-type="fig" rid="fig6">Figure 6e</xref>). Given that both BET inhibitors increased presynaptic density (<xref ref-type="fig" rid="fig3">Figure 3b and c</xref>), we focused on the set of DEGs that were shared between (+)-JQ1 and Birabresib treatment conditions for the remainder of our transcriptional analyses. Using ingenuity pathway analysis (IPA), we confirmed that BRD4 (p=1.61 × 10<sup>–17</sup>), (+)-JQ1 (p=0.000206), and Birabresib (p=4.59 × 10<sup>–18</sup>) were all strongly predicted to be upstream regulators of the shared DEGs (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). Signaling pathways such as ‘DNA methylation and transcriptional repression’ and ‘axonal guidance’ were enriched in the upregulated DEGs, while signaling pathways such as ‘wound healing’ and ‘neuroinflammation’ enriched in the downregulated DEGs (<xref ref-type="fig" rid="fig6">Figure 6f</xref>). We then leveraged SynGO (<xref ref-type="bibr" rid="bib49">Koopmans et al., 2019</xref>) to specifically analyze synaptic ontology terms, focusing on genes upregulated in both the (+)- JQ1 and Birabresib transcriptional datasets (<xref ref-type="fig" rid="fig6">Figure 6g and h</xref>, <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>). We found significant enrichment for the terms ‘integral component of postsynaptic membrane’ and ‘postsynaptic membrane’ with modest but significant enrichment for additional presynaptic terms (<xref ref-type="fig" rid="fig6">Figure 6g and h</xref>, <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>) consistent with a role for BET proteins in the regulation of pre- and postsynaptic genes. Examples of individual pre- and postsynaptic genes upregulated following BET inhibition include the presynaptic cell adhesion molecule <italic>Neurexin 3 (NRXN3),</italic> the synaptic vesicle gene <italic>Amphiphysin (AMPH),</italic> the transmembrane Eph receptor ligand <italic>Ephrin-B2 (EFNB2</italic>) involved in AMPAR stabilization<italic>,</italic> and the postsynaptic scaffolding factors <italic>BAR/IMD Domain Containing Adaptor Protein 2 (BAIAP2</italic>) and <italic>Homer Scaffold Protein 1</italic> (<italic>HOMER1</italic>) (<xref ref-type="fig" rid="fig6">Figure 6i</xref>). Indeed, (+)-JQ1 and Birabresib treatment each roughly doubled the expression of these pre- and postsynaptic genes. Additionally, western blot analysis revealed that both (+)-JQ1 and Birabresib significantly increased protein expression levels of the postsynaptic scaffolding factors BAIAP2 and Homer1 compared with DMSO-treated control (<xref ref-type="fig" rid="fig6">Figure 6j</xref>), paralleling the transcript-level changes.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Multiple BET inhibitors enhance synaptic gene expression.</title><p>(<bold>a</bold>) Schematic of mRNA-seq experiment using 3–6 replicates per treatment condition. hN + hpA co-cultures were treated with 0.1% DMSO, 0.5 µM (+)-JQ1 or 1 µM Birabresib for 72 hr prior to harvesting. (<bold>b, c</bold>) Volcano plots for (+)-JQ1 versus DMSO control (<bold>b</bold>) and Birabresib versus DMSO control (<bold>c</bold>). Log<sub>2</sub> fold change is shown on the x-axis, with the -log<sub>10</sub> of the adjusted p-value shown on the y-axis. Positive fold change reflects an increase in the treatment condition relative to DMSO control. Numbers of significantly differentially expressed genes (DEGs) are shown for each condition. (<bold>d</bold>) Overlap (shown as number of genes) between DEGs identified with (+)-JQ1 treatment (blue) and DEGs identified with Birabresib treatment (green). (<bold>e</bold>) Scatterplot of the fold change read counts of the genes upregulated by (+)-JQ1 and Birabresib. Note the strong positive Pearson’s r (94%) correlation between transcripts upregulated by (+)-JQ1 and Birabresib. Select gene examples are highlighted in red. (<bold>f</bold>) Select canonical pathways identified by IPA for DEGs upregulated in both (+)-JQ1 and Birabresib treatment conditions (top) or downregulated in both (+)-JQ1 and Birabresib treatment conditions (bottom). The x-axis shows -log<sub>10</sub> of the p-value for each pathway analysis term. (<bold>g</bold>) SynGO analysis showing the top 5 significantly enriched cellular component and biological process ontology terms identified using all genes upregulated by (+)-JQ1 and Birabresib. The x-axis shows -log<sub>10</sub> of the p-value for each ontology term; the top two terms also met a&lt;1% FDR threshold (<bold>h</bold>) SynGO analysis sunburst representation showing gene counts of the cellular components identified using all genes upregulated by (+)-JQ1 and Birabresib. (<bold>i</bold>) Graphs of transcript expression values for pre- and post-synaptic genes. Significance was calculated by Benjamini–Hochberg adjusted Wald test as part of the DEseq2 RNA-seq experiment. n=3 biological replicates. (<bold>j</bold>) Western blot analysis of BAIAP2 and Homer1 protein expression levels following treatment with DMSO, (+)-JQ1, or Birabresib (n = 4 biological replicates). Top, quantification (shown as % of DMSO control); bottom, example blots. For all figure panels, significance is indicated by *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001 relative to controls.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Source of western blots for BAIAP2 and Homer1 as well as Cofilin loading control following DMSO, (+)-JQ1, or Birabresib treatment conditions.</title><p>Arrowheads indicate bands used for quantification.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80168-fig6-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80168-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>BET proteins and inhibitors are identified as upstream regulators of the differentially expressed genes (DEGs) and BET inhibition impact astrocyte-secreted and pro-inflammatory factors.</title><p>(<bold>a</bold>) DEGs shared between (+)-JQ1 and Birabresib treatment conditions were used as input into ingenuity pathway analysis, and the activation z-scores and p-values of the overlap were quantified. Blue indicates a negative activation z-score (BRD4), and orange indicates a positive activation z-score ((+)-JQ1 and Birabresib). (<bold>b</bold>) Graphs of transcript expression values for astrocyte-secreted and pro-inflammatory genes in (+)-JQ1 or Birabresib conditions compared to 0.1% DMSO controls. Significance was calculated by Benjamini–Hochberg adjusted Wald test as part of the DEseq2 RNA-seq experiment. ***p&lt;0.001. n&gt;3 biological replicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80168-fig6-figsupp1-v1.tif"/></fig></fig-group><p>Consistent with the pathway analyses, we also observed modulation of the expression of several astrocyte-secreted factors including upregulation of the anti-inflammatory factor <italic>Interleukin 11 (IL11</italic>), downregulation of the pro-inflammatory factor Interleukin 6 (<italic>IL6</italic>), and downregulation of the synapse disassembly factor <italic>Secreted Protein Acidic And Cysteine Rich (SPARC</italic>) (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). Combined with downregulation of Caspase 1 (<italic>CASP1)</italic> and <italic>Gasdermin D (GSDMD</italic>) (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>), these results point to a general anti-inflammatory response following BET inhibition. Indeed, <italic>CASP1, GSDMD,</italic> and <italic>IL6</italic> have all previously been shown to be downregulated by (+)-JQ1 treatment, consistent with the known role of BET proteins in promotion of the inflammatory response (<xref ref-type="bibr" rid="bib108">Wang et al., 2021b</xref>; <xref ref-type="bibr" rid="bib120">Zhou et al., 2019</xref>). Importantly, changes in gene transcription were again highly concordant between both (+)-JQ1 and Birabresib treatment conditions, with similar magnitudes of effect (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>).</p><p>Collectively, these data indicate that BET inhibition can lead to upregulation of synaptic genes, consistent with our screening results showing an increase in presynaptic density and supporting a role for BET proteins in synapse assembly. These results also support the robustness of our platform for detecting human synaptic modulators in vitro.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Despite overwhelming evidence implicating synaptic dysfunction in complex human disease and clear species-specific differences in certain aspects of synaptic biology, human neurons and astrocytes have yet to be widely employed in studies of synaptic mechanisms. We therefore established a novel, automated, high-content synaptic platform using human neurons and astrocytes to facilitate dissection of human synaptic mechanisms and drug discovery efforts. Specifically, we (1) generated stable iNGN2-hPSC lines through TALEN editing to produce large, reproducible batches of post-mitotic glutamatergic hNs; (2) optimized hN + hpA co-culture and immunocytochemistry conditions for reliable quantification of synaptic markers on an automated high-content imaging platform; (3) employed liquid handling systems to standardize the dispensing steps and maximize accuracy for both co-culturing and immunocytochemistry; and (4) developed in silico automated pipelines for rigorous assessment of plating consistency and quantification of human synaptic connectivity. After extensive vetting of antibodies for synapse detection, SYNAPSIN1 on MAP2 was the only antibody combination sufficiently robust to be captured in our assay. While there is no single definitive synaptic marker, SYNAPSIN1 is one of the most robust markers utilized in the field, having been shown to label the vast majority of rodent glutamatergic cortical synapses (<xref ref-type="bibr" rid="bib62">Micheva et al., 2010</xref>) and frequently employed in studies of human cellular systems (<xref ref-type="bibr" rid="bib17">Chanda et al., 2019</xref>; <xref ref-type="bibr" rid="bib69">Pak et al., 2015</xref>; <xref ref-type="bibr" rid="bib113">Yi et al., 2016</xref>). The incomplete co-localization of SYNAPSIN1 with synaptophysin and PSD-95 could reflect factors such as developmental stage, as SYNAPSIN1 expression has been reported to precede synaptophysin and PSD-95 expression (<xref ref-type="bibr" rid="bib30">Friedman et al., 2000</xref>; <xref ref-type="bibr" rid="bib73">Pinto et al., 2013</xref>), or the weaker signal obtained by immunocytochemistry for the latter antibodies. Development of additional synaptic antibodies suited for immunocytochemical applications in human cells will be essential to more definitively address this question.</p><p>Of note, several open-source methods for synaptic quantification have been developed in recent years including SynQuant, SynapseJ, SynPAnal, and SynD (<xref ref-type="bibr" rid="bib21">Danielson and Lee, 2014</xref>; <xref ref-type="bibr" rid="bib65">Moreno Manrique et al., 2021</xref>; <xref ref-type="bibr" rid="bib82">Schmitz et al., 2011</xref>; <xref ref-type="bibr" rid="bib106">Wang et al., 2020</xref>) providing a solid foundation for the principle of synaptic quantification from immunofluorescence images. However, our platform is the first to use human neurons and human astrocytes for scaled analyses of synapses, and one of the few to fully automate each step of the process from co-culture to immunostaining to imaging, in order to enhance throughput, accuracy, and reproducibility. Through unbiased screening of 376 small molecules, we generated proof-of-concept data that our platform works robustly to identify synaptic modulators. Our results were also generally reproducible across independent hPSC lines. Given the known molecular and functional heterogeneity across individual hPSC lines (<xref ref-type="bibr" rid="bib44">Kajiwara et al., 2012</xref>; <xref ref-type="bibr" rid="bib46">Kilpinen et al., 2017</xref>; <xref ref-type="bibr" rid="bib40">HIPSCI Consortium et al., 2018</xref>), we would not expect identical results or magnitudes of effect, but our analyses support the robustness of our assay to detect differences in independent hPSC lines.</p><p>Importantly, the results from hNs co-cultured with hpAs did not correlate with the results from hNs cultured alone, underscoring the importance of including astrocytes in human synaptic assays. Indeed, our positive hits required the presence of hpAs to achieve a significant change in presynaptic density, supporting the relevance of non-cell-autonomous factors in synapse assembly. Our power calculations comparing the hN monoculture condition with the hN + hpA co-culture condition suggest we are reasonably powered to detect changes in both assays given the predicted effect sizes. While we cannot rule out the possibility of technical factors contributing to the lack of changes in presynaptic density in the hN monocultures, as opposed to differences in the biological contribution of hpAs, it is critical to note for future screening applications that the inclusion of astrocytes was either required for these biological changes or important for their practical detection. Indeed, large effect changes seen in the co-culture condition could be detected with a small number of replicates (e.g., three wells), while the monoculture condition required 50+wells for the same small molecules. Consistent with astrocytes playing a critical role in synapse formation, upon hpA co-culture, we observed a twofold increase in presynaptic density and the area of individual SYNAPSIN1 puncta compared with hN monocultures. While previous studies have shown that inclusion of rodent astrocytes with hNs can significantly increase physiological and/or morphological maturation (<xref ref-type="bibr" rid="bib43">Johnson et al., 2007</xref>; <xref ref-type="bibr" rid="bib66">Nehme et al., 2018</xref>; <xref ref-type="bibr" rid="bib93">Tang et al., 2013</xref>), the underlying mechanisms remain incompletely resolved. Studies examining the effects of physical astrocyte contact versus astrocyte conditioned media on hNs report that physical contact has a much more potent impact on synapse development compared with conditioned media (<xref ref-type="bibr" rid="bib43">Johnson et al., 2007</xref>; <xref ref-type="bibr" rid="bib93">Tang et al., 2013</xref>), suggesting that direct physical contact between hNs and hpAs may be particularly important. Our results imply that regulators of synapse formation may be missed in assays performed in the absence of astrocytes. Given that the inclusion of astrocytes more accurately mimics the in vivo synaptic milieu, and that astrocytes are not standardly included in hN screening strategies, it will be critical to consider this cell type in future human synaptic screening experiments.</p><p>Given that three separate BET inhibitors scored in our assay in two independent hPSC lines, our results also support a role for BET proteins in human synaptic development. While we were unable to separate hN and hpA transcriptomes from the co-culture (and the co-culture was required to see the effects of BET inhibition), we observed modulation of synaptic machinery in our global transcriptional analyses, consistent with our screening results. These data support a model whereby BET inhibition either leads to increased expression of specific synapse associated genes, or to the enhancement of presynaptic puncta which then triggers the expression of additional synaptic components. Indeed, BET protein expression is downregulated throughout neuronal differentiation, with knockdown of BET proteins sufficient to enhance differentiation (<xref ref-type="bibr" rid="bib54">Li et al., 2016</xref>) consistent with a role for BET proteins in negatively regulating neuronal development. These results contrast with a subset of data generated in adult mouse brain and are thus likely to be dependent upon factors such as brain cell type, developmental stage, and timing of drug treatment. Resolving potential neurological benefits and/or consequences of BET inhibition in different contexts including in diverse brain cell types and developmental stages is essential as these drugs are currently in use in clinical trials for cancer and are proposed for the treatment of developmental as well as degenerative diseases (<xref ref-type="bibr" rid="bib50">Korb et al., 2015</xref>; <xref ref-type="bibr" rid="bib107">Wang et al., 2021a</xref>).</p><p>While BET proteins have well-described roles in the inflammatory response, little is known about their role in astrocytes specifically. Future studies will be required to determine how BET inhibition impacts astrocytes and how this may in turn impact neuron function. Our results are consistent with BET inhibition enhancing synapse assembly and impacting both neuron and astrocyte transcriptomes, but it remains to be determined whether BET inhibition of astrocytes has a direct impact on synapse formation or whether BET inhibition primarily acts on neurons to impact synapse assembly. Overall, we speculate that hpAs provide critical synaptic support for hNs in our assay that then facilitates the health or receptiveness of hNs for further synaptic enhancement, given the disparities in SYNAPSIN1 parameters between hN monocultures and hN + hpA co-cultures, as well as the lack of effect of small molecules on hN monocultures.</p><p>Our robust, scalable and accessible platform provides several key advances for the field. Specifically: (1) we generated the first automated and quantitative high-content synaptic phenotyping platform for human neurons and astrocytes, which can now be leveraged for study of basic human synaptic mechanisms, dissection of complex human disease and drug discovery efforts; (2) our results demonstrate that the stable NGN2 integration strategy for scaled generation of hNs from hPSCs is well suited for screening applications; (3) our platform is compatible with both small molecule as well as siRNA-based manipulations; (4) our platform captures key parameters of human synaptic connectivity including the number and the area of individual presynaptic contacts as well as the coverage of MAP2-positive neurites and overall cell viability; (5) while compatible with analyses of hN monocultures, our analyses underscore the relevance of astrocytes when studying human synaptic mechanisms and drug response and (6) different human genetic backgrounds can be employed in our platform to dissect disease mechanisms. Future studies will focus on the incorporation of additional brain cell types to increase the complexity in our 2D co-culture systems, probing additional small molecule classes to explore novel human synaptogenic factors and improving the fidelity of astrocyte differentiation protocols in vitro to facilitate cell-type-specific genetic manipulations.</p><p>There are also several limitations to our approach: (1) our platform was specifically designed for use with human neurons and astrocytes and alterations to the neuronal differentiation paradigms or species, or the addition of other brain cell types may require modest customization steps; (2) our platform is based on high-content imaging, and neurophysiological function must be assessed using separate methodology, likely at lower throughput; (3) similarly, reliance on SYNAPSIN1 on MAP2 as a readout for presynaptic density in developing neurons may be capturing sites that do not then develop into fully functional/mature synapses with postsynaptic partners; (4) while the timepoints of manipulations and analyses can be altered in our assay, longitudinal studies in the same cells are not possible unless suitable genetically encoded fluorescent markers are employed; and (5) our platform is designed for 2D culture to allow for precise control over cell densities and ratios but does not fully reflect the structural complexity present in 3D systems (e.g., spheroids, organoids).</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">WA01</td><td align="left" valign="bottom">WiCell Research Institute</td><td align="left" valign="bottom">H1</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib94">Thomson et al., 1998</xref></td></tr><tr><td align="left" valign="bottom">cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Primary astrocytes</td><td align="left" valign="bottom">ScienCell Research Laboratories</td><td align="left" valign="bottom">Cat#1800</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">transfected construct (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">SYNAPSIN1 and control siRNA</td><td align="left" valign="bottom">Accell Dharmacon</td><td align="left" valign="bottom">Cat#A-12362-16-0005 and Cat#K-005000-R1-01</td><td align="left" valign="bottom">transfected construct <break/>(<italic>Homo sapiens</italic>)</td></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">Anti-human SYNAPSIN1 (Rabbit polyclonal)</td><td align="left" valign="bottom">Millipore</td><td align="left" valign="bottom">Cat#AB1543 RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2200400">AB_2200400</ext-link></td><td align="left" valign="bottom">IF (1:1000) WB (1:1000)</td></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">Anti-human MAP2 (Chicken polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat#ab5392 RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2138153">AB_2138153</ext-link></td><td align="left" valign="bottom">IF (1:1000)</td></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">Anti-human SYNAPTOPHYSIN (<italic>Mouse monoclonal</italic>)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#9020 RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2631095">AB_2631095</ext-link></td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">Anti-human PSD95 (<italic>Mouse monoclonal</italic>)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat#MA1-046 RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2092361">AB_2092361</ext-link></td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">Anti-human GAPDH (<italic>Mouse monoclonal</italic>)</td><td align="left" valign="bottom">Millipore</td><td align="left" valign="bottom">Cat#MAB374 RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2107445">AB_2107445</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">Anti-human HOMER (Rabbit polyclonal)</td><td align="left" valign="bottom">Synaptic Systems</td><td align="left" valign="bottom">Cat#160003 RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_887730">AB_887730</ext-link></td><td align="left" valign="bottom">WB (1:500)</td></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">Anti-human BAIAP2 (Rabbit polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat#PA5-30386 RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2547860">AB_2547860</ext-link></td><td align="left" valign="bottom">WB (1:500)</td></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">Anti-human COFILIN</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat#ab42824 RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_879739">AB_879739</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">recombinant DNA reagent</td><td align="left" valign="bottom">pAAVS1-iNGN2-Zeo (plasmid)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">sequence-based reagent</td><td align="left" valign="bottom">Forward NGN2</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">AGGAAATGGGGGTGTGTCAC</td></tr><tr><td align="left" valign="bottom">sequence-based reagent</td><td align="left" valign="bottom">Reverse NGN2</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GAGCTCCTCTGGCGATTCTC</td></tr><tr><td align="left" valign="bottom">commercial assay or kit</td><td align="left" valign="bottom">DNeasy Blood and tissue kit</td><td align="left" valign="bottom">Qiagen</td><td align="left" valign="bottom">Cat#695004</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">commercial assay or kit</td><td align="left" valign="bottom">RLTplus Lysis buffer</td><td align="left" valign="bottom">Qiagen</td><td align="left" valign="bottom">Cat#1053393</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">commercial assay or kit</td><td align="left" valign="bottom">RNeasy micro/mini kit</td><td align="left" valign="bottom">Qiagen</td><td align="left" valign="bottom">Cat#74034</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">Geneticin</td><td align="left" valign="bottom">Life Technologies</td><td align="left" valign="bottom">Cat#10131035</td><td align="left" valign="bottom">50 µg.mL<sup>–1</sup></td></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">SB431542</td><td align="left" valign="bottom">Tocris</td><td align="left" valign="bottom">Cat#1614</td><td align="left" valign="bottom">10 µM; 5 µM</td></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">XAV939</td><td align="left" valign="bottom">Stemgent</td><td align="left" valign="bottom">Cat#04–00046</td><td align="left" valign="bottom">2 µM; 1 µM</td></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">LDN-193189</td><td align="left" valign="bottom">Stemgent</td><td align="left" valign="bottom">Cat#04–0074</td><td align="char" char="." valign="bottom">100 nM; 50 nM</td></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">Doxycycline hyclate</td><td align="left" valign="bottom">SIgma</td><td align="left" valign="bottom">Cat#D9891</td><td align="left" valign="bottom">2 µg.mL<sup>–1</sup></td></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">Y27632</td><td align="left" valign="bottom">Stemgent</td><td align="left" valign="bottom">Cat#04–0012</td><td align="char" char="." valign="bottom">5 mM</td></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">Zeocin</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat#46–059</td><td align="left" valign="bottom">1 µg.mL<sup>–1</sup></td></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">BDNF</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat#248-BD/CF</td><td align="char" char="." valign="bottom">10 ng.mL<sup>–1</sup></td></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">CTNF</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat#257-NT-CF</td><td align="char" char="." valign="bottom">10 ng.mL<sup>–1</sup></td></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">GDNF</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat#212-GD/CF</td><td align="char" char="." valign="bottom">10 ng.mL<sup>–1</sup></td></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">Floxuridine</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat#F0503-100MG</td><td align="left" valign="bottom">10 µg.mL<sup>–1</sup></td></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">Compound library</td><td align="left" valign="bottom">SelleckChem</td><td align="left" valign="bottom">L3500</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">software, algorithm</td><td align="left" valign="bottom">Columbus Acapella</td><td align="left" valign="bottom">Perkin Elmer</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">software, algorithm</td><td align="left" valign="bottom">CellProfiler</td><td align="left" valign="bottom">The Broad Institute</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Stem cell culture</title><p>The XY human ESC line WA01 (H1) and the XY human iPSC line DS2U were commercially obtained from WiCell Research Institute (<xref ref-type="bibr" rid="bib94">Thomson et al., 1998</xref>; <xref ref-type="bibr" rid="bib109">Weick et al., 2013</xref>; <ext-link ext-link-type="uri" xlink:href="https://www.wicell.org/">https://www.wicell.org/</ext-link>). Stem cell culture was carried out as previously described (<xref ref-type="bibr" rid="bib37">Hazelbaker et al., 2020</xref>; <xref ref-type="bibr" rid="bib36">Hazelbaker et al., 2017</xref>). In brief, stem cells were grown and maintained in StemFlex medium (Gibco, A3349401) on geltrex precoated plates (Life Technologies, A1413301) under standard conditions (37°C, 5% CO<sub>2</sub>). Cells were passaged using TrypLE Express (Life Technologies, 12604021). All cell lines underwent QC testing to confirm normal karyotypes, absence of mycoplasma, expression of pluripotency markers, and tri-lineage potential. G-band karyotyping analysis was performed by Cell Line Genetics.</p></sec><sec id="s4-2"><title>Generation of inducible NGN2 system</title><p>TALENs (AAVS1-TALEN-L and AAVS1-TALEN-R; Addgene, 59025/59026; <xref ref-type="bibr" rid="bib32">González et al., 2014</xref>) were used to target the first intron of the constitutively expressed gene <italic>PPP1R12C</italic> at the AAVS1 locus with the pAAVS1-iNGN2-Zeo plasmid containing TetO-NGN2-P2A-Zeo and CAG-rtTA. In brief, hPSCs were dissociated into single-cell suspension with TrypLE (Gibco, 12604-021). 2.5 × 10<sup>6</sup> cells were resuspended in 120 µL of R Buffer (Thermo Fisher Scientific, MPK10096) and mixed with 1.5 µg each of AAVS1<italic>-</italic>TALEN-L and AAVS1-TALEN-R, and 10 µg of pAAVS1-iNGN2-Zeo plasmid. Cells were electroporated using the Neon Transfection electroporation system (Thermo Fisher Scientific, MPK10096) at 1050 V, 30 ms, and 2 pulses, and plated on a 10 cm plate. 24 hr after electroporation and indefinitely, the cells were selected with geneticin (50 µg.mL<sup>–1</sup>, Life Technologies, 10131035). At the fifth day of selection, 2 × 10<sup>4</sup> cells were plated on a 10 cm plate for clonal selection. After colony formation, colonies were picked and transferred to a 96-well plate for genomic DNA extraction and PCR analysis of plasmid integration.</p></sec><sec id="s4-3"><title>Genomic DNA isolation and genotyping PCR</title><p>Genomic DNA (gDNA) from the iNGN2-H1 cell line was extracted from hPSCs with the DNeasy Blood and Tissue kit according to the manufacturer’s instructions (QIAGEN, 69504). PCR of the gDNA was performed with the primer pair forward 5′-<named-content content-type="sequence">AGGAAATGGGGGTGTGTCAC</named-content>-3′ (in the AAVS1 locus) and reverse 5′- <named-content content-type="sequence">GAGCTCCTCTGGCGATTCTC</named-content>-3′ (in the NGN2 DNA sequence).</p></sec><sec id="s4-4"><title>Human neuron generation</title><p>Human neurons were generated as previously described (<xref ref-type="bibr" rid="bib66">Nehme et al., 2018</xref>; <xref ref-type="bibr" rid="bib117">Zhang et al., 2013</xref>). In brief, on day 0, hPSCs were differentiated in N2 medium (500 mL DMEM/F12 [1:1] [Gibco, 11320-033]), 5 mL Glutamax (Gibco, 35050-061), 7.5 mL sucrose (20%, Sigma, S0389), 5 mL N2 supplement B (StemCell Technologies, 07156) supplemented with SB431542 (10 µM, Tocris, 1614), XAV939 (2 µM, Stemgent, 04-00046), and LDN-193189 (100 nM, Stemgent, 04-0074) along with doxycycline hyclate (2 µg.mL<sup>–1</sup>, Sigma, D9891) and Y27632 (5 mM, Stemgent 04-0012). Day 1 was a step-down of small molecules, where N2 medium was supplemented with SB431542 (5 µM, Tocris, 1614), XAV939 (1 µM, Stemgent, 04-00046), and LDN-193189 (50 nM, Stemgent, 04-0074) with doxycycline hyclate (2 µg.mL<sup>–1</sup>, Sigma, D9891) and Zeocin (1 µg.mL<sup>–1</sup>, Invitrogen, 46-059). On day 2, N2 medium was supplemented with doxycycline hyclate (2 µg.mL<sup>–1</sup>, Sigma, D9891) and Zeocin (1 µg.mL<sup>–1</sup>, Invitrogen, 46-059). Starting on day 3, cells were maintained in Neurobasal media (500 mL Neurobasal [Gibco, 21103-049], 5 mL Glutamax [Gibco, 35050-061], 7.5 mL Sucrose [20%, Sigma, S0389], 2.5 mL NEAA [Corning, 25-0250 Cl]) supplemented with B27 (50x, Gibco, 17504-044), BDNF, CTNF, GDNF (10 ng.mL<sup>–1</sup>, R&amp;D Systems 248-BD/CF, 257-NT/CF, and 212-GD/CF) and doxycycline hyclate (2 µg.mL<sup>–1</sup>, Sigma, D9891). From day 4 to day 5, Neurobasal media was complemented with the antiproliferative agent floxuridine (10 µg.mL<sup>–1</sup>, Sigma-Aldrich, F0503-100MG).</p></sec><sec id="s4-5"><title>Human primary astrocytes</title><p>Human primary cortical astrocytes (hpAs) were obtained from ScienCell Research Laboratories (1800) and cultured according to the manufacturer’s instructions.</p></sec><sec id="s4-6"><title>mRNA sequencing and analysis</title><p>Three to six biological replicates of hN + hpA co-cultures per condition (72 hr DMSO treated, 72 hr (+)-JQ1 treated, 72 hr Birabresib treated) were harvested in RLTplus Lysis buffer (QIAGEN, 1053393). Total RNA was isolated using the RNeasy micro/mini plus kit (QIAGEN, 74034). Libraries were prepared using Roche Kapa mRNA HyperPrep strand-specific sample preparation kits from 200 ng of purified total RNA according to the manufacturer’s protocol using a Beckman Coulter Biomek i7. The finished dsDNA libraries were quantified by Qubit fluorometer and Agilent TapeStation 4200. Uniquely dual-indexed libraries were pooled in equimolar ratio and subjected to shallow sequencing on an Illumina MiSeq to evaluate library quality and pooling balance. The final pool was sequenced on an Illumina NovaSeq 6000 targeting 30 million 100 bp read pairs per library. Sequenced reads were aligned to the UCSC hg19 reference genome assembly and gene counts were quantified using STAR (v2.7.3a) (<xref ref-type="bibr" rid="bib27">Dobin et al., 2013</xref>). Differential gene expression testing was performed by DESeq2 (v1.22.1) (<xref ref-type="bibr" rid="bib58">Love et al., 2014</xref>). RNAseq analysis was performed using the VIPER snakemake pipeline (<xref ref-type="bibr" rid="bib19">Cornwell et al., 2018</xref>). Library preparation, Illumina sequencing, and VIPER workflow were performed by the Dana-Farber Cancer Institute Molecular Biology Core Facilities.</p></sec><sec id="s4-7"><title>Automated cell plating</title><p>hNs and hpAs were harvested with Accutase (Innovative Cell Technology, Inc, AT104-500), quenched in Neurobasal media, spun 5 min at 1000 rpm at room temperature (RT), passed through a 40 µm filter, and counted using the Countess Automated Cell Counter (Thermo Fisher Scientific, AMQAX1000). Cells were mixed in NBM media to reach a seeding density of 40,000 neurons.cm<sup>–2</sup> and 100,000 astrocytes.cm<sup>–2</sup> per well. A liquid handling dispenser (Personal Pipettor, ApricotDesigns) was used to uniformly plate the cell mixture in the geltrex-coated 60-inner wells of 96-well plates (PerkinElmer, CellCarrier-96, 6005558).</p></sec><sec id="s4-8"><title>Small molecule dilution and addition</title><p>The Selleck library (L3500) consisted of 8 × 96-well plates containing 376 small molecules at 10 mM in DMSO (100%). On the day of small molecule addition, the relevant plate was diluted with an automatic liquid handling dispenser (ApricotDesigns, Personal Pipettor). Each diluted plate was screened on the same day, with each small molecule tested against the cell type of interest in three different 96-well plates (in triplicate) at 3 µM.</p></sec><sec id="s4-9"><title>siRNA-mediated knockdown</title><p>Human SYNAPSIN1 and control siRNA (Accell Dharmacon, A-12362-16-0005 and K-005000-R1-01) were aliquoted (100 µM) and stored at –20°C according to the manufacturer’s recommendations. siRNA (1 µM) in Accell Delivery Media (Accell Dharmacon, B-002222-UB-100) was added to human co-cultures on day 18 of hN differentiation for 72 hr followed by fixation and analysis. Normality was confirmed using the Kolmogorov–Smirnov test.</p></sec><sec id="s4-10"><title>Immunocytochemistry</title><p>Immunofluorescence was performed using an automatic liquid handling dispenser (ApricotDesigns, Personal Pipettor). Cells were washed abundantly in 1× PBS, fixed for 20 min in PFA (4%, Electron Microscopy Sciences, 15714S) plus Sucrose (4%, Sigma, S0389), washed abundantly in 1× PBS, permeabilized and blocked for 20 min in horse serum (4%, Thermo Fisher, 16050114), Triton X-100 (0.3%, Sigma, T9284), and glycine (0.1 M, Sigma, G7126) in 1× PBS. Primary antibodies were then applied at 4°C overnight in 1× PBS supplemented with horse serum (4%, Thermo Fisher, 16050114). The following synaptic antibodies were used: rabbit anti-human SYNAPSIN1 (1:1000, Millipore, AB1543), chicken anti-human MAP2 (1:1000, Abcam, ab5392), mouse anti-synaptophysin (1:500; 7H12 Cell Signaling Technology, 9020), and mouse anti-PSD-95 (1:500 7E3-1B8 Invitrogen, MA1-046). After abundant washes with Triton X-100 (0.3%, Sigma, T9284) in 1× PBS, cells were exposed for 1 hr at RT to secondary antibodies: goat anti-chicken Alexa Fluor 488 (1:1000, Thermo Fisher, A21131), donkey anti-rabbit Alexa Fluor 555 (1:1000, Thermo Fisher, A31572), goat anti-mouse Alexa Fluor 647 (1:1000, Thermo Fisher), as well as DAPI (1:5000, Thermo Fisher Scientific, D1306) and TrueBlack (1:5000, Biotium, 23007) in 1× PBS supplemented with horse serum (4%, Thermo Fisher, 16050114). Finally, cells were abundantly washed with 1× PBS and stored at 4°C.</p></sec><sec id="s4-11"><title>Immunoblotting</title><p>Cell lysates were made from iNGN2-H1 hNs monocultures or from hN + hpA co-cultures (40,000 neurons.cm<sup>–2</sup> and 100,000 astrocytes.cm<sup>–2</sup> per well) on 6-well plates. Medium was refreshed once per week. Cells were treated with the selected small molecules at the optimal concentration for 72 hr starting on day 18 of hN differentiation. Cells were abundantly washed with PBS 1× before lysis in RIPA buffer (Life Technologies, 89901) supplemented with protease and phosphatase inhibitor (Thermo Scientific, 88669). Before blotting, samples were triturated with repetitive up and down using U-100 Insulin Syringe (B-D, 329461), centrifuged at 10,000 × <italic>g</italic> for 15 min at 4°C, and the supernatants were collected. Proteins were denatured by boiling at 95°C for 10 min and subjected to a Pierce BCA protein assay (Life Technologies, 23227) for determination of the protein concentration. For each sample, the same amount of total protein extracted (5–10 µg) was loaded and separated by SDS-PAGE. The proteins were then transferred to a PVDF membrane (Bio-Rad, 1704156), blocked in 5% Difco Skim Milk (BD, 232100) in TBS-Tween 20 (1/1000; Sigma-Aldrich, T5912-1L and P9416-50ML) before blotting with the primary antibodies: rabbit anti-human SYNAPSIN1 (1:1000, Millipore, AB1543), rabbit anti-human Homer (1/500, Synaptic Systems, 160003), rabbit anti-human BAIAP2 (1/500, Thermo Fisher Scientific, PA5-30386), and mouse anti-human GAPDH (1:1000, Millipore, MAB374). For visualization, donkey anti-mouse IRDye 800CW (1:5000, LI-COR, 926-32212) and donkey anti-rabbit IRDye 680RD (1:5000, LI-COR, 926-68073) were used before detection with Odyssey DLx imaging system (LI-COR, 9140).</p></sec><sec id="s4-12"><title>Image acquisition and analysis paradigms</title><sec id="s4-12-1"><title>Plating consistency</title><p>24 hr after co-culture, a random 96-well-plate was fixed and stained. 2 channels (DAPI, MAP2), 4 stacks.field<sup>–1</sup>, each stack separated by 0.5 µm, 25 fields.well<sup>–1</sup>, 60 wells.96-well plate<sup>–1</sup> were acquired at ×20 (Plan Apo λ, NA 0.75, air objective, Nikon) with a high-content screening confocal microscope (ImageXpress Micro 4, Molecular Devices). Acquired images were transferred and stored on a Columbus (PerkinElmer) server. A Columbus Acapella software (PerkinElmer) algorithm was designed to discriminate hN nuclei from hpA nuclei. DAPI and MAP2 channels of each field were merged in a single plane to create maximum projection images. DAPI projected images were filtered using a Gaussian method and the nuclei population was detected based on the C method (diameter &gt;20 µm). Intensity and morphological properties of each identified nuclei were calculated. Among all nuclei, the hN nuclei were identified according to their intensity, contrast, as well as area, roundness, and distinct MAP2-positive soma (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). This script allowed quantification of the mean number (and the standard deviation) of hNs identified in each well, and the coefficient of variance (%) per plate. Thresholding for plating consistency was set above 4000 hNs per well and a covariance below 8% per plate.</p></sec><sec id="s4-12-2"><title>Synapse detection</title><p>Three channels (DAPI, MAP2, SYNAPSIN1), 5–8 stacks.field<sup>–1</sup> at 0.3 µm distance, 12 fields.well<sup>–1</sup>, 60 wells.96-well plate<sup>–1</sup> were acquired with a ×20 objective (NA 1.0, water objective) with a high-content screening confocal microscope (Opera Phenix, PerkinElmer). Image analysis pipelines were built using the open-source CellProfiler 3.1.5 software (<ext-link ext-link-type="uri" xlink:href="https://www.cellprofiler.org/">https://www.cellprofiler.org/</ext-link>; <xref ref-type="bibr" rid="bib15">Carpenter et al., 2006</xref>; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_007358">SCR_007358</ext-link>). Each of the 12 fields per well were analyzed independently. The first pipeline was designed to merge in a single plane (maximum projection) the 5–8 stacks of the raw image for each channel. The output files generated by the first pipeline were the input files for a second pipeline. The second pipeline was developed to report different features in MAP2 and SYNAPSIN1 channels. First, translational misalignment was corrected by maximizing the mutual information of the DAPI and MAP2 channels. The same alignment measurements obtained from the first two input images were applied for the SYNAPSIN1 channel. Illumination correction functions were created by averaging each pixel intensity of all images from each channel across each plate then smoothing the resulting image with a Gaussian filter and a large filter size of 100 × 100 pixels. A rescale intensity function was used to stretch each image of each channel to the full intensity range (so that the minimum intensity value had an intensity of zero and the maximum had an intensity of 1). The MAP2 pixel intensities were enhanced by a tophat Tubeness filter with a scale of 2 sigma of the Gaussian. Once the lower and upper bounds of the three-class Otsu thresholding method were set for the MAP2 pixel detection, the resulting images were converted into segmented objects. The SYNAPSIN1 pixels were enhanced using a tophat Speckles filter, thresholded using a two-class Otsu method, processed for SYNAPSIN1 puncta identification within an equivalent diameter range of 1–6 pixels, and de-clumped before being converted into segmented objects. A colocalization module then assigned the relationships between the identified SYNAPSIN1 puncta contained within or only partly touching the MAP2 objects. Finally, the area and the number of the synaptic objects were measured and exported to a *.csv spreadsheet. The CellProfiler pipelines are available at <ext-link ext-link-type="uri" xlink:href="https://github.com/mberryer/ALPAQAS">https://github.com/mberryer/ALPAQAS</ext-link> (copy archived at <xref ref-type="bibr" rid="bib8">Berryer, 2023</xref>).</p></sec></sec><sec id="s4-13"><title>Data analysis</title><sec id="s4-13-1"><title>Quality control</title><p>The output CellProfiler *.csv files were imported in Genedata Screener. As the *.csv files were loaded, a parameterized parser conducted quality control. The mean and standard deviation of the area covered by MAP2 pixels were calculated across all fields in an inter-plate basis. Fields in which the area covered by MAP2 pixels was outside the range of the inter-plate mean ± standard deviation values were removed. Wells containing fewer than five fields were also excluded. The area and the number of the synaptic objects of the remaining fields were averaged and condensed to well-level before being imported into Genedata Screener to perform relevant calculations.</p></sec><sec id="s4-13-2"><title>Synaptic measurements</title><p>We analyzed the area occupied by MAP2-positive neurites and the number, area, and density of SYNAPSIN1 puncta localized on MAP2-positive neurites (respectively AreaOccupied and Count of MAP2PositiveNeurites and SYNAPSIN1PunctaOnMAP2PositiveNeurites in the ALPAQAS pipeline). On a well-basis, density was defined as the number of SYNAPSIN1-positive puncta colocalized on MAP2-positive pixels divided by the area covered by the MAP2 positive pixels. The mean values for number and density were calculated for each well and expressed as a percentage of the intra-plate DMSO control-treated wells. Computed on an intra-plate basis, the Z-score for the value X was defined as the difference between X and the mean value of all DMSO-treated wells, divided by the standard deviation value of all DMSO-treated wells.</p></sec><sec id="s4-13-3"><title>SynGO analysis</title><p>Individual upregulated DEGs shared between (+)-JQ1 and Birabresib treatment conditions (p<sub>adj</sub>&lt;0.05 and log<sub>2</sub>FC≥1) were used as input with default settings. All genes with average counts ≥1 in the 0.1% DMSO control conditions were used as the background list (for a total of 11,704 genes).</p></sec><sec id="s4-13-4"><title>Power calculations</title><p>Cohen’s d was calculated for each compound compared to DMSO using pooled standard deviation. The statistical power of each compound was calculated from Cohen’s d, number of fields/wells, with alpha 0.05, hypothesis as specified (‘two-sided,’ ‘greater,’ or ‘less’) using the function pwr.norm.test from R package pwr (1.3–0). The number of fields or wells was calculated for increasing Cohen’s d and power, with alpha 0.05, using the function pwr.norm.test from R package pwr (1.3–0). Power plots were generated with ggplot2 (3.3.5).</p></sec></sec><sec id="s4-14"><title>Statistical analyses</title><p>All experiments were performed in three biological replicates and three technical replicates, except the small molecule validation experiments were performed in two biological replicates and eight technical replicates and the siRNA experiment was performed in one biological replicate and six technical replicates. Biological replicates refer to independent batches of cells/differentiations, and technical replicates refer to independent wells. For the dose–response, the small molecule validation, the hN monoculture experiments, and the immunoblot quantification, significance was assessed using one-way ANOVA with Dunnett’s multiple comparisons test; *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001. In the hN + hpA co-culture versus hN monoculture experiment, the quantification of the density and the area of the individual SYNAPSIN1 puncta and the area covered by MAP2-positive neurites, the significance was determined by a Kolmogorov–Smirnov unpaired <italic>t</italic>-test, ***p&lt;0.001. For mRNA-seq analyses, we used an adjusted p-value cutoff of 0.05 and a log<sub>2</sub>fold change cutoff of ±1. p-Values (or adjusted p-values where relevant) 0.05 were considered statistically significant.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>Reviewing editor, eLife. LLR is a founder of Elevian, Rejuveron, and Vesalius Therapeutics, a member of their scientific advisory boards and a private equity shareholder. All are interested in formulating approaches intended to treat diseases of the nervous system and other tissues. He is also on the advisory board of Alkahest, a Grifols company, focused on the plasma proteome and brain aging. None of these companies provided any financial support for the work in this paper</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing, Performed stem cell, neuron and astrocyte cultures, immunostaining, development, optimization and performance of the assays and analyses, and helped to develop CellProfiler pipelines</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Supervision, Methodology, Provided strategic and technical assistance with screening experiments</p></fn><fn fn-type="con" id="con3"><p>Data curation, Investigation, Performed protein expression experiments and analyses</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation, Performed immunostaining and analyses</p></fn><fn fn-type="con" id="con5"><p>Data curation, Investigation, Assisted with cell culture and performed protein expression and immunostaining experiments</p></fn><fn fn-type="con" id="con6"><p>Resources, Generated TALEN edited cell lines</p></fn><fn fn-type="con" id="con7"><p>Resources, Generated TALEN edited cell lines</p></fn><fn fn-type="con" id="con8"><p>Resources, Generated TALEN edited cell lines</p></fn><fn fn-type="con" id="con9"><p>Formal analysis, Performed power calculations</p></fn><fn fn-type="con" id="con10"><p>Software, Methodology, Developed CellProfiler pipelines</p></fn><fn fn-type="con" id="con11"><p>Supervision, Methodology, Writing – review and editing, Developed CellProfiler pipelines</p></fn><fn fn-type="con" id="con12"><p>Supervision, Methodology, Provided strategic and technical assistance with screening experiments</p></fn><fn fn-type="con" id="con13"><p>Supervision, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Supervision, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Supervision, Funding acquisition, Writing – original draft, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>List of the 376 small molecules used in the primary screen including molecule name, synonyms, library, supplier, catalog number, target, additional notes, and pathway.</title></caption><media xlink:href="elife-80168-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Power calculations for the primary screen overall, the primary screen by compound, co-cultures at the field level, co-cultures at the well level, neuron monocultures at the field level, and neuron monocultures at the well level.</title></caption><media xlink:href="elife-80168-supp2-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Transcriptional analyses after (+)-JQ1 inhibition.</title></caption><media xlink:href="elife-80168-supp3-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Transcriptional analyses after Birabresib inhibition.</title></caption><media xlink:href="elife-80168-supp4-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>SynGO analyses including the GO term ID, domain, name, and p-value.</title></caption><media xlink:href="elife-80168-supp5-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-80168-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Data, resource and code availability: All data is available in the manuscript or the supplemental materials. The analysis codes generated in this study are available from GitHub at: <ext-link ext-link-type="uri" xlink:href="https://github.com/mberryer/ALPAQAS">https://github.com/mberryer/ALPAQAS</ext-link> (copy archived at <xref ref-type="bibr" rid="bib8">Berryer, 2023</xref>). Engineered cell lines are available upon request and following appropriate institutional guidelines for their use and distribution.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank members of the Barrett and Rubin labs for insightful discussions and critical reading of the manuscript. We appreciate the support from Ralda Nehme for her useful inputs on the neuronal induction protocol, Maria Alimova and Patrick Byrne at CDoT for their high-throughput imaging expertise, Sam Bryant and Rachel Fox at the Stanley Center for their analytical insights, Jessica Moffitt for technical support, and Francesca Rapino and Maura Charlton for their wisdom and guidance throughout the project. We also thank Ajamete Kaykas and Katie Worringer for the NGN2 AAVS1 targeting construct. We appreciate the analytical support from Zach Herbert at the Dana-Farber Cancer Institute Molecular Biology Core Facilities. This work was supported by a Broad<italic>next</italic>10 grant to LEB and LLR, as well as support from the Stanley Center for Psychiatric Research. KWK, BAC, and AEC were supported in part by a grant from the National Institutes of Health NIH R35 GM122547 to AEC.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>NJ</given-names></name><name><surname>Bennett</surname><given-names>ML</given-names></name><name><surname>Foo</surname><given-names>LC</given-names></name><name><surname>Wang</surname><given-names>GX</given-names></name><name><surname>Chakraborty</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>SJ</given-names></name><name><surname>Barres</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Astrocyte glypicans 4 and 6 promote formation of excitatory synapses via glua1 AMPA receptors</article-title><source>Nature</source><volume>486</volume><fpage>410</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1038/nature11059</pub-id><pub-id pub-id-type="pmid">22722203</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>NJ</given-names></name><name><surname>Eroglu</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cell biology of astrocyte-synapse interactions</article-title><source>Neuron</source><volume>96</volume><fpage>697</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2017.09.056</pub-id><pub-id pub-id-type="pmid">29096081</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arikkath</surname><given-names>J</given-names></name><name><surname>Reichardt</surname><given-names>LF</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Cadherins and catenins at synapses: roles in synaptogenesis and synaptic plasticity</article-title><source>Trends in Neurosciences</source><volume>31</volume><fpage>487</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2008.07.001</pub-id><pub-id pub-id-type="pmid">18684518</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakken</surname><given-names>TE</given-names></name><name><surname>Miller</surname><given-names>JA</given-names></name><name><surname>Ding</surname><given-names>S-L</given-names></name><name><surname>Sunkin</surname><given-names>SM</given-names></name><name><surname>Smith</surname><given-names>KA</given-names></name><name><surname>Ng</surname><given-names>L</given-names></name><name><surname>Szafer</surname><given-names>A</given-names></name><name><surname>Dalley</surname><given-names>RA</given-names></name><name><surname>Royall</surname><given-names>JJ</given-names></name><name><surname>Lemon</surname><given-names>T</given-names></name><name><surname>Shapouri</surname><given-names>S</given-names></name><name><surname>Aiona</surname><given-names>K</given-names></name><name><surname>Arnold</surname><given-names>J</given-names></name><name><surname>Bennett</surname><given-names>JL</given-names></name><name><surname>Bertagnolli</surname><given-names>D</given-names></name><name><surname>Bickley</surname><given-names>K</given-names></name><name><surname>Boe</surname><given-names>A</given-names></name><name><surname>Brouner</surname><given-names>K</given-names></name><name><surname>Butler</surname><given-names>S</given-names></name><name><surname>Byrnes</surname><given-names>E</given-names></name><name><surname>Caldejon</surname><given-names>S</given-names></name><name><surname>Carey</surname><given-names>A</given-names></name><name><surname>Cate</surname><given-names>S</given-names></name><name><surname>Chapin</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Dee</surname><given-names>N</given-names></name><name><surname>Desta</surname><given-names>T</given-names></name><name><surname>Dolbeare</surname><given-names>TA</given-names></name><name><surname>Dotson</surname><given-names>N</given-names></name><name><surname>Ebbert</surname><given-names>A</given-names></name><name><surname>Fulfs</surname><given-names>E</given-names></name><name><surname>Gee</surname><given-names>G</given-names></name><name><surname>Gilbert</surname><given-names>TL</given-names></name><name><surname>Goldy</surname><given-names>J</given-names></name><name><surname>Gourley</surname><given-names>L</given-names></name><name><surname>Gregor</surname><given-names>B</given-names></name><name><surname>Gu</surname><given-names>G</given-names></name><name><surname>Hall</surname><given-names>J</given-names></name><name><surname>Haradon</surname><given-names>Z</given-names></name><name><surname>Haynor</surname><given-names>DR</given-names></name><name><surname>Hejazinia</surname><given-names>N</given-names></name><name><surname>Hoerder-Suabedissen</surname><given-names>A</given-names></name><name><surname>Howard</surname><given-names>R</given-names></name><name><surname>Jochim</surname><given-names>J</given-names></name><name><surname>Kinnunen</surname><given-names>M</given-names></name><name><surname>Kriedberg</surname><given-names>A</given-names></name><name><surname>Kuan</surname><given-names>CL</given-names></name><name><surname>Lau</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>C-K</given-names></name><name><surname>Lee</surname><given-names>F</given-names></name><name><surname>Luong</surname><given-names>L</given-names></name><name><surname>Mastan</surname><given-names>N</given-names></name><name><surname>May</surname><given-names>R</given-names></name><name><surname>Melchor</surname><given-names>J</given-names></name><name><surname>Mosqueda</surname><given-names>N</given-names></name><name><surname>Mott</surname><given-names>E</given-names></name><name><surname>Ngo</surname><given-names>K</given-names></name><name><surname>Nyhus</surname><given-names>J</given-names></name><name><surname>Oldre</surname><given-names>A</given-names></name><name><surname>Olson</surname><given-names>E</given-names></name><name><surname>Parente</surname><given-names>J</given-names></name><name><surname>Parker</surname><given-names>PD</given-names></name><name><surname>Parry</surname><given-names>S</given-names></name><name><surname>Pendergraft</surname><given-names>J</given-names></name><name><surname>Potekhina</surname><given-names>L</given-names></name><name><surname>Reding</surname><given-names>M</given-names></name><name><surname>Riley</surname><given-names>ZL</given-names></name><name><surname>Roberts</surname><given-names>T</given-names></name><name><surname>Rogers</surname><given-names>B</given-names></name><name><surname>Roll</surname><given-names>K</given-names></name><name><surname>Rosen</surname><given-names>D</given-names></name><name><surname>Sandman</surname><given-names>D</given-names></name><name><surname>Sarreal</surname><given-names>M</given-names></name><name><surname>Shapovalova</surname><given-names>N</given-names></name><name><surname>Shi</surname><given-names>S</given-names></name><name><surname>Sjoquist</surname><given-names>N</given-names></name><name><surname>Sodt</surname><given-names>AJ</given-names></name><name><surname>Townsend</surname><given-names>R</given-names></name><name><surname>Velasquez</surname><given-names>L</given-names></name><name><surname>Wagley</surname><given-names>U</given-names></name><name><surname>Wakeman</surname><given-names>WB</given-names></name><name><surname>White</surname><given-names>C</given-names></name><name><surname>Bennett</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Young</surname><given-names>R</given-names></name><name><surname>Youngstrom</surname><given-names>BL</given-names></name><name><surname>Wohnoutka</surname><given-names>P</given-names></name><name><surname>Gibbs</surname><given-names>RA</given-names></name><name><surname>Rogers</surname><given-names>J</given-names></name><name><surname>Hohmann</surname><given-names>JG</given-names></name><name><surname>Hawrylycz</surname><given-names>MJ</given-names></name><name><surname>Hevner</surname><given-names>RF</given-names></name><name><surname>Molnár</surname><given-names>Z</given-names></name><name><surname>Phillips</surname><given-names>JW</given-names></name><name><surname>Dang</surname><given-names>C</given-names></name><name><surname>Jones</surname><given-names>AR</given-names></name><name><surname>Amaral</surname><given-names>DG</given-names></name><name><surname>Bernard</surname><given-names>A</given-names></name><name><surname>Lein</surname><given-names>ES</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A comprehensive transcriptional map of primate brain development</article-title><source>Nature</source><volume>535</volume><fpage>367</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1038/nature18637</pub-id><pub-id pub-id-type="pmid">27409810</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beaulieu-Laroche</surname><given-names>L</given-names></name><name><surname>Toloza</surname><given-names>EHS</given-names></name><name><surname>van der Goes</surname><given-names>M-S</given-names></name><name><surname>Lafourcade</surname><given-names>M</given-names></name><name><surname>Barnagian</surname><given-names>D</given-names></name><name><surname>Williams</surname><given-names>ZM</given-names></name><name><surname>Eskandar</surname><given-names>EN</given-names></name><name><surname>Frosch</surname><given-names>MP</given-names></name><name><surname>Cash</surname><given-names>SS</given-names></name><name><surname>Harnett</surname><given-names>MT</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Enhanced dendritic compartmentalization in human cortical neurons</article-title><source>Cell</source><volume>175</volume><fpage>643</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.08.045</pub-id><pub-id pub-id-type="pmid">30340039</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benavides-Piccione</surname><given-names>R</given-names></name><name><surname>Ballesteros-Yáñez</surname><given-names>I</given-names></name><name><surname>DeFelipe</surname><given-names>J</given-names></name><name><surname>Yuste</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Cortical area and species differences in dendritic spine morphology</article-title><source>Journal of Neurocytology</source><volume>31</volume><fpage>337</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1023/a:1024134312173</pub-id><pub-id pub-id-type="pmid">12815251</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernardinelli</surname><given-names>Y</given-names></name><name><surname>Randall</surname><given-names>J</given-names></name><name><surname>Janett</surname><given-names>E</given-names></name><name><surname>Nikonenko</surname><given-names>I</given-names></name><name><surname>König</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>EV</given-names></name><name><surname>Flores</surname><given-names>CE</given-names></name><name><surname>Murai</surname><given-names>KK</given-names></name><name><surname>Bochet</surname><given-names>CG</given-names></name><name><surname>Holtmaat</surname><given-names>A</given-names></name><name><surname>Muller</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Activity-Dependent structural plasticity of perisynaptic astrocytic domains promotes excitatory synapse stability</article-title><source>Current Biology</source><volume>24</volume><fpage>1679</fpage><lpage>1688</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2014.06.025</pub-id><pub-id pub-id-type="pmid">25042585</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Berryer</surname><given-names>MH</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>ALPAQAS</data-title><version designator="swh:1:rev:880d1348d431b76554bfdde2213d648a15721c01">swh:1:rev:880d1348d431b76554bfdde2213d648a15721c01</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:51b36c61ff74abf7796b4614297972d6e3d19974;origin=https://github.com/mberryer/ALPAQAS;visit=swh:1:snp:000f8720ec299fcf61c10c94f72950b4c56631a9;anchor=swh:1:rev:880d1348d431b76554bfdde2213d648a15721c01">https://archive.softwareheritage.org/swh:1:dir:51b36c61ff74abf7796b4614297972d6e3d19974;origin=https://github.com/mberryer/ALPAQAS;visit=swh:1:snp:000f8720ec299fcf61c10c94f72950b4c56631a9;anchor=swh:1:rev:880d1348d431b76554bfdde2213d648a15721c01</ext-link></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boccadoro</surname><given-names>M</given-names></name><name><surname>Morgan</surname><given-names>G</given-names></name><name><surname>Cavenagh</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy</article-title><source>Cancer Cell International</source><volume>5</volume><elocation-id>18</elocation-id><pub-id pub-id-type="doi">10.1186/1475-2867-5-18</pub-id><pub-id pub-id-type="pmid">15929791</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourgeron</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>From the genetic architecture to synaptic plasticity in autism spectrum disorder</article-title><source>Nature Reviews. Neuroscience</source><volume>16</volume><fpage>551</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1038/nrn3992</pub-id><pub-id pub-id-type="pmid">26289574</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brownjohn</surname><given-names>PW</given-names></name><name><surname>Smith</surname><given-names>J</given-names></name><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Serneels</surname><given-names>L</given-names></name><name><surname>Kvartsberg</surname><given-names>H</given-names></name><name><surname>De Strooper</surname><given-names>B</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Livesey</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Phenotypic screening identifies modulators of amyloid precursor protein processing in human stem cell models of Alzheimer’s disease</article-title><source>Stem Cell Reports</source><volume>8</volume><fpage>870</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2017.02.006</pub-id><pub-id pub-id-type="pmid">28285880</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bullock</surname><given-names>TH</given-names></name><name><surname>Hagiwara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1957">1957</year><article-title>Intracellular recording from the giant synapse of the squid</article-title><source>The Journal of General Physiology</source><volume>40</volume><fpage>565</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1085/jgp.40.4.565</pub-id><pub-id pub-id-type="pmid">13416531</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busskamp</surname><given-names>V</given-names></name><name><surname>Lewis</surname><given-names>NE</given-names></name><name><surname>Guye</surname><given-names>P</given-names></name><name><surname>Ng</surname><given-names>AHM</given-names></name><name><surname>Shipman</surname><given-names>SL</given-names></name><name><surname>Byrne</surname><given-names>SM</given-names></name><name><surname>Sanjana</surname><given-names>NE</given-names></name><name><surname>Murn</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Stadler</surname><given-names>M</given-names></name><name><surname>Weiss</surname><given-names>R</given-names></name><name><surname>Church</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Rapid neurogenesis through transcriptional activation in human stem cells</article-title><source>Molecular Systems Biology</source><volume>10</volume><elocation-id>760</elocation-id><pub-id pub-id-type="doi">10.15252/msb.20145508</pub-id><pub-id pub-id-type="pmid">25403753</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caceres</surname><given-names>A</given-names></name><name><surname>Binder</surname><given-names>LI</given-names></name><name><surname>Payne</surname><given-names>MR</given-names></name><name><surname>Bender</surname><given-names>P</given-names></name><name><surname>Rebhun</surname><given-names>L</given-names></name><name><surname>Steward</surname><given-names>O</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>Differential subcellular localization of tubulin and the microtubule-associated protein MAP2 in brain tissue as revealed by immunocytochemistry with monoclonal hybridoma antibodies</article-title><source>The Journal of Neuroscience</source><volume>4</volume><fpage>394</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.04-02-00394.1984</pub-id><pub-id pub-id-type="pmid">6699682</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carpenter</surname><given-names>AE</given-names></name><name><surname>Jones</surname><given-names>TR</given-names></name><name><surname>Lamprecht</surname><given-names>MR</given-names></name><name><surname>Clarke</surname><given-names>C</given-names></name><name><surname>Kang</surname><given-names>IH</given-names></name><name><surname>Friman</surname><given-names>O</given-names></name><name><surname>Guertin</surname><given-names>DA</given-names></name><name><surname>Chang</surname><given-names>JH</given-names></name><name><surname>Lindquist</surname><given-names>RA</given-names></name><name><surname>Moffat</surname><given-names>J</given-names></name><name><surname>Golland</surname><given-names>P</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>CellProfiler: image analysis software for identifying and quantifying cell phenotypes</article-title><source>Genome Biology</source><volume>7</volume><elocation-id>R100</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2006-7-10-r100</pub-id><pub-id pub-id-type="pmid">17076895</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chambers</surname><given-names>SM</given-names></name><name><surname>Fasano</surname><given-names>CA</given-names></name><name><surname>Papapetrou</surname><given-names>EP</given-names></name><name><surname>Tomishima</surname><given-names>M</given-names></name><name><surname>Sadelain</surname><given-names>M</given-names></name><name><surname>Studer</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Highly efficient neural conversion of human ES and iPS cells by dual inhibition of Smad signaling</article-title><source>Nature Biotechnology</source><volume>27</volume><fpage>275</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1038/nbt.1529</pub-id><pub-id pub-id-type="pmid">19252484</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chanda</surname><given-names>S</given-names></name><name><surname>Ang</surname><given-names>CE</given-names></name><name><surname>Lee</surname><given-names>QY</given-names></name><name><surname>Ghebrial</surname><given-names>M</given-names></name><name><surname>Haag</surname><given-names>D</given-names></name><name><surname>Shibuya</surname><given-names>Y</given-names></name><name><surname>Wernig</surname><given-names>M</given-names></name><name><surname>Südhof</surname><given-names>TC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Direct reprogramming of human neurons identifies MARCKSL1 as a pathogenic mediator of valproic acid-induced teratogenicity</article-title><source>Cell Stem Cell</source><volume>25</volume><fpage>103</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2019.04.021</pub-id><pub-id pub-id-type="pmid">31155484</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>WS</given-names></name><name><surname>Allen</surname><given-names>NJ</given-names></name><name><surname>Eroglu</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Astrocytes control synapse formation, function, and elimination</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>7</volume><elocation-id>a020370</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a020370</pub-id><pub-id pub-id-type="pmid">25663667</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cornwell</surname><given-names>M</given-names></name><name><surname>Vangala</surname><given-names>M</given-names></name><name><surname>Taing</surname><given-names>L</given-names></name><name><surname>Herbert</surname><given-names>Z</given-names></name><name><surname>Köster</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name><name><surname>Pun</surname><given-names>M</given-names></name><name><surname>Jeselsohn</surname><given-names>R</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>XS</given-names></name><name><surname>Long</surname><given-names>HW</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Viper: visualization pipeline for RNA-seq, a snakemake workflow for efficient and complete RNA-seq analysis</article-title><source>BMC Bioinformatics</source><volume>19</volume><elocation-id>135</elocation-id><pub-id pub-id-type="doi">10.1186/s12859-018-2139-9</pub-id><pub-id pub-id-type="pmid">29649993</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cullen</surname><given-names>DK</given-names></name><name><surname>Gilroy</surname><given-names>ME</given-names></name><name><surname>Irons</surname><given-names>HR</given-names></name><name><surname>Laplaca</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Synapse-to-neuron ratio is inversely related to neuronal density in mature neuronal cultures</article-title><source>Brain Research</source><volume>1359</volume><fpage>44</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2010.08.058</pub-id><pub-id pub-id-type="pmid">20800585</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danielson</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>SynPAnal: software for rapid quantification of the density and intensity of protein puncta from fluorescence microscopy images of neurons</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e115298</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0115298</pub-id><pub-id pub-id-type="pmid">25531531</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeFelipe</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The evolution of the brain, the human nature of cortical circuits, and intellectual creativity</article-title><source>Frontiers in Neuroanatomy</source><volume>5</volume><elocation-id>29</elocation-id><pub-id pub-id-type="doi">10.3389/fnana.2011.00029</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Rubeis</surname><given-names>S</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Goldberg</surname><given-names>AP</given-names></name><name><surname>Poultney</surname><given-names>CS</given-names></name><name><surname>Samocha</surname><given-names>K</given-names></name><name><surname>Cicek</surname><given-names>AE</given-names></name><name><surname>Kou</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Fromer</surname><given-names>M</given-names></name><name><surname>Walker</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>T</given-names></name><name><surname>Klei</surname><given-names>L</given-names></name><name><surname>Kosmicki</surname><given-names>J</given-names></name><name><surname>Shih-Chen</surname><given-names>F</given-names></name><name><surname>Aleksic</surname><given-names>B</given-names></name><name><surname>Biscaldi</surname><given-names>M</given-names></name><name><surname>Bolton</surname><given-names>PF</given-names></name><name><surname>Brownfeld</surname><given-names>JM</given-names></name><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Campbell</surname><given-names>NG</given-names></name><name><surname>Carracedo</surname><given-names>A</given-names></name><name><surname>Chahrour</surname><given-names>MH</given-names></name><name><surname>Chiocchetti</surname><given-names>AG</given-names></name><name><surname>Coon</surname><given-names>H</given-names></name><name><surname>Crawford</surname><given-names>EL</given-names></name><name><surname>Curran</surname><given-names>SR</given-names></name><name><surname>Dawson</surname><given-names>G</given-names></name><name><surname>Duketis</surname><given-names>E</given-names></name><name><surname>Fernandez</surname><given-names>BA</given-names></name><name><surname>Gallagher</surname><given-names>L</given-names></name><name><surname>Geller</surname><given-names>E</given-names></name><name><surname>Guter</surname><given-names>SJ</given-names></name><name><surname>Hill</surname><given-names>RS</given-names></name><name><surname>Ionita-Laza</surname><given-names>J</given-names></name><name><surname>Jimenz Gonzalez</surname><given-names>P</given-names></name><name><surname>Kilpinen</surname><given-names>H</given-names></name><name><surname>Klauck</surname><given-names>SM</given-names></name><name><surname>Kolevzon</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>I</given-names></name><name><surname>Lei</surname><given-names>I</given-names></name><name><surname>Lei</surname><given-names>J</given-names></name><name><surname>Lehtimäki</surname><given-names>T</given-names></name><name><surname>Lin</surname><given-names>C-F</given-names></name><name><surname>Ma’ayan</surname><given-names>A</given-names></name><name><surname>Marshall</surname><given-names>CR</given-names></name><name><surname>McInnes</surname><given-names>AL</given-names></name><name><surname>Neale</surname><given-names>B</given-names></name><name><surname>Owen</surname><given-names>MJ</given-names></name><name><surname>Ozaki</surname><given-names>N</given-names></name><name><surname>Parellada</surname><given-names>M</given-names></name><name><surname>Parr</surname><given-names>JR</given-names></name><name><surname>Purcell</surname><given-names>S</given-names></name><name><surname>Puura</surname><given-names>K</given-names></name><name><surname>Rajagopalan</surname><given-names>D</given-names></name><name><surname>Rehnström</surname><given-names>K</given-names></name><name><surname>Reichenberg</surname><given-names>A</given-names></name><name><surname>Sabo</surname><given-names>A</given-names></name><name><surname>Sachse</surname><given-names>M</given-names></name><name><surname>Sanders</surname><given-names>SJ</given-names></name><name><surname>Schafer</surname><given-names>C</given-names></name><name><surname>Schulte-Rüther</surname><given-names>M</given-names></name><name><surname>Skuse</surname><given-names>D</given-names></name><name><surname>Stevens</surname><given-names>C</given-names></name><name><surname>Szatmari</surname><given-names>P</given-names></name><name><surname>Tammimies</surname><given-names>K</given-names></name><name><surname>Valladares</surname><given-names>O</given-names></name><name><surname>Voran</surname><given-names>A</given-names></name><name><surname>Li-San</surname><given-names>W</given-names></name><name><surname>Weiss</surname><given-names>LA</given-names></name><name><surname>Willsey</surname><given-names>AJ</given-names></name><name><surname>Yu</surname><given-names>TW</given-names></name><name><surname>Yuen</surname><given-names>RKC</given-names></name><collab>DDD Study</collab><collab>Homozygosity Mapping Collaborative for Autism</collab><collab>UK10K Consortium</collab><name><surname>Cook</surname><given-names>EH</given-names></name><name><surname>Freitag</surname><given-names>CM</given-names></name><name><surname>Gill</surname><given-names>M</given-names></name><name><surname>Hultman</surname><given-names>CM</given-names></name><name><surname>Lehner</surname><given-names>T</given-names></name><name><surname>Palotie</surname><given-names>A</given-names></name><name><surname>Schellenberg</surname><given-names>GD</given-names></name><name><surname>Sklar</surname><given-names>P</given-names></name><name><surname>State</surname><given-names>MW</given-names></name><name><surname>Sutcliffe</surname><given-names>JS</given-names></name><name><surname>Walsh</surname><given-names>CA</given-names></name><name><surname>Scherer</surname><given-names>SW</given-names></name><name><surname>Zwick</surname><given-names>ME</given-names></name><name><surname>Barett</surname><given-names>JC</given-names></name><name><surname>Cutler</surname><given-names>DJ</given-names></name><name><surname>Roeder</surname><given-names>K</given-names></name><name><surname>Devlin</surname><given-names>B</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>Buxbaum</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Synaptic, transcriptional and chromatin genes disrupted in autism</article-title><source>Nature</source><volume>515</volume><fpage>209</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1038/nature13772</pub-id><pub-id pub-id-type="pmid">25363760</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>del Castillo</surname><given-names>J</given-names></name><name><surname>Katz</surname><given-names>B</given-names></name></person-group><year iso-8601-date="1954">1954</year><article-title>Quantal components of the end-plate potential</article-title><source>The Journal of Physiology</source><volume>124</volume><fpage>560</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.1954.sp005129</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deneault</surname><given-names>E</given-names></name><name><surname>White</surname><given-names>SH</given-names></name><name><surname>Rodrigues</surname><given-names>DC</given-names></name><name><surname>Ross</surname><given-names>PJ</given-names></name><name><surname>Faheem</surname><given-names>M</given-names></name><name><surname>Zaslavsky</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Alexandrova</surname><given-names>R</given-names></name><name><surname>Pellecchia</surname><given-names>G</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Piekna</surname><given-names>A</given-names></name><name><surname>Kaur</surname><given-names>G</given-names></name><name><surname>Howe</surname><given-names>JL</given-names></name><name><surname>Kwan</surname><given-names>V</given-names></name><name><surname>Thiruvahindrapuram</surname><given-names>B</given-names></name><name><surname>Walker</surname><given-names>S</given-names></name><name><surname>Lionel</surname><given-names>AC</given-names></name><name><surname>Pasceri</surname><given-names>P</given-names></name><name><surname>Merico</surname><given-names>D</given-names></name><name><surname>Yuen</surname><given-names>RKC</given-names></name><name><surname>Singh</surname><given-names>KK</given-names></name><name><surname>Ellis</surname><given-names>J</given-names></name><name><surname>Scherer</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Complete disruption of autism-susceptibility genes by gene editing predominantly reduces functional connectivity of isogenic human neurons</article-title><source>Stem Cell Reports</source><volume>11</volume><fpage>1211</fpage><lpage>1225</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2018.10.003</pub-id><pub-id pub-id-type="pmid">30392976</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Castro</surname><given-names>MA</given-names></name><name><surname>Chuquet</surname><given-names>J</given-names></name><name><surname>Liaudet</surname><given-names>N</given-names></name><name><surname>Bhaukaurally</surname><given-names>K</given-names></name><name><surname>Santello</surname><given-names>M</given-names></name><name><surname>Bouvier</surname><given-names>D</given-names></name><name><surname>Tiret</surname><given-names>P</given-names></name><name><surname>Volterra</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Local Ca2+ detection and modulation of synaptic release by astrocytes</article-title><source>Nature Neuroscience</source><volume>14</volume><fpage>1276</fpage><lpage>1284</lpage><pub-id pub-id-type="doi">10.1038/nn.2929</pub-id><pub-id pub-id-type="pmid">21909085</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Drenkow</surname><given-names>J</given-names></name><name><surname>Zaleski</surname><given-names>C</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><name><surname>Batut</surname><given-names>P</given-names></name><name><surname>Chaisson</surname><given-names>M</given-names></name><name><surname>Gingeras</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Star: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elmariah</surname><given-names>SB</given-names></name><name><surname>Crumling</surname><given-names>MA</given-names></name><name><surname>Parsons</surname><given-names>TD</given-names></name><name><surname>Balice-Gordon</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Postsynaptic trkb-mediated signaling modulates excitatory and inhibitory neurotransmitter receptor clustering at hippocampal synapses</article-title><source>The Journal of Neuroscience</source><volume>24</volume><fpage>2380</fpage><lpage>2393</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4112-03.2004</pub-id><pub-id pub-id-type="pmid">15014113</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eyal</surname><given-names>G</given-names></name><name><surname>Verhoog</surname><given-names>MB</given-names></name><name><surname>Testa-Silva</surname><given-names>G</given-names></name><name><surname>Deitcher</surname><given-names>Y</given-names></name><name><surname>Lodder</surname><given-names>JC</given-names></name><name><surname>Benavides-Piccione</surname><given-names>R</given-names></name><name><surname>Morales</surname><given-names>J</given-names></name><name><surname>DeFelipe</surname><given-names>J</given-names></name><name><surname>de Kock</surname><given-names>CP</given-names></name><name><surname>Mansvelder</surname><given-names>HD</given-names></name><name><surname>Segev</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Unique membrane properties and enhanced signal processing in human neocortical neurons</article-title><source>eLife</source><volume>5</volume><elocation-id>e16553</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.16553</pub-id><pub-id pub-id-type="pmid">27710767</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>HV</given-names></name><name><surname>Bresler</surname><given-names>T</given-names></name><name><surname>Garner</surname><given-names>CC</given-names></name><name><surname>Ziv</surname><given-names>NE</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Assembly of new individual excitatory synapses: time course and temporal order of synaptic molecule recruitment</article-title><source>Neuron</source><volume>27</volume><fpage>57</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/s0896-6273(00)00009-x</pub-id><pub-id pub-id-type="pmid">10939331</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fromer</surname><given-names>M</given-names></name><name><surname>Pocklington</surname><given-names>AJ</given-names></name><name><surname>Kavanagh</surname><given-names>DH</given-names></name><name><surname>Williams</surname><given-names>HJ</given-names></name><name><surname>Dwyer</surname><given-names>S</given-names></name><name><surname>Gormley</surname><given-names>P</given-names></name><name><surname>Georgieva</surname><given-names>L</given-names></name><name><surname>Rees</surname><given-names>E</given-names></name><name><surname>Palta</surname><given-names>P</given-names></name><name><surname>Ruderfer</surname><given-names>DM</given-names></name><name><surname>Carrera</surname><given-names>N</given-names></name><name><surname>Humphreys</surname><given-names>I</given-names></name><name><surname>Johnson</surname><given-names>JS</given-names></name><name><surname>Roussos</surname><given-names>P</given-names></name><name><surname>Barker</surname><given-names>DD</given-names></name><name><surname>Banks</surname><given-names>E</given-names></name><name><surname>Milanova</surname><given-names>V</given-names></name><name><surname>Grant</surname><given-names>SG</given-names></name><name><surname>Hannon</surname><given-names>E</given-names></name><name><surname>Rose</surname><given-names>SA</given-names></name><name><surname>Chambert</surname><given-names>K</given-names></name><name><surname>Mahajan</surname><given-names>M</given-names></name><name><surname>Scolnick</surname><given-names>EM</given-names></name><name><surname>Moran</surname><given-names>JL</given-names></name><name><surname>Kirov</surname><given-names>G</given-names></name><name><surname>Palotie</surname><given-names>A</given-names></name><name><surname>McCarroll</surname><given-names>SA</given-names></name><name><surname>Holmans</surname><given-names>P</given-names></name><name><surname>Sklar</surname><given-names>P</given-names></name><name><surname>Owen</surname><given-names>MJ</given-names></name><name><surname>Purcell</surname><given-names>SM</given-names></name><name><surname>O’Donovan</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>De novo mutations in schizophrenia implicate synaptic networks</article-title><source>Nature</source><volume>506</volume><fpage>179</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1038/nature12929</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>González</surname><given-names>F</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Shi</surname><given-names>Z-D</given-names></name><name><surname>Lelli</surname><given-names>K</given-names></name><name><surname>Verma</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>QV</given-names></name><name><surname>Huangfu</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>An icrispr platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells</article-title><source>Cell Stem Cell</source><volume>15</volume><fpage>215</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2014.05.018</pub-id><pub-id pub-id-type="pmid">24931489</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graf</surname><given-names>ER</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Jin</surname><given-names>SX</given-names></name><name><surname>Linhoff</surname><given-names>MW</given-names></name><name><surname>Craig</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Neurexins induce differentiation of GABA and glutamate postsynaptic specializations via neuroligins</article-title><source>Cell</source><volume>119</volume><fpage>1013</fpage><lpage>1026</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2004.11.035</pub-id><pub-id pub-id-type="pmid">15620359</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>MV</given-names></name><name><surname>Pengo</surname><given-names>T</given-names></name><name><surname>Raybuck</surname><given-names>JD</given-names></name><name><surname>Naqvi</surname><given-names>T</given-names></name><name><surname>McMullan</surname><given-names>HM</given-names></name><name><surname>Hawkinson</surname><given-names>JE</given-names></name><name><surname>Marron Fernandez de Velasco</surname><given-names>E</given-names></name><name><surname>Muntean</surname><given-names>BS</given-names></name><name><surname>Martemyanov</surname><given-names>KA</given-names></name><name><surname>Satterfield</surname><given-names>R</given-names></name><name><surname>Young</surname><given-names>SM</given-names></name><name><surname>Thayer</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Automated live-cell imaging of synapses in rat and human neuronal cultures</article-title><source>Frontiers in Cellular Neuroscience</source><volume>13</volume><elocation-id>467</elocation-id><pub-id pub-id-type="doi">10.3389/fncel.2019.00467</pub-id><pub-id pub-id-type="pmid">31680875</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawrylycz</surname><given-names>MJ</given-names></name><name><surname>Lein</surname><given-names>ES</given-names></name><name><surname>Guillozet-Bongaarts</surname><given-names>AL</given-names></name><name><surname>Shen</surname><given-names>EH</given-names></name><name><surname>Ng</surname><given-names>L</given-names></name><name><surname>Miller</surname><given-names>JA</given-names></name><name><surname>van de Lagemaat</surname><given-names>LN</given-names></name><name><surname>Smith</surname><given-names>KA</given-names></name><name><surname>Ebbert</surname><given-names>A</given-names></name><name><surname>Riley</surname><given-names>ZL</given-names></name><name><surname>Abajian</surname><given-names>C</given-names></name><name><surname>Beckmann</surname><given-names>CF</given-names></name><name><surname>Bernard</surname><given-names>A</given-names></name><name><surname>Bertagnolli</surname><given-names>D</given-names></name><name><surname>Boe</surname><given-names>AF</given-names></name><name><surname>Cartagena</surname><given-names>PM</given-names></name><name><surname>Chakravarty</surname><given-names>MM</given-names></name><name><surname>Chapin</surname><given-names>M</given-names></name><name><surname>Chong</surname><given-names>J</given-names></name><name><surname>Dalley</surname><given-names>RA</given-names></name><name><surname>David Daly</surname><given-names>B</given-names></name><name><surname>Dang</surname><given-names>C</given-names></name><name><surname>Datta</surname><given-names>S</given-names></name><name><surname>Dee</surname><given-names>N</given-names></name><name><surname>Dolbeare</surname><given-names>TA</given-names></name><name><surname>Faber</surname><given-names>V</given-names></name><name><surname>Feng</surname><given-names>D</given-names></name><name><surname>Fowler</surname><given-names>DR</given-names></name><name><surname>Goldy</surname><given-names>J</given-names></name><name><surname>Gregor</surname><given-names>BW</given-names></name><name><surname>Haradon</surname><given-names>Z</given-names></name><name><surname>Haynor</surname><given-names>DR</given-names></name><name><surname>Hohmann</surname><given-names>JG</given-names></name><name><surname>Horvath</surname><given-names>S</given-names></name><name><surname>Howard</surname><given-names>RE</given-names></name><name><surname>Jeromin</surname><given-names>A</given-names></name><name><surname>Jochim</surname><given-names>JM</given-names></name><name><surname>Kinnunen</surname><given-names>M</given-names></name><name><surname>Lau</surname><given-names>C</given-names></name><name><surname>Lazarz</surname><given-names>ET</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Lemon</surname><given-names>TA</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Morris</surname><given-names>JA</given-names></name><name><surname>Overly</surname><given-names>CC</given-names></name><name><surname>Parker</surname><given-names>PD</given-names></name><name><surname>Parry</surname><given-names>SE</given-names></name><name><surname>Reding</surname><given-names>M</given-names></name><name><surname>Royall</surname><given-names>JJ</given-names></name><name><surname>Schulkin</surname><given-names>J</given-names></name><name><surname>Sequeira</surname><given-names>PA</given-names></name><name><surname>Slaughterbeck</surname><given-names>CR</given-names></name><name><surname>Smith</surname><given-names>SC</given-names></name><name><surname>Sodt</surname><given-names>AJ</given-names></name><name><surname>Sunkin</surname><given-names>SM</given-names></name><name><surname>Swanson</surname><given-names>BE</given-names></name><name><surname>Vawter</surname><given-names>MP</given-names></name><name><surname>Williams</surname><given-names>D</given-names></name><name><surname>Wohnoutka</surname><given-names>P</given-names></name><name><surname>Zielke</surname><given-names>HR</given-names></name><name><surname>Geschwind</surname><given-names>DH</given-names></name><name><surname>Hof</surname><given-names>PR</given-names></name><name><surname>Smith</surname><given-names>SM</given-names></name><name><surname>Koch</surname><given-names>C</given-names></name><name><surname>Grant</surname><given-names>SGN</given-names></name><name><surname>Jones</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>An anatomically comprehensive atlas of the adult human brain transcriptome</article-title><source>Nature</source><volume>489</volume><fpage>391</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1038/nature11405</pub-id><pub-id pub-id-type="pmid">22996553</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hazelbaker</surname><given-names>DZ</given-names></name><name><surname>Beccard</surname><given-names>A</given-names></name><name><surname>Bara</surname><given-names>AM</given-names></name><name><surname>Dabkowski</surname><given-names>N</given-names></name><name><surname>Messana</surname><given-names>A</given-names></name><name><surname>Mazzucato</surname><given-names>P</given-names></name><name><surname>Lam</surname><given-names>D</given-names></name><name><surname>Manning</surname><given-names>D</given-names></name><name><surname>Eggan</surname><given-names>K</given-names></name><name><surname>Barrett</surname><given-names>LE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A scaled framework for CRISPR editing of human pluripotent stem cells to study psychiatric disease</article-title><source>Stem Cell Reports</source><volume>9</volume><fpage>1315</fpage><lpage>1327</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2017.09.006</pub-id><pub-id pub-id-type="pmid">29020615</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hazelbaker</surname><given-names>DZ</given-names></name><name><surname>Beccard</surname><given-names>A</given-names></name><name><surname>Angelini</surname><given-names>G</given-names></name><name><surname>Mazzucato</surname><given-names>P</given-names></name><name><surname>Messana</surname><given-names>A</given-names></name><name><surname>Lam</surname><given-names>D</given-names></name><name><surname>Eggan</surname><given-names>K</given-names></name><name><surname>Barrett</surname><given-names>LE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A multiplexed grna piggybac transposon system facilitates efficient induction of crispri and crispra in human pluripotent stem cells</article-title><source>Scientific Reports</source><volume>10</volume><elocation-id>635</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-57500-1</pub-id><pub-id pub-id-type="pmid">31959800</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hempel</surname><given-names>CM</given-names></name><name><surname>Sivula</surname><given-names>M</given-names></name><name><surname>Levenson</surname><given-names>JM</given-names></name><name><surname>Rose</surname><given-names>DM</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Sirianni</surname><given-names>AC</given-names></name><name><surname>Xia</surname><given-names>E</given-names></name><name><surname>Ryan</surname><given-names>TA</given-names></name><name><surname>Gerber</surname><given-names>DJ</given-names></name><name><surname>Cottrell</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A system for performing high throughput assays of synaptic function</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e25999</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0025999</pub-id><pub-id pub-id-type="pmid">21998743</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henderson</surname><given-names>NT</given-names></name><name><surname>Dalva</surname><given-names>MB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>EphBs and ephrin-bs: trans-synaptic organizers of synapse development and function</article-title><source>Molecular and Cellular Neurosciences</source><volume>91</volume><fpage>108</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.mcn.2018.07.002</pub-id><pub-id pub-id-type="pmid">30031105</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>HIPSCI Consortium</collab><name><surname>Schwartzentruber</surname><given-names>J</given-names></name><name><surname>Foskolou</surname><given-names>S</given-names></name><name><surname>Kilpinen</surname><given-names>H</given-names></name><name><surname>Rodrigues</surname><given-names>J</given-names></name><name><surname>Alasoo</surname><given-names>K</given-names></name><name><surname>Knights</surname><given-names>AJ</given-names></name><name><surname>Patel</surname><given-names>M</given-names></name><name><surname>Goncalves</surname><given-names>A</given-names></name><name><surname>Ferreira</surname><given-names>R</given-names></name><name><surname>Benn</surname><given-names>CL</given-names></name><name><surname>Wilbrey</surname><given-names>A</given-names></name><name><surname>Bictash</surname><given-names>M</given-names></name><name><surname>Impey</surname><given-names>E</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Lainez</surname><given-names>S</given-names></name><name><surname>Loucif</surname><given-names>AJ</given-names></name><name><surname>Whiting</surname><given-names>PJ</given-names></name><name><surname>Gutteridge</surname><given-names>A</given-names></name><name><surname>Gaffney</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Molecular and functional variation in iPSC-derived sensory neurons</article-title><source>Nature Genetics</source><volume>50</volume><fpage>54</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1038/s41588-017-0005-8</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodge</surname><given-names>RD</given-names></name><name><surname>Bakken</surname><given-names>TE</given-names></name><name><surname>Miller</surname><given-names>JA</given-names></name><name><surname>Smith</surname><given-names>KA</given-names></name><name><surname>Barkan</surname><given-names>ER</given-names></name><name><surname>Graybuck</surname><given-names>LT</given-names></name><name><surname>Close</surname><given-names>JL</given-names></name><name><surname>Long</surname><given-names>B</given-names></name><name><surname>Johansen</surname><given-names>N</given-names></name><name><surname>Penn</surname><given-names>O</given-names></name><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Eggermont</surname><given-names>J</given-names></name><name><surname>Höllt</surname><given-names>T</given-names></name><name><surname>Levi</surname><given-names>BP</given-names></name><name><surname>Shehata</surname><given-names>SI</given-names></name><name><surname>Aevermann</surname><given-names>B</given-names></name><name><surname>Beller</surname><given-names>A</given-names></name><name><surname>Bertagnolli</surname><given-names>D</given-names></name><name><surname>Brouner</surname><given-names>K</given-names></name><name><surname>Casper</surname><given-names>T</given-names></name><name><surname>Cobbs</surname><given-names>C</given-names></name><name><surname>Dalley</surname><given-names>R</given-names></name><name><surname>Dee</surname><given-names>N</given-names></name><name><surname>Ding</surname><given-names>S-L</given-names></name><name><surname>Ellenbogen</surname><given-names>RG</given-names></name><name><surname>Fong</surname><given-names>O</given-names></name><name><surname>Garren</surname><given-names>E</given-names></name><name><surname>Goldy</surname><given-names>J</given-names></name><name><surname>Gwinn</surname><given-names>RP</given-names></name><name><surname>Hirschstein</surname><given-names>D</given-names></name><name><surname>Keene</surname><given-names>CD</given-names></name><name><surname>Keshk</surname><given-names>M</given-names></name><name><surname>Ko</surname><given-names>AL</given-names></name><name><surname>Lathia</surname><given-names>K</given-names></name><name><surname>Mahfouz</surname><given-names>A</given-names></name><name><surname>Maltzer</surname><given-names>Z</given-names></name><name><surname>McGraw</surname><given-names>M</given-names></name><name><surname>Nguyen</surname><given-names>TN</given-names></name><name><surname>Nyhus</surname><given-names>J</given-names></name><name><surname>Ojemann</surname><given-names>JG</given-names></name><name><surname>Oldre</surname><given-names>A</given-names></name><name><surname>Parry</surname><given-names>S</given-names></name><name><surname>Reynolds</surname><given-names>S</given-names></name><name><surname>Rimorin</surname><given-names>C</given-names></name><name><surname>Shapovalova</surname><given-names>NV</given-names></name><name><surname>Somasundaram</surname><given-names>S</given-names></name><name><surname>Szafer</surname><given-names>A</given-names></name><name><surname>Thomsen</surname><given-names>ER</given-names></name><name><surname>Tieu</surname><given-names>M</given-names></name><name><surname>Quon</surname><given-names>G</given-names></name><name><surname>Scheuermann</surname><given-names>RH</given-names></name><name><surname>Yuste</surname><given-names>R</given-names></name><name><surname>Sunkin</surname><given-names>SM</given-names></name><name><surname>Lelieveldt</surname><given-names>B</given-names></name><name><surname>Feng</surname><given-names>D</given-names></name><name><surname>Ng</surname><given-names>L</given-names></name><name><surname>Bernard</surname><given-names>A</given-names></name><name><surname>Hawrylycz</surname><given-names>M</given-names></name><name><surname>Phillips</surname><given-names>JW</given-names></name><name><surname>Tasic</surname><given-names>B</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Jones</surname><given-names>AR</given-names></name><name><surname>Koch</surname><given-names>C</given-names></name><name><surname>Lein</surname><given-names>ES</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Conserved cell types with divergent features in human versus mouse cortex</article-title><source>Nature</source><volume>573</volume><fpage>61</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1506-7</pub-id><pub-id pub-id-type="pmid">31435019</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Israel</surname><given-names>MA</given-names></name><name><surname>Yuan</surname><given-names>SH</given-names></name><name><surname>Bardy</surname><given-names>C</given-names></name><name><surname>Reyna</surname><given-names>SM</given-names></name><name><surname>Mu</surname><given-names>Y</given-names></name><name><surname>Herrera</surname><given-names>C</given-names></name><name><surname>Hefferan</surname><given-names>MP</given-names></name><name><surname>Van Gorp</surname><given-names>S</given-names></name><name><surname>Nazor</surname><given-names>KL</given-names></name><name><surname>Boscolo</surname><given-names>FS</given-names></name><name><surname>Carson</surname><given-names>CT</given-names></name><name><surname>Laurent</surname><given-names>LC</given-names></name><name><surname>Marsala</surname><given-names>M</given-names></name><name><surname>Gage</surname><given-names>FH</given-names></name><name><surname>Remes</surname><given-names>AM</given-names></name><name><surname>Koo</surname><given-names>EH</given-names></name><name><surname>Goldstein</surname><given-names>LSB</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells</article-title><source>Nature</source><volume>482</volume><fpage>216</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1038/nature10821</pub-id><pub-id pub-id-type="pmid">22278060</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>MA</given-names></name><name><surname>Weick</surname><given-names>JP</given-names></name><name><surname>Pearce</surname><given-names>RA</given-names></name><name><surname>Zhang</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Functional neural development from human embryonic stem cells: accelerated synaptic activity via astrocyte coculture</article-title><source>The Journal of Neuroscience</source><volume>27</volume><fpage>3069</fpage><lpage>3077</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4562-06.2007</pub-id><pub-id pub-id-type="pmid">17376968</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kajiwara</surname><given-names>M</given-names></name><name><surname>Aoi</surname><given-names>T</given-names></name><name><surname>Okita</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>R</given-names></name><name><surname>Inoue</surname><given-names>H</given-names></name><name><surname>Takayama</surname><given-names>N</given-names></name><name><surname>Endo</surname><given-names>H</given-names></name><name><surname>Eto</surname><given-names>K</given-names></name><name><surname>Toguchida</surname><given-names>J</given-names></name><name><surname>Uemoto</surname><given-names>S</given-names></name><name><surname>Yamanaka</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells</article-title><source>PNAS</source><volume>109</volume><fpage>12538</fpage><lpage>12543</lpage><pub-id pub-id-type="doi">10.1073/pnas.1209979109</pub-id><pub-id pub-id-type="pmid">22802639</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kfoury</surname><given-names>N</given-names></name><name><surname>Qi</surname><given-names>Z</given-names></name><name><surname>Prager</surname><given-names>BC</given-names></name><name><surname>Wilkinson</surname><given-names>MN</given-names></name><name><surname>Broestl</surname><given-names>L</given-names></name><name><surname>Berrett</surname><given-names>KC</given-names></name><name><surname>Moudgil</surname><given-names>A</given-names></name><name><surname>Sankararaman</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Gertz</surname><given-names>J</given-names></name><name><surname>Rich</surname><given-names>JN</given-names></name><name><surname>Mitra</surname><given-names>RD</given-names></name><name><surname>Rubin</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Brd4-bound enhancers drive cell-intrinsic sex differences in glioblastoma</article-title><source>PNAS</source><volume>118</volume><elocation-id>e2017148118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2017148118</pub-id><pub-id pub-id-type="pmid">33850013</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kilpinen</surname><given-names>H</given-names></name><name><surname>Goncalves</surname><given-names>A</given-names></name><name><surname>Leha</surname><given-names>A</given-names></name><name><surname>Afzal</surname><given-names>V</given-names></name><name><surname>Alasoo</surname><given-names>K</given-names></name><name><surname>Ashford</surname><given-names>S</given-names></name><name><surname>Bala</surname><given-names>S</given-names></name><name><surname>Bensaddek</surname><given-names>D</given-names></name><name><surname>Casale</surname><given-names>FP</given-names></name><name><surname>Culley</surname><given-names>OJ</given-names></name><name><surname>Danecek</surname><given-names>P</given-names></name><name><surname>Faulconbridge</surname><given-names>A</given-names></name><name><surname>Harrison</surname><given-names>PW</given-names></name><name><surname>Kathuria</surname><given-names>A</given-names></name><name><surname>McCarthy</surname><given-names>D</given-names></name><name><surname>McCarthy</surname><given-names>SA</given-names></name><name><surname>Meleckyte</surname><given-names>R</given-names></name><name><surname>Memari</surname><given-names>Y</given-names></name><name><surname>Moens</surname><given-names>N</given-names></name><name><surname>Soares</surname><given-names>F</given-names></name><name><surname>Mann</surname><given-names>A</given-names></name><name><surname>Streeter</surname><given-names>I</given-names></name><name><surname>Agu</surname><given-names>CA</given-names></name><name><surname>Alderton</surname><given-names>A</given-names></name><name><surname>Nelson</surname><given-names>R</given-names></name><name><surname>Harper</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>M</given-names></name><name><surname>White</surname><given-names>A</given-names></name><name><surname>Patel</surname><given-names>SR</given-names></name><name><surname>Clarke</surname><given-names>L</given-names></name><name><surname>Halai</surname><given-names>R</given-names></name><name><surname>Kirton</surname><given-names>CM</given-names></name><name><surname>Kolb-Kokocinski</surname><given-names>A</given-names></name><name><surname>Beales</surname><given-names>P</given-names></name><name><surname>Birney</surname><given-names>E</given-names></name><name><surname>Danovi</surname><given-names>D</given-names></name><name><surname>Lamond</surname><given-names>AI</given-names></name><name><surname>Ouwehand</surname><given-names>WH</given-names></name><name><surname>Vallier</surname><given-names>L</given-names></name><name><surname>Watt</surname><given-names>FM</given-names></name><name><surname>Durbin</surname><given-names>R</given-names></name><name><surname>Stegle</surname><given-names>O</given-names></name><name><surname>Gaffney</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Corrigendum: common genetic variation drives molecular heterogeneity in human iPSCs</article-title><source>Nature</source><volume>546</volume><fpage>370</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1038/nature23012</pub-id><pub-id pub-id-type="pmid">28614302</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirov</surname><given-names>G</given-names></name><name><surname>Pocklington</surname><given-names>AJ</given-names></name><name><surname>Holmans</surname><given-names>P</given-names></name><name><surname>Ivanov</surname><given-names>D</given-names></name><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Ruderfer</surname><given-names>D</given-names></name><name><surname>Moran</surname><given-names>J</given-names></name><name><surname>Chambert</surname><given-names>K</given-names></name><name><surname>Toncheva</surname><given-names>D</given-names></name><name><surname>Georgieva</surname><given-names>L</given-names></name><name><surname>Grozeva</surname><given-names>D</given-names></name><name><surname>Fjodorova</surname><given-names>M</given-names></name><name><surname>Wollerton</surname><given-names>R</given-names></name><name><surname>Rees</surname><given-names>E</given-names></name><name><surname>Nikolov</surname><given-names>I</given-names></name><name><surname>van de Lagemaat</surname><given-names>LN</given-names></name><name><surname>Bayés</surname><given-names>À</given-names></name><name><surname>Fernandez</surname><given-names>E</given-names></name><name><surname>Olason</surname><given-names>PI</given-names></name><name><surname>Böttcher</surname><given-names>Y</given-names></name><name><surname>Komiyama</surname><given-names>NH</given-names></name><name><surname>Collins</surname><given-names>MO</given-names></name><name><surname>Choudhary</surname><given-names>J</given-names></name><name><surname>Stefansson</surname><given-names>K</given-names></name><name><surname>Stefansson</surname><given-names>H</given-names></name><name><surname>Grant</surname><given-names>SGN</given-names></name><name><surname>Purcell</surname><given-names>S</given-names></name><name><surname>Sklar</surname><given-names>P</given-names></name><name><surname>O’Donovan</surname><given-names>MC</given-names></name><name><surname>Owen</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia</article-title><source>Molecular Psychiatry</source><volume>17</volume><fpage>142</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1038/mp.2011.154</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>T</given-names></name><name><surname>Imamura</surname><given-names>K</given-names></name><name><surname>Funayama</surname><given-names>M</given-names></name><name><surname>Tsukita</surname><given-names>K</given-names></name><name><surname>Miyake</surname><given-names>M</given-names></name><name><surname>Ohta</surname><given-names>A</given-names></name><name><surname>Woltjen</surname><given-names>K</given-names></name><name><surname>Nakagawa</surname><given-names>M</given-names></name><name><surname>Asada</surname><given-names>T</given-names></name><name><surname>Arai</surname><given-names>T</given-names></name><name><surname>Kawakatsu</surname><given-names>S</given-names></name><name><surname>Izumi</surname><given-names>Y</given-names></name><name><surname>Kaji</surname><given-names>R</given-names></name><name><surname>Iwata</surname><given-names>N</given-names></name><name><surname>Inoue</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>IPSC-based compound screening and in vitro trials identify a synergistic anti-amyloid β combination for Alzheimer’s disease</article-title><source>Cell Reports</source><volume>21</volume><fpage>2304</fpage><lpage>2312</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.10.109</pub-id><pub-id pub-id-type="pmid">29166618</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koopmans</surname><given-names>F</given-names></name><name><surname>van Nierop</surname><given-names>P</given-names></name><name><surname>Andres-Alonso</surname><given-names>M</given-names></name><name><surname>Byrnes</surname><given-names>A</given-names></name><name><surname>Cijsouw</surname><given-names>T</given-names></name><name><surname>Coba</surname><given-names>MP</given-names></name><name><surname>Cornelisse</surname><given-names>LN</given-names></name><name><surname>Farrell</surname><given-names>RJ</given-names></name><name><surname>Goldschmidt</surname><given-names>HL</given-names></name><name><surname>Howrigan</surname><given-names>DP</given-names></name><name><surname>Hussain</surname><given-names>NK</given-names></name><name><surname>Imig</surname><given-names>C</given-names></name><name><surname>de Jong</surname><given-names>APH</given-names></name><name><surname>Jung</surname><given-names>H</given-names></name><name><surname>Kohansalnodehi</surname><given-names>M</given-names></name><name><surname>Kramarz</surname><given-names>B</given-names></name><name><surname>Lipstein</surname><given-names>N</given-names></name><name><surname>Lovering</surname><given-names>RC</given-names></name><name><surname>MacGillavry</surname><given-names>H</given-names></name><name><surname>Mariano</surname><given-names>V</given-names></name><name><surname>Mi</surname><given-names>H</given-names></name><name><surname>Ninov</surname><given-names>M</given-names></name><name><surname>Osumi-Sutherland</surname><given-names>D</given-names></name><name><surname>Pielot</surname><given-names>R</given-names></name><name><surname>Smalla</surname><given-names>K-H</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Tashman</surname><given-names>K</given-names></name><name><surname>Toonen</surname><given-names>RFG</given-names></name><name><surname>Verpelli</surname><given-names>C</given-names></name><name><surname>Reig-Viader</surname><given-names>R</given-names></name><name><surname>Watanabe</surname><given-names>K</given-names></name><name><surname>van Weering</surname><given-names>J</given-names></name><name><surname>Achsel</surname><given-names>T</given-names></name><name><surname>Ashrafi</surname><given-names>G</given-names></name><name><surname>Asi</surname><given-names>N</given-names></name><name><surname>Brown</surname><given-names>TC</given-names></name><name><surname>De Camilli</surname><given-names>P</given-names></name><name><surname>Feuermann</surname><given-names>M</given-names></name><name><surname>Foulger</surname><given-names>RE</given-names></name><name><surname>Gaudet</surname><given-names>P</given-names></name><name><surname>Joglekar</surname><given-names>A</given-names></name><name><surname>Kanellopoulos</surname><given-names>A</given-names></name><name><surname>Malenka</surname><given-names>R</given-names></name><name><surname>Nicoll</surname><given-names>RA</given-names></name><name><surname>Pulido</surname><given-names>C</given-names></name><name><surname>de Juan-Sanz</surname><given-names>J</given-names></name><name><surname>Sheng</surname><given-names>M</given-names></name><name><surname>Südhof</surname><given-names>TC</given-names></name><name><surname>Tilgner</surname><given-names>HU</given-names></name><name><surname>Bagni</surname><given-names>C</given-names></name><name><surname>Bayés</surname><given-names>À</given-names></name><name><surname>Biederer</surname><given-names>T</given-names></name><name><surname>Brose</surname><given-names>N</given-names></name><name><surname>Chua</surname><given-names>JJE</given-names></name><name><surname>Dieterich</surname><given-names>DC</given-names></name><name><surname>Gundelfinger</surname><given-names>ED</given-names></name><name><surname>Hoogenraad</surname><given-names>C</given-names></name><name><surname>Huganir</surname><given-names>RL</given-names></name><name><surname>Jahn</surname><given-names>R</given-names></name><name><surname>Kaeser</surname><given-names>PS</given-names></name><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Kreutz</surname><given-names>MR</given-names></name><name><surname>McPherson</surname><given-names>PS</given-names></name><name><surname>Neale</surname><given-names>BM</given-names></name><name><surname>O’Connor</surname><given-names>V</given-names></name><name><surname>Posthuma</surname><given-names>D</given-names></name><name><surname>Ryan</surname><given-names>TA</given-names></name><name><surname>Sala</surname><given-names>C</given-names></name><name><surname>Feng</surname><given-names>G</given-names></name><name><surname>Hyman</surname><given-names>SE</given-names></name><name><surname>Thomas</surname><given-names>PD</given-names></name><name><surname>Smit</surname><given-names>AB</given-names></name><name><surname>Verhage</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>SynGO: an evidence-based, expert-curated knowledge base for the synapse</article-title><source>Neuron</source><volume>103</volume><fpage>217</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2019.05.002</pub-id><pub-id pub-id-type="pmid">31171447</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korb</surname><given-names>E</given-names></name><name><surname>Herre</surname><given-names>M</given-names></name><name><surname>Zucker-Scharff</surname><given-names>I</given-names></name><name><surname>Darnell</surname><given-names>RB</given-names></name><name><surname>Allis</surname><given-names>CD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Bet protein Brd4 activates transcription in neurons and Bet inhibitor JQ1 blocks memory in mice</article-title><source>Nature Neuroscience</source><volume>18</volume><fpage>1464</fpage><lpage>1473</lpage><pub-id pub-id-type="doi">10.1038/nn.4095</pub-id><pub-id pub-id-type="pmid">26301327</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krencik</surname><given-names>R</given-names></name><name><surname>van Asperen</surname><given-names>JV</given-names></name><name><surname>Ullian</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Human astrocytes are distinct contributors to the complexity of synaptic function</article-title><source>Brain Research Bulletin</source><volume>129</volume><fpage>66</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.brainresbull.2016.08.012</pub-id><pub-id pub-id-type="pmid">27570101</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krey</surname><given-names>JF</given-names></name><name><surname>Paşca</surname><given-names>SP</given-names></name><name><surname>Shcheglovitov</surname><given-names>A</given-names></name><name><surname>Yazawa</surname><given-names>M</given-names></name><name><surname>Schwemberger</surname><given-names>R</given-names></name><name><surname>Rasmusson</surname><given-names>R</given-names></name><name><surname>Dolmetsch</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Timothy syndrome is associated with activity-dependent dendritic retraction in rodent and human neurons</article-title><source>Nature Neuroscience</source><volume>16</volume><fpage>201</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1038/nn.3307</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunkle</surname><given-names>BW</given-names></name><name><surname>Grenier-Boley</surname><given-names>B</given-names></name><name><surname>Sims</surname><given-names>R</given-names></name><name><surname>Bis</surname><given-names>JC</given-names></name><name><surname>Damotte</surname><given-names>V</given-names></name><name><surname>Naj</surname><given-names>AC</given-names></name><name><surname>Boland</surname><given-names>A</given-names></name><name><surname>Vronskaya</surname><given-names>M</given-names></name><name><surname>van der Lee</surname><given-names>SJ</given-names></name><name><surname>Amlie-Wolf</surname><given-names>A</given-names></name><name><surname>Bellenguez</surname><given-names>C</given-names></name><name><surname>Frizatti</surname><given-names>A</given-names></name><name><surname>Chouraki</surname><given-names>V</given-names></name><name><surname>Martin</surname><given-names>ER</given-names></name><name><surname>Sleegers</surname><given-names>K</given-names></name><name><surname>Badarinarayan</surname><given-names>N</given-names></name><name><surname>Jakobsdottir</surname><given-names>J</given-names></name><name><surname>Hamilton-Nelson</surname><given-names>KL</given-names></name><name><surname>Moreno-Grau</surname><given-names>S</given-names></name><name><surname>Olaso</surname><given-names>R</given-names></name><name><surname>Raybould</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Kuzma</surname><given-names>AB</given-names></name><name><surname>Hiltunen</surname><given-names>M</given-names></name><name><surname>Morgan</surname><given-names>T</given-names></name><name><surname>Ahmad</surname><given-names>S</given-names></name><name><surname>Vardarajan</surname><given-names>BN</given-names></name><name><surname>Epelbaum</surname><given-names>J</given-names></name><name><surname>Hoffmann</surname><given-names>P</given-names></name><name><surname>Boada</surname><given-names>M</given-names></name><name><surname>Beecham</surname><given-names>GW</given-names></name><name><surname>Garnier</surname><given-names>JG</given-names></name><name><surname>Harold</surname><given-names>D</given-names></name><name><surname>Fitzpatrick</surname><given-names>AL</given-names></name><name><surname>Valladares</surname><given-names>O</given-names></name><name><surname>Moutet</surname><given-names>ML</given-names></name><name><surname>Gerrish</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>AV</given-names></name><name><surname>Qu</surname><given-names>L</given-names></name><name><surname>Bacq</surname><given-names>D</given-names></name><name><surname>Denning</surname><given-names>N</given-names></name><name><surname>Jian</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Del Zompo</surname><given-names>M</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name><name><surname>Choi</surname><given-names>SH</given-names></name><name><surname>Mateo</surname><given-names>I</given-names></name><name><surname>Hughes</surname><given-names>JT</given-names></name><name><surname>Adams</surname><given-names>HH</given-names></name><name><surname>Malamon</surname><given-names>J</given-names></name><name><surname>Sanchez-Garcia</surname><given-names>F</given-names></name><name><surname>Patel</surname><given-names>Y</given-names></name><name><surname>Brody</surname><given-names>JA</given-names></name><name><surname>Dombroski</surname><given-names>BA</given-names></name><name><surname>Naranjo</surname><given-names>MCD</given-names></name><name><surname>Daniilidou</surname><given-names>M</given-names></name><name><surname>Eiriksdottir</surname><given-names>G</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Wallon</surname><given-names>D</given-names></name><name><surname>Uphill</surname><given-names>J</given-names></name><name><surname>Aspelund</surname><given-names>T</given-names></name><name><surname>Cantwell</surname><given-names>LB</given-names></name><name><surname>Garzia</surname><given-names>F</given-names></name><name><surname>Galimberti</surname><given-names>D</given-names></name><name><surname>Hofer</surname><given-names>E</given-names></name><name><surname>Butkiewicz</surname><given-names>M</given-names></name><name><surname>Fin</surname><given-names>B</given-names></name><name><surname>Scarpini</surname><given-names>E</given-names></name><name><surname>Sarnowski</surname><given-names>C</given-names></name><name><surname>Bush</surname><given-names>WS</given-names></name><name><surname>Meslage</surname><given-names>S</given-names></name><name><surname>Kornhuber</surname><given-names>J</given-names></name><name><surname>White</surname><given-names>CC</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Barber</surname><given-names>RC</given-names></name><name><surname>Engelborghs</surname><given-names>S</given-names></name><name><surname>Sordon</surname><given-names>S</given-names></name><name><surname>Voijnovic</surname><given-names>D</given-names></name><name><surname>Adams</surname><given-names>PM</given-names></name><name><surname>Vandenberghe</surname><given-names>R</given-names></name><name><surname>Mayhaus</surname><given-names>M</given-names></name><name><surname>Cupples</surname><given-names>LA</given-names></name><name><surname>Albert</surname><given-names>MS</given-names></name><name><surname>De Deyn</surname><given-names>PP</given-names></name><name><surname>Gu</surname><given-names>W</given-names></name><name><surname>Himali</surname><given-names>JJ</given-names></name><name><surname>Beekly</surname><given-names>D</given-names></name><name><surname>Squassina</surname><given-names>A</given-names></name><name><surname>Hartmann</surname><given-names>AM</given-names></name><name><surname>Orellana</surname><given-names>A</given-names></name><name><surname>Blacker</surname><given-names>D</given-names></name><name><surname>Rodriguez-Rodriguez</surname><given-names>E</given-names></name><name><surname>Lovestone</surname><given-names>S</given-names></name><name><surname>Garcia</surname><given-names>ME</given-names></name><name><surname>Doody</surname><given-names>RS</given-names></name><name><surname>Munoz-Fernadez</surname><given-names>C</given-names></name><name><surname>Sussams</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Fairchild</surname><given-names>TJ</given-names></name><name><surname>Benito</surname><given-names>YA</given-names></name><name><surname>Holmes</surname><given-names>C</given-names></name><name><surname>Karamujić-Čomić</surname><given-names>H</given-names></name><name><surname>Frosch</surname><given-names>MP</given-names></name><name><surname>Thonberg</surname><given-names>H</given-names></name><name><surname>Maier</surname><given-names>W</given-names></name><name><surname>Roshchupkin</surname><given-names>G</given-names></name><name><surname>Ghetti</surname><given-names>B</given-names></name><name><surname>Giedraitis</surname><given-names>V</given-names></name><name><surname>Kawalia</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Huebinger</surname><given-names>RM</given-names></name><name><surname>Kilander</surname><given-names>L</given-names></name><name><surname>Moebus</surname><given-names>S</given-names></name><name><surname>Hernández</surname><given-names>I</given-names></name><name><surname>Kamboh</surname><given-names>MI</given-names></name><name><surname>Brundin</surname><given-names>R</given-names></name><name><surname>Turton</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Katz</surname><given-names>MJ</given-names></name><name><surname>Concari</surname><given-names>L</given-names></name><name><surname>Lord</surname><given-names>J</given-names></name><name><surname>Beiser</surname><given-names>AS</given-names></name><name><surname>Keene</surname><given-names>CD</given-names></name><name><surname>Helisalmi</surname><given-names>S</given-names></name><name><surname>Kloszewska</surname><given-names>I</given-names></name><name><surname>Kukull</surname><given-names>WA</given-names></name><name><surname>Koivisto</surname><given-names>AM</given-names></name><name><surname>Lynch</surname><given-names>A</given-names></name><name><surname>Tarraga</surname><given-names>L</given-names></name><name><surname>Larson</surname><given-names>EB</given-names></name><name><surname>Haapasalo</surname><given-names>A</given-names></name><name><surname>Lawlor</surname><given-names>B</given-names></name><name><surname>Mosley</surname><given-names>TH</given-names></name><name><surname>Lipton</surname><given-names>RB</given-names></name><name><surname>Solfrizzi</surname><given-names>V</given-names></name><name><surname>Gill</surname><given-names>M</given-names></name><name><surname>Longstreth</surname><given-names>WT</given-names></name><name><surname>Montine</surname><given-names>TJ</given-names></name><name><surname>Frisardi</surname><given-names>V</given-names></name><name><surname>Diez-Fairen</surname><given-names>M</given-names></name><name><surname>Rivadeneira</surname><given-names>F</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Deramecourt</surname><given-names>V</given-names></name><name><surname>Alvarez</surname><given-names>I</given-names></name><name><surname>Salani</surname><given-names>F</given-names></name><name><surname>Ciaramella</surname><given-names>A</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Reiman</surname><given-names>EM</given-names></name><name><surname>Fievet</surname><given-names>N</given-names></name><name><surname>Rotter</surname><given-names>JI</given-names></name><name><surname>Reisch</surname><given-names>JS</given-names></name><name><surname>Hanon</surname><given-names>O</given-names></name><name><surname>Cupidi</surname><given-names>C</given-names></name><name><surname>Uitterlinden</surname><given-names>AGA</given-names></name><name><surname>Royall</surname><given-names>DR</given-names></name><name><surname>Dufouil</surname><given-names>C</given-names></name><name><surname>Maletta</surname><given-names>RG</given-names></name><name><surname>de Rojas</surname><given-names>I</given-names></name><name><surname>Sano</surname><given-names>M</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><name><surname>Cecchetti</surname><given-names>R</given-names></name><name><surname>George-Hyslop</surname><given-names>PS</given-names></name><name><surname>Ritchie</surname><given-names>K</given-names></name><name><surname>Tsolaki</surname><given-names>M</given-names></name><name><surname>Tsuang</surname><given-names>DW</given-names></name><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Craig</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>CK</given-names></name><name><surname>Soininen</surname><given-names>H</given-names></name><name><surname>Avramidou</surname><given-names>D</given-names></name><name><surname>Albin</surname><given-names>RL</given-names></name><name><surname>Fratiglioni</surname><given-names>L</given-names></name><name><surname>Germanou</surname><given-names>A</given-names></name><name><surname>Apostolova</surname><given-names>LG</given-names></name><name><surname>Keller</surname><given-names>L</given-names></name><name><surname>Koutroumani</surname><given-names>M</given-names></name><name><surname>Arnold</surname><given-names>SE</given-names></name><name><surname>Panza</surname><given-names>F</given-names></name><name><surname>Gkatzima</surname><given-names>O</given-names></name><name><surname>Asthana</surname><given-names>S</given-names></name><name><surname>Hannequin</surname><given-names>D</given-names></name><name><surname>Whitehead</surname><given-names>P</given-names></name><name><surname>Atwood</surname><given-names>CS</given-names></name><name><surname>Caffarra</surname><given-names>P</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Quintela</surname><given-names>I</given-names></name><name><surname>Carracedo</surname><given-names>Á</given-names></name><name><surname>Lannfelt</surname><given-names>L</given-names></name><name><surname>Rubinsztein</surname><given-names>DC</given-names></name><name><surname>Barnes</surname><given-names>LL</given-names></name><name><surname>Pasquier</surname><given-names>F</given-names></name><name><surname>Frölich</surname><given-names>L</given-names></name><name><surname>Barral</surname><given-names>S</given-names></name><name><surname>McGuinness</surname><given-names>B</given-names></name><name><surname>Beach</surname><given-names>TG</given-names></name><name><surname>Johnston</surname><given-names>JA</given-names></name><name><surname>Becker</surname><given-names>JT</given-names></name><name><surname>Passmore</surname><given-names>P</given-names></name><name><surname>Bigio</surname><given-names>EH</given-names></name><name><surname>Schott</surname><given-names>JM</given-names></name><name><surname>Bird</surname><given-names>TD</given-names></name><name><surname>Warren</surname><given-names>JD</given-names></name><name><surname>Boeve</surname><given-names>BF</given-names></name><name><surname>Lupton</surname><given-names>MK</given-names></name><name><surname>Bowen</surname><given-names>JD</given-names></name><name><surname>Proitsi</surname><given-names>P</given-names></name><name><surname>Boxer</surname><given-names>A</given-names></name><name><surname>Powell</surname><given-names>JF</given-names></name><name><surname>Burke</surname><given-names>JR</given-names></name><name><surname>Kauwe</surname><given-names>JSK</given-names></name><name><surname>Burns</surname><given-names>JM</given-names></name><name><surname>Mancuso</surname><given-names>M</given-names></name><name><surname>Buxbaum</surname><given-names>JD</given-names></name><name><surname>Bonuccelli</surname><given-names>U</given-names></name><name><surname>Cairns</surname><given-names>NJ</given-names></name><name><surname>McQuillin</surname><given-names>A</given-names></name><name><surname>Cao</surname><given-names>C</given-names></name><name><surname>Livingston</surname><given-names>G</given-names></name><name><surname>Carlson</surname><given-names>CS</given-names></name><name><surname>Bass</surname><given-names>NJ</given-names></name><name><surname>Carlsson</surname><given-names>CM</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Carney</surname><given-names>RM</given-names></name><name><surname>Bras</surname><given-names>J</given-names></name><name><surname>Carrasquillo</surname><given-names>MM</given-names></name><name><surname>Guerreiro</surname><given-names>R</given-names></name><name><surname>Allen</surname><given-names>M</given-names></name><name><surname>Chui</surname><given-names>HC</given-names></name><name><surname>Fisher</surname><given-names>E</given-names></name><name><surname>Masullo</surname><given-names>C</given-names></name><name><surname>Crocco</surname><given-names>EA</given-names></name><name><surname>DeCarli</surname><given-names>C</given-names></name><name><surname>Bisceglio</surname><given-names>G</given-names></name><name><surname>Dick</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Duara</surname><given-names>R</given-names></name><name><surname>Graff-Radford</surname><given-names>NR</given-names></name><name><surname>Evans</surname><given-names>DA</given-names></name><name><surname>Hodges</surname><given-names>A</given-names></name><name><surname>Faber</surname><given-names>KM</given-names></name><name><surname>Scherer</surname><given-names>M</given-names></name><name><surname>Fallon</surname><given-names>KB</given-names></name><name><surname>Riemenschneider</surname><given-names>M</given-names></name><name><surname>Fardo</surname><given-names>DW</given-names></name><name><surname>Heun</surname><given-names>R</given-names></name><name><surname>Farlow</surname><given-names>MR</given-names></name><name><surname>Kölsch</surname><given-names>H</given-names></name><name><surname>Ferris</surname><given-names>S</given-names></name><name><surname>Leber</surname><given-names>M</given-names></name><name><surname>Foroud</surname><given-names>TM</given-names></name><name><surname>Heuser</surname><given-names>I</given-names></name><name><surname>Galasko</surname><given-names>DR</given-names></name><name><surname>Giegling</surname><given-names>I</given-names></name><name><surname>Gearing</surname><given-names>M</given-names></name><name><surname>Hüll</surname><given-names>M</given-names></name><name><surname>Geschwind</surname><given-names>DH</given-names></name><name><surname>Gilbert</surname><given-names>JR</given-names></name><name><surname>Morris</surname><given-names>J</given-names></name><name><surname>Green</surname><given-names>RC</given-names></name><name><surname>Mayo</surname><given-names>K</given-names></name><name><surname>Growdon</surname><given-names>JH</given-names></name><name><surname>Feulner</surname><given-names>T</given-names></name><name><surname>Hamilton</surname><given-names>RL</given-names></name><name><surname>Harrell</surname><given-names>LE</given-names></name><name><surname>Drichel</surname><given-names>D</given-names></name><name><surname>Honig</surname><given-names>LS</given-names></name><name><surname>Cushion</surname><given-names>TD</given-names></name><name><surname>Huentelman</surname><given-names>MJ</given-names></name><name><surname>Hollingworth</surname><given-names>P</given-names></name><name><surname>Hulette</surname><given-names>CM</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Marshall</surname><given-names>R</given-names></name><name><surname>Jarvik</surname><given-names>GP</given-names></name><name><surname>Meggy</surname><given-names>A</given-names></name><name><surname>Abner</surname><given-names>E</given-names></name><name><surname>Menzies</surname><given-names>GE</given-names></name><name><surname>Jin</surname><given-names>LW</given-names></name><name><surname>Leonenko</surname><given-names>G</given-names></name><name><surname>Real</surname><given-names>LM</given-names></name><name><surname>Jun</surname><given-names>GR</given-names></name><name><surname>Baldwin</surname><given-names>CT</given-names></name><name><surname>Grozeva</surname><given-names>D</given-names></name><name><surname>Karydas</surname><given-names>A</given-names></name><name><surname>Russo</surname><given-names>G</given-names></name><name><surname>Kaye</surname><given-names>JA</given-names></name><name><surname>Kim</surname><given-names>R</given-names></name><name><surname>Jessen</surname><given-names>F</given-names></name><name><surname>Kowall</surname><given-names>NW</given-names></name><name><surname>Vellas</surname><given-names>B</given-names></name><name><surname>Kramer</surname><given-names>JH</given-names></name><name><surname>Vardy</surname><given-names>E</given-names></name><name><surname>LaFerla</surname><given-names>FM</given-names></name><name><surname>Jöckel</surname><given-names>KH</given-names></name><name><surname>Lah</surname><given-names>JJ</given-names></name><name><surname>Dichgans</surname><given-names>M</given-names></name><name><surname>Leverenz</surname><given-names>JB</given-names></name><name><surname>Mann</surname><given-names>D</given-names></name><name><surname>Levey</surname><given-names>AI</given-names></name><name><surname>Pickering-Brown</surname><given-names>S</given-names></name><name><surname>Lieberman</surname><given-names>AP</given-names></name><name><surname>Klopp</surname><given-names>N</given-names></name><name><surname>Lunetta</surname><given-names>KL</given-names></name><name><surname>Wichmann</surname><given-names>HE</given-names></name><name><surname>Lyketsos</surname><given-names>CG</given-names></name><name><surname>Morgan</surname><given-names>K</given-names></name><name><surname>Marson</surname><given-names>DC</given-names></name><name><surname>Brown</surname><given-names>K</given-names></name><name><surname>Martiniuk</surname><given-names>F</given-names></name><name><surname>Medway</surname><given-names>C</given-names></name><name><surname>Mash</surname><given-names>DC</given-names></name><name><surname>Nöthen</surname><given-names>MM</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Hooper</surname><given-names>NM</given-names></name><name><surname>McCormick</surname><given-names>WC</given-names></name><name><surname>Daniele</surname><given-names>A</given-names></name><name><surname>McCurry</surname><given-names>SM</given-names></name><name><surname>Bayer</surname><given-names>A</given-names></name><name><surname>McDavid</surname><given-names>AN</given-names></name><name><surname>Gallacher</surname><given-names>J</given-names></name><name><surname>McKee</surname><given-names>AC</given-names></name><name><surname>van den Bussche</surname><given-names>H</given-names></name><name><surname>Mesulam</surname><given-names>M</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name><name><surname>Miller</surname><given-names>BL</given-names></name><name><surname>Riedel-Heller</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>CA</given-names></name><name><surname>Miller</surname><given-names>JW</given-names></name><name><surname>Al-Chalabi</surname><given-names>A</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Shaw</surname><given-names>CE</given-names></name><name><surname>Myers</surname><given-names>AJ</given-names></name><name><surname>Wiltfang</surname><given-names>J</given-names></name><name><surname>O’Bryant</surname><given-names>S</given-names></name><name><surname>Olichney</surname><given-names>JM</given-names></name><name><surname>Alvarez</surname><given-names>V</given-names></name><name><surname>Parisi</surname><given-names>JE</given-names></name><name><surname>Singleton</surname><given-names>AB</given-names></name><name><surname>Paulson</surname><given-names>HL</given-names></name><name><surname>Collinge</surname><given-names>J</given-names></name><name><surname>Perry</surname><given-names>WR</given-names></name><name><surname>Mead</surname><given-names>S</given-names></name><name><surname>Peskind</surname><given-names>E</given-names></name><name><surname>Cribbs</surname><given-names>DH</given-names></name><name><surname>Rossor</surname><given-names>M</given-names></name><name><surname>Pierce</surname><given-names>A</given-names></name><name><surname>Ryan</surname><given-names>NS</given-names></name><name><surname>Poon</surname><given-names>WW</given-names></name><name><surname>Nacmias</surname><given-names>B</given-names></name><name><surname>Potter</surname><given-names>H</given-names></name><name><surname>Sorbi</surname><given-names>S</given-names></name><name><surname>Quinn</surname><given-names>JF</given-names></name><name><surname>Sacchinelli</surname><given-names>E</given-names></name><name><surname>Raj</surname><given-names>A</given-names></name><name><surname>Spalletta</surname><given-names>G</given-names></name><name><surname>Raskind</surname><given-names>M</given-names></name><name><surname>Caltagirone</surname><given-names>C</given-names></name><name><surname>Bossù</surname><given-names>P</given-names></name><name><surname>Orfei</surname><given-names>MD</given-names></name><name><surname>Reisberg</surname><given-names>B</given-names></name><name><surname>Clarke</surname><given-names>R</given-names></name><name><surname>Reitz</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>AD</given-names></name><name><surname>Ringman</surname><given-names>JM</given-names></name><name><surname>Warden</surname><given-names>D</given-names></name><name><surname>Roberson</surname><given-names>ED</given-names></name><name><surname>Wilcock</surname><given-names>G</given-names></name><name><surname>Rogaeva</surname><given-names>E</given-names></name><name><surname>Bruni</surname><given-names>AC</given-names></name><name><surname>Rosen</surname><given-names>HJ</given-names></name><name><surname>Gallo</surname><given-names>M</given-names></name><name><surname>Rosenberg</surname><given-names>RN</given-names></name><name><surname>Ben-Shlomo</surname><given-names>Y</given-names></name><name><surname>Sager</surname><given-names>MA</given-names></name><name><surname>Mecocci</surname><given-names>P</given-names></name><name><surname>Saykin</surname><given-names>AJ</given-names></name><name><surname>Pastor</surname><given-names>P</given-names></name><name><surname>Cuccaro</surname><given-names>ML</given-names></name><name><surname>Vance</surname><given-names>JM</given-names></name><name><surname>Schneider</surname><given-names>JA</given-names></name><name><surname>Schneider</surname><given-names>LS</given-names></name><name><surname>Slifer</surname><given-names>S</given-names></name><name><surname>Seeley</surname><given-names>WW</given-names></name><name><surname>Smith</surname><given-names>AG</given-names></name><name><surname>Sonnen</surname><given-names>JA</given-names></name><name><surname>Spina</surname><given-names>S</given-names></name><name><surname>Stern</surname><given-names>RA</given-names></name><name><surname>Swerdlow</surname><given-names>RH</given-names></name><name><surname>Tang</surname><given-names>M</given-names></name><name><surname>Tanzi</surname><given-names>RE</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Troncoso</surname><given-names>JC</given-names></name><name><surname>Van Deerlin</surname><given-names>VM</given-names></name><name><surname>Van Eldik</surname><given-names>LJ</given-names></name><name><surname>Vinters</surname><given-names>HV</given-names></name><name><surname>Vonsattel</surname><given-names>JP</given-names></name><name><surname>Weintraub</surname><given-names>S</given-names></name><name><surname>Welsh-Bohmer</surname><given-names>KA</given-names></name><name><surname>Wilhelmsen</surname><given-names>KC</given-names></name><name><surname>Williamson</surname><given-names>J</given-names></name><name><surname>Wingo</surname><given-names>TS</given-names></name><name><surname>Woltjer</surname><given-names>RL</given-names></name><name><surname>Wright</surname><given-names>CB</given-names></name><name><surname>Yu</surname><given-names>CE</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Saba</surname><given-names>Y</given-names></name><collab>Alzheimer Disease Genetics Consortium</collab><collab>European Alzheimer’s Disease Initiative</collab><collab>Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium</collab><collab>Genetic and Environmental Risk in AD/Defining Genetic, Polygenic and Environmental Risk for Alzheimer’s Disease Consortium</collab><name><surname>Pilotto</surname><given-names>A</given-names></name><name><surname>Bullido</surname><given-names>MJ</given-names></name><name><surname>Peters</surname><given-names>O</given-names></name><name><surname>Crane</surname><given-names>PK</given-names></name><name><surname>Bennett</surname><given-names>D</given-names></name><name><surname>Bosco</surname><given-names>P</given-names></name><name><surname>Coto</surname><given-names>E</given-names></name><name><surname>Boccardi</surname><given-names>V</given-names></name><name><surname>De Jager</surname><given-names>PL</given-names></name><name><surname>Lleo</surname><given-names>A</given-names></name><name><surname>Warner</surname><given-names>N</given-names></name><name><surname>Lopez</surname><given-names>OL</given-names></name><name><surname>Ingelsson</surname><given-names>M</given-names></name><name><surname>Deloukas</surname><given-names>P</given-names></name><name><surname>Cruchaga</surname><given-names>C</given-names></name><name><surname>Graff</surname><given-names>C</given-names></name><name><surname>Gwilliam</surname><given-names>R</given-names></name><name><surname>Fornage</surname><given-names>M</given-names></name><name><surname>Goate</surname><given-names>AM</given-names></name><name><surname>Sanchez-Juan</surname><given-names>P</given-names></name><name><surname>Kehoe</surname><given-names>PG</given-names></name><name><surname>Amin</surname><given-names>N</given-names></name><name><surname>Ertekin-Taner</surname><given-names>N</given-names></name><name><surname>Berr</surname><given-names>C</given-names></name><name><surname>Debette</surname><given-names>S</given-names></name><name><surname>Love</surname><given-names>S</given-names></name><name><surname>Launer</surname><given-names>LJ</given-names></name><name><surname>Younkin</surname><given-names>SG</given-names></name><name><surname>Dartigues</surname><given-names>JF</given-names></name><name><surname>Corcoran</surname><given-names>C</given-names></name><name><surname>Ikram</surname><given-names>MA</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Nicolas</surname><given-names>G</given-names></name><name><surname>Campion</surname><given-names>D</given-names></name><name><surname>Tschanz</surname><given-names>J</given-names></name><name><surname>Schmidt</surname><given-names>H</given-names></name><name><surname>Hakonarson</surname><given-names>H</given-names></name><name><surname>Clarimon</surname><given-names>J</given-names></name><name><surname>Munger</surname><given-names>R</given-names></name><name><surname>Schmidt</surname><given-names>R</given-names></name><name><surname>Farrer</surname><given-names>LA</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name><name><surname>O’Donovan</surname><given-names>MC</given-names></name><name><surname>DeStefano</surname><given-names>AL</given-names></name><name><surname>Jones</surname><given-names>L</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Deleuze</surname><given-names>JF</given-names></name><name><surname>Owen</surname><given-names>MJ</given-names></name><name><surname>Gudnason</surname><given-names>V</given-names></name><name><surname>Mayeux</surname><given-names>R</given-names></name><name><surname>Escott-Price</surname><given-names>V</given-names></name><name><surname>Psaty</surname><given-names>BM</given-names></name><name><surname>Ramirez</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>LS</given-names></name><name><surname>Ruiz</surname><given-names>A</given-names></name><name><surname>van Duijn</surname><given-names>CM</given-names></name><name><surname>Holmans</surname><given-names>PA</given-names></name><name><surname>Seshadri</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>J</given-names></name><name><surname>Amouyel</surname><given-names>P</given-names></name><name><surname>Schellenberg</surname><given-names>GD</given-names></name><name><surname>Lambert</surname><given-names>JC</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Author correction: genetic meta-analysis of diagnosed alzheimer’s disease identifies new risk loci and implicates aβ, tau, immunity and lipid processing</article-title><source>Nature Genetics</source><volume>51</volume><fpage>1423</fpage><lpage>1424</lpage><pub-id pub-id-type="doi">10.1038/s41588-019-0495-7</pub-id><pub-id pub-id-type="pmid">31417202</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Meng</surname><given-names>G</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Tough</surname><given-names>D</given-names></name><name><surname>Lindon</surname><given-names>M</given-names></name><name><surname>Rioja</surname><given-names>I</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Mei</surname><given-names>H</given-names></name><name><surname>Prinjha</surname><given-names>R</given-names></name><name><surname>Zhong</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Bet bromodomain inhibition promotes neurogenesis while inhibiting gliogenesis in neural progenitor cells</article-title><source>Stem Cell Research</source><volume>17</volume><fpage>212</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.scr.2016.07.006</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>CW</given-names></name><name><surname>Sim</surname><given-names>S</given-names></name><name><surname>Ainsworth</surname><given-names>A</given-names></name><name><surname>Okada</surname><given-names>M</given-names></name><name><surname>Kelsch</surname><given-names>W</given-names></name><name><surname>Lois</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Genetically increased cell-intrinsic excitability enhances neuronal integration into adult brain circuits</article-title><source>Neuron</source><volume>65</volume><fpage>32</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2009.12.001</pub-id><pub-id pub-id-type="pmid">20152111</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Y-T</given-names></name><name><surname>Seo</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Feldman</surname><given-names>HM</given-names></name><name><surname>Wen</surname><given-names>H-L</given-names></name><name><surname>Penney</surname><given-names>J</given-names></name><name><surname>Cam</surname><given-names>HP</given-names></name><name><surname>Gjoneska</surname><given-names>E</given-names></name><name><surname>Raja</surname><given-names>WK</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Rueda</surname><given-names>R</given-names></name><name><surname>Kritskiy</surname><given-names>O</given-names></name><name><surname>Abdurrob</surname><given-names>F</given-names></name><name><surname>Peng</surname><given-names>Z</given-names></name><name><surname>Milo</surname><given-names>B</given-names></name><name><surname>Yu</surname><given-names>CJ</given-names></name><name><surname>Elmsaouri</surname><given-names>S</given-names></name><name><surname>Dey</surname><given-names>D</given-names></name><name><surname>Ko</surname><given-names>T</given-names></name><name><surname>Yankner</surname><given-names>BA</given-names></name><name><surname>Tsai</surname><given-names>L-H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Apoe4 causes widespread molecular and cellular alterations associated with Alzheimer’s disease phenotypes in human iPSC-derived brain cell types</article-title><source>Neuron</source><volume>98</volume><fpage>1141</fpage><lpage>1154</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2018.05.008</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linhoff</surname><given-names>MW</given-names></name><name><surname>Laurén</surname><given-names>J</given-names></name><name><surname>Cassidy</surname><given-names>RM</given-names></name><name><surname>Dobie</surname><given-names>FA</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Nygaard</surname><given-names>HB</given-names></name><name><surname>Airaksinen</surname><given-names>MS</given-names></name><name><surname>Strittmatter</surname><given-names>SM</given-names></name><name><surname>Craig</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>An unbiased expression screen for synaptogenic proteins identifies the LRRTM protein family as synaptic organizers</article-title><source>Neuron</source><volume>61</volume><fpage>734</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2009.01.017</pub-id><pub-id pub-id-type="pmid">19285470</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-Seq data with deseq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>C</given-names></name><name><surname>Keown</surname><given-names>CL</given-names></name><name><surname>Kurihara</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Castanon</surname><given-names>R</given-names></name><name><surname>Lucero</surname><given-names>J</given-names></name><name><surname>Nery</surname><given-names>JR</given-names></name><name><surname>Sandoval</surname><given-names>JP</given-names></name><name><surname>Bui</surname><given-names>B</given-names></name><name><surname>Sejnowski</surname><given-names>TJ</given-names></name><name><surname>Harkins</surname><given-names>TT</given-names></name><name><surname>Mukamel</surname><given-names>EA</given-names></name><name><surname>Behrens</surname><given-names>MM</given-names></name><name><surname>Ecker</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Single-Cell methylomes identify neuronal subtypes and regulatory elements in mammalian cortex</article-title><source>Science</source><volume>357</volume><fpage>600</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1126/science.aan3351</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchetto</surname><given-names>MC</given-names></name><name><surname>Belinson</surname><given-names>H</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Freitas</surname><given-names>BC</given-names></name><name><surname>Fu</surname><given-names>C</given-names></name><name><surname>Vadodaria</surname><given-names>KC</given-names></name><name><surname>Beltrao-Braga</surname><given-names>PC</given-names></name><name><surname>Trujillo</surname><given-names>CA</given-names></name><name><surname>Mendes</surname><given-names>APD</given-names></name><name><surname>Padmanabhan</surname><given-names>K</given-names></name><name><surname>Nunez</surname><given-names>Y</given-names></name><name><surname>Ou</surname><given-names>J</given-names></name><name><surname>Ghosh</surname><given-names>H</given-names></name><name><surname>Wright</surname><given-names>R</given-names></name><name><surname>Brennand</surname><given-names>KJ</given-names></name><name><surname>Pierce</surname><given-names>K</given-names></name><name><surname>Eichenfield</surname><given-names>L</given-names></name><name><surname>Pramparo</surname><given-names>T</given-names></name><name><surname>Eyler</surname><given-names>LT</given-names></name><name><surname>Barnes</surname><given-names>CC</given-names></name><name><surname>Courchesne</surname><given-names>E</given-names></name><name><surname>Geschwind</surname><given-names>DH</given-names></name><name><surname>Gage</surname><given-names>FH</given-names></name><name><surname>Wynshaw-Boris</surname><given-names>A</given-names></name><name><surname>Muotri</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Altered proliferation and networks in neural cells derived from idiopathic autistic individuals</article-title><source>Molecular Psychiatry</source><volume>22</volume><fpage>820</fpage><lpage>835</lpage><pub-id pub-id-type="doi">10.1038/mp.2016.95</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meijer</surname><given-names>M</given-names></name><name><surname>Rehbach</surname><given-names>K</given-names></name><name><surname>Brunner</surname><given-names>JW</given-names></name><name><surname>Classen</surname><given-names>JA</given-names></name><name><surname>Lammertse</surname><given-names>HCA</given-names></name><name><surname>van Linge</surname><given-names>LA</given-names></name><name><surname>Schut</surname><given-names>D</given-names></name><name><surname>Krutenko</surname><given-names>T</given-names></name><name><surname>Hebisch</surname><given-names>M</given-names></name><name><surname>Cornelisse</surname><given-names>LN</given-names></name><name><surname>Sullivan</surname><given-names>PF</given-names></name><name><surname>Peitz</surname><given-names>M</given-names></name><name><surname>Toonen</surname><given-names>RF</given-names></name><name><surname>Brüstle</surname><given-names>O</given-names></name><name><surname>Verhage</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A single-cell model for synaptic transmission and plasticity in human iPSC-derived neurons</article-title><source>Cell Reports</source><volume>27</volume><fpage>2199</fpage><lpage>2211</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.04.058</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Micheva</surname><given-names>KD</given-names></name><name><surname>Busse</surname><given-names>B</given-names></name><name><surname>Weiler</surname><given-names>NC</given-names></name><name><surname>O’Rourke</surname><given-names>N</given-names></name><name><surname>Smith</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Single-synapse analysis of a diverse synapse population: proteomic imaging methods and markers</article-title><source>Neuron</source><volume>68</volume><fpage>639</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2010.09.024</pub-id><pub-id pub-id-type="pmid">21092855</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohan</surname><given-names>H</given-names></name><name><surname>Verhoog</surname><given-names>MB</given-names></name><name><surname>Doreswamy</surname><given-names>KK</given-names></name><name><surname>Eyal</surname><given-names>G</given-names></name><name><surname>Aardse</surname><given-names>R</given-names></name><name><surname>Lodder</surname><given-names>BN</given-names></name><name><surname>Goriounova</surname><given-names>NA</given-names></name><name><surname>Asamoah</surname><given-names>B</given-names></name><name><surname>B Brakspear</surname><given-names>ABC</given-names></name><name><surname>Groot</surname><given-names>C</given-names></name><name><surname>van der Sluis</surname><given-names>S</given-names></name><name><surname>Testa-Silva</surname><given-names>G</given-names></name><name><surname>Obermayer</surname><given-names>J</given-names></name><name><surname>Boudewijns</surname><given-names>ZSRM</given-names></name><name><surname>Narayanan</surname><given-names>RT</given-names></name><name><surname>Baayen</surname><given-names>JC</given-names></name><name><surname>Segev</surname><given-names>I</given-names></name><name><surname>Mansvelder</surname><given-names>HD</given-names></name><name><surname>de Kock</surname><given-names>CPJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Dendritic and axonal architecture of individual pyramidal neurons across layers of adult human neocortex</article-title><source>Cerebral Cortex</source><volume>25</volume><fpage>4839</fpage><lpage>4853</lpage><pub-id pub-id-type="doi">10.1093/cercor/bhv188</pub-id><pub-id pub-id-type="pmid">26318661</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molnár</surname><given-names>G</given-names></name><name><surname>Rózsa</surname><given-names>M</given-names></name><name><surname>Baka</surname><given-names>J</given-names></name><name><surname>Holderith</surname><given-names>N</given-names></name><name><surname>Barzó</surname><given-names>P</given-names></name><name><surname>Nusser</surname><given-names>Z</given-names></name><name><surname>Tamás</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Human pyramidal to interneuron synapses are mediated by multi-vesicular release and multiple docked vesicles</article-title><source>eLife</source><volume>5</volume><elocation-id>e18167</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.18167</pub-id><pub-id pub-id-type="pmid">27536876</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno Manrique</surname><given-names>JF</given-names></name><name><surname>Voit</surname><given-names>PR</given-names></name><name><surname>Windsor</surname><given-names>KE</given-names></name><name><surname>Karla</surname><given-names>AR</given-names></name><name><surname>Rodriguez</surname><given-names>SR</given-names></name><name><surname>Beaudoin</surname><given-names>GMJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SynapseJ: an automated, synapse identification macro for imagej</article-title><source>Frontiers in Neural Circuits</source><volume>15</volume><elocation-id>731333</elocation-id><pub-id pub-id-type="doi">10.3389/fncir.2021.731333</pub-id><pub-id pub-id-type="pmid">34675779</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nehme</surname><given-names>R</given-names></name><name><surname>Zuccaro</surname><given-names>E</given-names></name><name><surname>Ghosh</surname><given-names>SD</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Sherwood</surname><given-names>JL</given-names></name><name><surname>Pietilainen</surname><given-names>O</given-names></name><name><surname>Barrett</surname><given-names>LE</given-names></name><name><surname>Limone</surname><given-names>F</given-names></name><name><surname>Worringer</surname><given-names>KA</given-names></name><name><surname>Kommineni</surname><given-names>S</given-names></name><name><surname>Zang</surname><given-names>Y</given-names></name><name><surname>Cacchiarelli</surname><given-names>D</given-names></name><name><surname>Meissner</surname><given-names>A</given-names></name><name><surname>Adolfsson</surname><given-names>R</given-names></name><name><surname>Haggarty</surname><given-names>S</given-names></name><name><surname>Madison</surname><given-names>J</given-names></name><name><surname>Muller</surname><given-names>M</given-names></name><name><surname>Arlotta</surname><given-names>P</given-names></name><name><surname>Fu</surname><given-names>Z</given-names></name><name><surname>Feng</surname><given-names>G</given-names></name><name><surname>Eggan</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Combining NGN2 programming with developmental patterning generates human excitatory neurons with NMDAR-mediated synaptic transmission</article-title><source>Cell Reports</source><volume>23</volume><fpage>2509</fpage><lpage>2523</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.04.066</pub-id><pub-id pub-id-type="pmid">29791859</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieland</surname><given-names>TJF</given-names></name><name><surname>Logan</surname><given-names>DJ</given-names></name><name><surname>Saulnier</surname><given-names>J</given-names></name><name><surname>Lam</surname><given-names>D</given-names></name><name><surname>Johnson</surname><given-names>C</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><name><surname>Carpenter</surname><given-names>AE</given-names></name><name><surname>Sabatini</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>High content image analysis identifies novel regulators of synaptogenesis in a high-throughput rnai screen of primary neurons</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e91744</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0091744</pub-id><pub-id pub-id-type="pmid">24633176</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oberheim</surname><given-names>NA</given-names></name><name><surname>Takano</surname><given-names>T</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>W</given-names></name><name><surname>Lin</surname><given-names>JHC</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Wyatt</surname><given-names>JD</given-names></name><name><surname>Pilcher</surname><given-names>W</given-names></name><name><surname>Ojemann</surname><given-names>JG</given-names></name><name><surname>Ransom</surname><given-names>BR</given-names></name><name><surname>Goldman</surname><given-names>SA</given-names></name><name><surname>Nedergaard</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Uniquely hominid features of adult human astrocytes</article-title><source>The Journal of Neuroscience</source><volume>29</volume><fpage>3276</fpage><lpage>3287</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4707-08.2009</pub-id><pub-id pub-id-type="pmid">19279265</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pak</surname><given-names>C</given-names></name><name><surname>Danko</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Aoto</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>G</given-names></name><name><surname>Maxeiner</surname><given-names>S</given-names></name><name><surname>Yi</surname><given-names>F</given-names></name><name><surname>Wernig</surname><given-names>M</given-names></name><name><surname>Südhof</surname><given-names>TC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Human neuropsychiatric disease modeling using conditional deletion reveals synaptic transmission defects caused by heterozygous mutations in NRXN1</article-title><source>Cell Stem Cell</source><volume>17</volume><fpage>316</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2015.07.017</pub-id><pub-id pub-id-type="pmid">26279266</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panatier</surname><given-names>A</given-names></name><name><surname>Vallée</surname><given-names>J</given-names></name><name><surname>Haber</surname><given-names>M</given-names></name><name><surname>Murai</surname><given-names>KK</given-names></name><name><surname>Lacaille</surname><given-names>J-C</given-names></name><name><surname>Robitaille</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Astrocytes are endogenous regulators of basal transmission at central synapses</article-title><source>Cell</source><volume>146</volume><fpage>785</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.07.022</pub-id><pub-id pub-id-type="pmid">21855979</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patzke</surname><given-names>C</given-names></name><name><surname>Brockmann</surname><given-names>MM</given-names></name><name><surname>Dai</surname><given-names>J</given-names></name><name><surname>Gan</surname><given-names>KJ</given-names></name><name><surname>Grauel</surname><given-names>MK</given-names></name><name><surname>Fenske</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Acuna</surname><given-names>C</given-names></name><name><surname>Rosenmund</surname><given-names>C</given-names></name><name><surname>Südhof</surname><given-names>TC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Neuromodulator signaling bidirectionally controls vesicle numbers in human synapses</article-title><source>Cell</source><volume>179</volume><fpage>498</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.09.011</pub-id><pub-id pub-id-type="pmid">31585084</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Catalan</surname><given-names>NA</given-names></name><name><surname>Doe</surname><given-names>CQ</given-names></name><name><surname>Ackerman</surname><given-names>SD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The role of astrocyte-mediated plasticity in neural circuit development and function</article-title><source>Neural Development</source><volume>16</volume><elocation-id>1</elocation-id><pub-id pub-id-type="doi">10.1186/s13064-020-00151-9</pub-id><pub-id pub-id-type="pmid">33413602</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>JGA</given-names></name><name><surname>Jones</surname><given-names>DG</given-names></name><name><surname>Murphy</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Comparing development of synaptic proteins in rat visual, somatosensory, and frontal cortex</article-title><source>Frontiers in Neural Circuits</source><volume>7</volume><elocation-id>97</elocation-id><pub-id pub-id-type="doi">10.3389/fncir.2013.00097</pub-id><pub-id pub-id-type="pmid">23754984</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piva</surname><given-names>R</given-names></name><name><surname>Ruggeri</surname><given-names>B</given-names></name><name><surname>Williams</surname><given-names>M</given-names></name><name><surname>Costa</surname><given-names>G</given-names></name><name><surname>Tamagno</surname><given-names>I</given-names></name><name><surname>Ferrero</surname><given-names>D</given-names></name><name><surname>Giai</surname><given-names>V</given-names></name><name><surname>Coscia</surname><given-names>M</given-names></name><name><surname>Peola</surname><given-names>S</given-names></name><name><surname>Massaia</surname><given-names>M</given-names></name><name><surname>Pezzoni</surname><given-names>G</given-names></name><name><surname>Allievi</surname><given-names>C</given-names></name><name><surname>Pescalli</surname><given-names>N</given-names></name><name><surname>Cassin</surname><given-names>M</given-names></name><name><surname>di Giovine</surname><given-names>S</given-names></name><name><surname>Nicoli</surname><given-names>P</given-names></name><name><surname>de Feudis</surname><given-names>P</given-names></name><name><surname>Strepponi</surname><given-names>I</given-names></name><name><surname>Roato</surname><given-names>I</given-names></name><name><surname>Ferracini</surname><given-names>R</given-names></name><name><surname>Bussolati</surname><given-names>B</given-names></name><name><surname>Camussi</surname><given-names>G</given-names></name><name><surname>Jones-Bolin</surname><given-names>S</given-names></name><name><surname>Hunter</surname><given-names>K</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Neri</surname><given-names>A</given-names></name><name><surname>Palumbo</surname><given-names>A</given-names></name><name><surname>Berkers</surname><given-names>C</given-names></name><name><surname>Ovaa</surname><given-names>H</given-names></name><name><surname>Bernareggi</surname><given-names>A</given-names></name><name><surname>Inghirami</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>CEP-18770: A novel, orally active proteasome inhibitor with A tumor-selective pharmacologic profile competitive with bortezomib</article-title><source>Blood</source><volume>111</volume><fpage>2765</fpage><lpage>2775</lpage><pub-id pub-id-type="doi">10.1182/blood-2007-07-100651</pub-id><pub-id pub-id-type="pmid">18057228</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pruunsild</surname><given-names>P</given-names></name><name><surname>Bengtson</surname><given-names>CP</given-names></name><name><surname>Bading</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Networks of cultured iPSC-derived neurons reveal the human synaptic activity-regulated adaptive gene program</article-title><source>Cell Reports</source><volume>18</volume><fpage>122</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.12.018</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purcell</surname><given-names>SM</given-names></name><name><surname>Moran</surname><given-names>JL</given-names></name><name><surname>Fromer</surname><given-names>M</given-names></name><name><surname>Ruderfer</surname><given-names>D</given-names></name><name><surname>Solovieff</surname><given-names>N</given-names></name><name><surname>Roussos</surname><given-names>P</given-names></name><name><surname>O’Dushlaine</surname><given-names>C</given-names></name><name><surname>Chambert</surname><given-names>K</given-names></name><name><surname>Bergen</surname><given-names>SE</given-names></name><name><surname>Kähler</surname><given-names>A</given-names></name><name><surname>Duncan</surname><given-names>L</given-names></name><name><surname>Stahl</surname><given-names>E</given-names></name><name><surname>Genovese</surname><given-names>G</given-names></name><name><surname>Fernández</surname><given-names>E</given-names></name><name><surname>Collins</surname><given-names>MO</given-names></name><name><surname>Komiyama</surname><given-names>NH</given-names></name><name><surname>Choudhary</surname><given-names>JS</given-names></name><name><surname>Magnusson</surname><given-names>PKE</given-names></name><name><surname>Banks</surname><given-names>E</given-names></name><name><surname>Shakir</surname><given-names>K</given-names></name><name><surname>Garimella</surname><given-names>K</given-names></name><name><surname>Fennell</surname><given-names>T</given-names></name><name><surname>DePristo</surname><given-names>M</given-names></name><name><surname>Grant</surname><given-names>SGN</given-names></name><name><surname>Haggarty</surname><given-names>SJ</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Scolnick</surname><given-names>EM</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Hultman</surname><given-names>CM</given-names></name><name><surname>Sullivan</surname><given-names>PF</given-names></name><name><surname>McCarroll</surname><given-names>SA</given-names></name><name><surname>Sklar</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A polygenic burden of rare disruptive mutations in schizophrenia</article-title><source>Nature</source><volume>506</volume><fpage>185</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1038/nature12975</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>MVR</given-names></name><name><surname>Venkatapuram</surname><given-names>P</given-names></name><name><surname>Mallireddigari</surname><given-names>MR</given-names></name><name><surname>Pallela</surname><given-names>VR</given-names></name><name><surname>Cosenza</surname><given-names>SC</given-names></name><name><surname>Robell</surname><given-names>KA</given-names></name><name><surname>Akula</surname><given-names>B</given-names></name><name><surname>Hoffman</surname><given-names>BS</given-names></name><name><surname>Reddy</surname><given-names>EP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2’,4’,6’-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.na): synthesis, structure-activity relationship, and biological activity</article-title><source>Journal of Medicinal Chemistry</source><volume>54</volume><fpage>6254</fpage><lpage>6276</lpage><pub-id pub-id-type="doi">10.1021/jm200570p</pub-id><pub-id pub-id-type="pmid">21812421</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rohrbough</surname><given-names>J</given-names></name><name><surname>Rushton</surname><given-names>E</given-names></name><name><surname>Woodruff</surname><given-names>E</given-names><suffix>III</suffix></name><name><surname>Fergestad</surname><given-names>T</given-names></name><name><surname>Vigneswaran</surname><given-names>K</given-names></name><name><surname>Broadie</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Presynaptic establishment of the synaptic cleft extracellular matrix is required for post-synaptic differentiation</article-title><source>Genes &amp; Development</source><volume>21</volume><fpage>2607</fpage><lpage>2628</lpage><pub-id pub-id-type="doi">10.1101/gad.1574107</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>KR</given-names></name><name><surname>Sirenko</surname><given-names>O</given-names></name><name><surname>Parham</surname><given-names>F</given-names></name><name><surname>Hsieh</surname><given-names>JH</given-names></name><name><surname>Cromwell</surname><given-names>EF</given-names></name><name><surname>Tice</surname><given-names>RR</given-names></name><name><surname>Behl</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Neurite outgrowth in human induced pluripotent stem cell-derived neurons as a high-throughput screen for developmental neurotoxicity or neurotoxicity</article-title><source>Neurotoxicology</source><volume>53</volume><fpage>271</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1016/j.neuro.2016.02.003</pub-id><pub-id pub-id-type="pmid">26854185</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sánchez-Danés</surname><given-names>A</given-names></name><name><surname>Richaud-Patin</surname><given-names>Y</given-names></name><name><surname>Carballo-Carbajal</surname><given-names>I</given-names></name><name><surname>Jiménez-Delgado</surname><given-names>S</given-names></name><name><surname>Caig</surname><given-names>C</given-names></name><name><surname>Mora</surname><given-names>S</given-names></name><name><surname>Di Guglielmo</surname><given-names>C</given-names></name><name><surname>Ezquerra</surname><given-names>M</given-names></name><name><surname>Patel</surname><given-names>B</given-names></name><name><surname>Giralt</surname><given-names>A</given-names></name><name><surname>Canals</surname><given-names>JM</given-names></name><name><surname>Memo</surname><given-names>M</given-names></name><name><surname>Alberch</surname><given-names>J</given-names></name><name><surname>López-Barneo</surname><given-names>J</given-names></name><name><surname>Vila</surname><given-names>M</given-names></name><name><surname>Cuervo</surname><given-names>AM</given-names></name><name><surname>Tolosa</surname><given-names>E</given-names></name><name><surname>Consiglio</surname><given-names>A</given-names></name><name><surname>Raya</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Disease-Specific phenotypes in dopamine neurons from human ips-based models of genetic and sporadic Parkinson’s disease</article-title><source>EMBO Molecular Medicine</source><volume>4</volume><fpage>380</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1002/emmm.201200215</pub-id><pub-id pub-id-type="pmid">22407749</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanes</surname><given-names>JR</given-names></name><name><surname>Lichtman</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Induction, assembly, maturation and maintenance of a postsynaptic apparatus</article-title><source>Nature Reviews Neuroscience</source><volume>2</volume><fpage>791</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1038/35097557</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitz</surname><given-names>SK</given-names></name><name><surname>Hjorth</surname><given-names>JJJ</given-names></name><name><surname>Joemai</surname><given-names>RMS</given-names></name><name><surname>Wijntjes</surname><given-names>R</given-names></name><name><surname>Eijgenraam</surname><given-names>S</given-names></name><name><surname>de Bruijn</surname><given-names>P</given-names></name><name><surname>Georgiou</surname><given-names>C</given-names></name><name><surname>de Jong</surname><given-names>APH</given-names></name><name><surname>van Ooyen</surname><given-names>A</given-names></name><name><surname>Verhage</surname><given-names>M</given-names></name><name><surname>Cornelisse</surname><given-names>LN</given-names></name><name><surname>Toonen</surname><given-names>RF</given-names></name><name><surname>Veldkamp</surname><given-names>WJH</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Automated analysis of neuronal morphology, synapse number and synaptic recruitment</article-title><source>Journal of Neuroscience Methods</source><volume>195</volume><fpage>185</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/j.jneumeth.2010.12.011</pub-id><pub-id pub-id-type="pmid">21167201</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Ando</surname><given-names>DM</given-names></name><name><surname>Daub</surname><given-names>A</given-names></name><name><surname>Kaye</surname><given-names>JA</given-names></name><name><surname>Finkbeiner</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>High-throughput screening in primary neurons</article-title><source>Methods in Enzymology</source><volume>506</volume><fpage>331</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-391856-7.00041-X</pub-id><pub-id pub-id-type="pmid">22341232</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>K</given-names></name><name><surname>Choi</surname><given-names>S-Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Nieland</surname><given-names>TJF</given-names></name><name><surname>Long</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Huganir</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>High-Throughput genetic screen for synaptogenic factors: identification of LRP6 as critical for excitatory synapse development</article-title><source>Cell Reports</source><volume>5</volume><fpage>1330</fpage><lpage>1341</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2013.11.008</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherman</surname><given-names>SP</given-names></name><name><surname>Bang</surname><given-names>AG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>High-Throughput screen for compounds that modulate neurite growth of human induced pluripotent stem cell-derived neurons</article-title><source>Disease Models &amp; Mechanisms</source><volume>11</volume><elocation-id>dmm031906</elocation-id><pub-id pub-id-type="doi">10.1242/dmm.031906</pub-id><pub-id pub-id-type="pmid">29361516</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spicer</surname><given-names>TP</given-names></name><name><surname>Hubbs</surname><given-names>C</given-names></name><name><surname>Vaissiere</surname><given-names>T</given-names></name><name><surname>Collia</surname><given-names>D</given-names></name><name><surname>Rojas</surname><given-names>C</given-names></name><name><surname>Kilinc</surname><given-names>M</given-names></name><name><surname>Vick</surname><given-names>K</given-names></name><name><surname>Madoux</surname><given-names>F</given-names></name><name><surname>Baillargeon</surname><given-names>P</given-names></name><name><surname>Shumate</surname><given-names>J</given-names></name><name><surname>Martemyanov</surname><given-names>KA</given-names></name><name><surname>Page</surname><given-names>DT</given-names></name><name><surname>Puthanveettil</surname><given-names>S</given-names></name><name><surname>Hodder</surname><given-names>P</given-names></name><name><surname>Davis</surname><given-names>R</given-names></name><name><surname>Miller</surname><given-names>CA</given-names></name><name><surname>Scampavia</surname><given-names>L</given-names></name><name><surname>Rumbaugh</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Improved scalability of neuron-based phenotypic screening assays for therapeutic discovery in neuropsychiatric disorders</article-title><source>Molecular Neuropsychiatry</source><volume>3</volume><fpage>141</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1159/000481731</pub-id><pub-id pub-id-type="pmid">29594133</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spires-Jones</surname><given-names>TL</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The intersection of amyloid beta and tau at synapses in Alzheimer’s disease</article-title><source>Neuron</source><volume>82</volume><fpage>756</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2014.05.004</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Südhof</surname><given-names>TC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Synaptic neurexin complexes: a molecular code for the logic of neural circuits</article-title><source>Cell</source><volume>171</volume><fpage>745</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.10.024</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>JM</given-names></name><name><surname>Badimon</surname><given-names>A</given-names></name><name><surname>Schaefer</surname><given-names>U</given-names></name><name><surname>Ayata</surname><given-names>P</given-names></name><name><surname>Gray</surname><given-names>J</given-names></name><name><surname>Chung</surname><given-names>C</given-names></name><name><surname>von Schimmelmann</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Garton</surname><given-names>N</given-names></name><name><surname>Smithers</surname><given-names>N</given-names></name><name><surname>Lewis</surname><given-names>H</given-names></name><name><surname>Tarakhovsky</surname><given-names>A</given-names></name><name><surname>Prinjha</surname><given-names>RK</given-names></name><name><surname>Schaefer</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Autism-Like syndrome is induced by pharmacological suppression of BET proteins in young mice</article-title><source>Journal of Experimental Medicine</source><volume>212</volume><fpage>1771</fpage><lpage>1781</lpage><pub-id pub-id-type="doi">10.1084/jem.20151271</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Susco</surname><given-names>SG</given-names></name><name><surname>Arias-García</surname><given-names>MA</given-names></name><name><surname>López-Huerta</surname><given-names>VG</given-names></name><name><surname>Beccard</surname><given-names>A</given-names></name><name><surname>Bara</surname><given-names>AM</given-names></name><name><surname>Moffitt</surname><given-names>J</given-names></name><name><surname>Korn</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>Z</given-names></name><name><surname>Barrett</surname><given-names>LE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Fmr1 loss in a human stem cell model reveals early changes to intrinsic membrane excitability</article-title><source>Developmental Biology</source><volume>468</volume><fpage>93</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2020.09.012</pub-id><pub-id pub-id-type="pmid">32976839</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swanger</surname><given-names>SA</given-names></name><name><surname>Mattheyses</surname><given-names>AL</given-names></name><name><surname>Gentry</surname><given-names>EG</given-names></name><name><surname>Herskowitz</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Rock1 and ROCK2 inhibition alters dendritic spine morphology in hippocampal neurons</article-title><source>Cellular Logistics</source><volume>5</volume><elocation-id>e1133266</elocation-id><pub-id pub-id-type="doi">10.1080/21592799.2015.1133266</pub-id><pub-id pub-id-type="pmid">27054047</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szegedi</surname><given-names>V</given-names></name><name><surname>Paizs</surname><given-names>M</given-names></name><name><surname>Csakvari</surname><given-names>E</given-names></name><name><surname>Molnar</surname><given-names>G</given-names></name><name><surname>Barzo</surname><given-names>P</given-names></name><name><surname>Tamas</surname><given-names>G</given-names></name><name><surname>Lamsa</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Plasticity in single axon glutamatergic connection to gabaergic interneurons regulates complex events in the human neocortex</article-title><source>PLOS Biology</source><volume>14</volume><elocation-id>e2000237</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.2000237</pub-id><pub-id pub-id-type="pmid">27828957</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Wagner</surname><given-names>AM</given-names></name><name><surname>Marchetto</surname><given-names>MCN</given-names></name><name><surname>Muotri</surname><given-names>AR</given-names></name><name><surname>Gage</surname><given-names>FH</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Astroglial cells regulate the developmental timeline of human neurons differentiated from induced pluripotent stem cells</article-title><source>Stem Cell Research</source><volume>11</volume><fpage>743</fpage><lpage>757</lpage><pub-id pub-id-type="doi">10.1016/j.scr.2013.05.002</pub-id><pub-id pub-id-type="pmid">23759711</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomson</surname><given-names>JA</given-names></name><name><surname>Itskovitz-Eldor</surname><given-names>J</given-names></name><name><surname>Shapiro</surname><given-names>SS</given-names></name><name><surname>Waknitz</surname><given-names>MA</given-names></name><name><surname>Swiergiel</surname><given-names>JJ</given-names></name><name><surname>Marshall</surname><given-names>VS</given-names></name><name><surname>Jones</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Embryonic stem cell lines derived from human blastocysts</article-title><source>Science</source><volume>282</volume><fpage>1145</fpage><lpage>1147</lpage><pub-id pub-id-type="doi">10.1126/science.282.5391.1145</pub-id><pub-id pub-id-type="pmid">9804556</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>R</given-names></name><name><surname>Gachechiladze</surname><given-names>MA</given-names></name><name><surname>Ludwig</surname><given-names>CH</given-names></name><name><surname>Laurie</surname><given-names>MT</given-names></name><name><surname>Hong</surname><given-names>JY</given-names></name><name><surname>Nathaniel</surname><given-names>D</given-names></name><name><surname>Prabhu</surname><given-names>AV</given-names></name><name><surname>Fernandopulle</surname><given-names>MS</given-names></name><name><surname>Patel</surname><given-names>R</given-names></name><name><surname>Abshari</surname><given-names>M</given-names></name><name><surname>Ward</surname><given-names>ME</given-names></name><name><surname>Kampmann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>CRISPR interference-based platform for multimodal genetic screens in human ipsc-derived neurons</article-title><source>Neuron</source><volume>104</volume><fpage>239</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2019.07.014</pub-id><pub-id pub-id-type="pmid">31422865</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>R</given-names></name><name><surname>Abarientos</surname><given-names>A</given-names></name><name><surname>Hong</surname><given-names>J</given-names></name><name><surname>Hashemi</surname><given-names>SH</given-names></name><name><surname>Yan</surname><given-names>R</given-names></name><name><surname>Dräger</surname><given-names>N</given-names></name><name><surname>Leng</surname><given-names>K</given-names></name><name><surname>Nalls</surname><given-names>MA</given-names></name><name><surname>Singleton</surname><given-names>AB</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Faghri</surname><given-names>F</given-names></name><name><surname>Kampmann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Genome-wide crispri/a screens in human neurons link lysosomal failure to ferroptosis</article-title><source>Nature Neuroscience</source><volume>24</volume><fpage>1020</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1038/s41593-021-00862-0</pub-id><pub-id pub-id-type="pmid">34031600</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trujillo</surname><given-names>CA</given-names></name><name><surname>Adams</surname><given-names>JW</given-names></name><name><surname>Negraes</surname><given-names>PD</given-names></name><name><surname>Carromeu</surname><given-names>C</given-names></name><name><surname>Tejwani</surname><given-names>L</given-names></name><name><surname>Acab</surname><given-names>A</given-names></name><name><surname>Tsuda</surname><given-names>B</given-names></name><name><surname>Thomas</surname><given-names>CA</given-names></name><name><surname>Sodhi</surname><given-names>N</given-names></name><name><surname>Fichter</surname><given-names>KM</given-names></name><name><surname>Romero</surname><given-names>S</given-names></name><name><surname>Zanella</surname><given-names>F</given-names></name><name><surname>Sejnowski</surname><given-names>TJ</given-names></name><name><surname>Ulrich</surname><given-names>H</given-names></name><name><surname>Muotri</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Pharmacological reversal of synaptic and network pathology in human MECP2-KO neurons and cortical organoids</article-title><source>EMBO Molecular Medicine</source><volume>13</volume><elocation-id>e12523</elocation-id><pub-id pub-id-type="doi">10.15252/emmm.202012523</pub-id><pub-id pub-id-type="pmid">33501759</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ullian</surname><given-names>EM</given-names></name><name><surname>Sapperstein</surname><given-names>SK</given-names></name><name><surname>Christopherson</surname><given-names>KS</given-names></name><name><surname>Barres</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Control of synapse number by glia</article-title><source>Science</source><volume>291</volume><fpage>657</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1126/science.291.5504.657</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Kant</surname><given-names>R</given-names></name><name><surname>Langness</surname><given-names>VF</given-names></name><name><surname>Herrera</surname><given-names>CM</given-names></name><name><surname>Williams</surname><given-names>DA</given-names></name><name><surname>Fong</surname><given-names>LK</given-names></name><name><surname>Leestemaker</surname><given-names>Y</given-names></name><name><surname>Steenvoorden</surname><given-names>E</given-names></name><name><surname>Rynearson</surname><given-names>KD</given-names></name><name><surname>Brouwers</surname><given-names>JF</given-names></name><name><surname>Helms</surname><given-names>JB</given-names></name><name><surname>Ovaa</surname><given-names>H</given-names></name><name><surname>Giera</surname><given-names>M</given-names></name><name><surname>Wagner</surname><given-names>SL</given-names></name><name><surname>Bang</surname><given-names>AG</given-names></name><name><surname>Goldstein</surname><given-names>LSB</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cholesterol metabolism is a druggable axis that independently regulates tau and amyloid-β in iPSC-derived Alzheimer’s disease neurons</article-title><source>Cell Stem Cell</source><volume>24</volume><fpage>363</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2018.12.013</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varoqueaux</surname><given-names>F</given-names></name><name><surname>Aramuni</surname><given-names>G</given-names></name><name><surname>Rawson</surname><given-names>RL</given-names></name><name><surname>Mohrmann</surname><given-names>R</given-names></name><name><surname>Missler</surname><given-names>M</given-names></name><name><surname>Gottmann</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Südhof</surname><given-names>TC</given-names></name><name><surname>Brose</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Neuroligins determine synapse maturation and function</article-title><source>Neuron</source><volume>51</volume><fpage>741</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2006.09.003</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vera</surname><given-names>E</given-names></name><name><surname>Bosco</surname><given-names>N</given-names></name><name><surname>Studer</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Generating late-onset human ipsc-based disease models by inducing neuronal age-related phenotypes through telomerase manipulation</article-title><source>Cell Reports</source><volume>17</volume><fpage>1184</fpage><lpage>1192</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.09.062</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verhoog</surname><given-names>MB</given-names></name><name><surname>Goriounova</surname><given-names>NA</given-names></name><name><surname>Obermayer</surname><given-names>J</given-names></name><name><surname>Stroeder</surname><given-names>J</given-names></name><name><surname>Hjorth</surname><given-names>JJJ</given-names></name><name><surname>Testa-Silva</surname><given-names>G</given-names></name><name><surname>Baayen</surname><given-names>JC</given-names></name><name><surname>de Kock</surname><given-names>CPJ</given-names></name><name><surname>Meredith</surname><given-names>RM</given-names></name><name><surname>Mansvelder</surname><given-names>HD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mechanisms underlying the rules for associative plasticity at adult human neocortical synapses</article-title><source>The Journal of Neuroscience</source><volume>33</volume><fpage>17197</fpage><lpage>17208</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3158-13.2013</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verstraelen</surname><given-names>P</given-names></name><name><surname>Pintelon</surname><given-names>I</given-names></name><name><surname>Nuydens</surname><given-names>R</given-names></name><name><surname>Cornelissen</surname><given-names>F</given-names></name><name><surname>Meert</surname><given-names>T</given-names></name><name><surname>Timmermans</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Pharmacological characterization of cultivated neuronal networks: relevance to synaptogenesis and synaptic connectivity</article-title><source>Cellular and Molecular Neurobiology</source><volume>34</volume><fpage>757</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1007/s10571-014-0057-6</pub-id><pub-id pub-id-type="pmid">24748115</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waites</surname><given-names>CL</given-names></name><name><surname>Garner</surname><given-names>CC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Presynaptic function in health and disease</article-title><source>Trends in Neurosciences</source><volume>34</volume><fpage>326</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2011.03.004</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Ward</surname><given-names>ME</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Tracy</surname><given-names>TE</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Xie</surname><given-names>M</given-names></name><name><surname>Sohn</surname><given-names>PD</given-names></name><name><surname>Ludwig</surname><given-names>C</given-names></name><name><surname>Meyer-Franke</surname><given-names>A</given-names></name><name><surname>Karch</surname><given-names>CM</given-names></name><name><surname>Ding</surname><given-names>S</given-names></name><name><surname>Gan</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Scalable production of iPSC-derived human neurons to identify tau-lowering compounds by high-content screening</article-title><source>Stem Cell Reports</source><volume>9</volume><fpage>1221</fpage><lpage>1233</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2017.08.019</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Ranefall</surname><given-names>P</given-names></name><name><surname>Broussard</surname><given-names>GJ</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>G</given-names></name><name><surname>Lyu</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>CT</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SynQuant: an automatic tool to quantify synapses from microscopy images</article-title><source>Bioinformatics</source><volume>36</volume><fpage>1599</fpage><lpage>1606</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btz760</pub-id><pub-id pub-id-type="pmid">31596456</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Khalid</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Pan</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Inhibiting BRD4 alleviated PTSD-like behaviors and fear memory through regulating immediate early genes expression and neuroinflammation in rats</article-title><source>Journal of Neurochemistry</source><volume>158</volume><fpage>912</fpage><lpage>927</lpage><pub-id pub-id-type="doi">10.1111/jnc.15439</pub-id><pub-id pub-id-type="pmid">34050937</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Wu</surname><given-names>R</given-names></name><name><surname>Tang</surname><given-names>D</given-names></name><name><surname>Kang</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>The BET family in immunity and disease</article-title><source>Signal Transduction and Targeted Therapy</source><volume>6</volume><elocation-id>23</elocation-id><pub-id pub-id-type="doi">10.1038/s41392-020-00384-4</pub-id><pub-id pub-id-type="pmid">33462181</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weick</surname><given-names>JP</given-names></name><name><surname>Held</surname><given-names>DL</given-names></name><name><surname>Bonadurer</surname><given-names>GF</given-names></name><name><surname>Doers</surname><given-names>ME</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Maguire</surname><given-names>C</given-names></name><name><surname>Clark</surname><given-names>A</given-names></name><name><surname>Knackert</surname><given-names>JA</given-names></name><name><surname>Molinarolo</surname><given-names>K</given-names></name><name><surname>Musser</surname><given-names>M</given-names></name><name><surname>Yao</surname><given-names>L</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>SC</given-names></name><name><surname>Bhattacharyya</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Deficits in human trisomy 21 ipscs and neurons</article-title><source>PNAS</source><volume>110</volume><fpage>9962</fpage><lpage>9967</lpage><pub-id pub-id-type="doi">10.1073/pnas.1216575110</pub-id><pub-id pub-id-type="pmid">23716668</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiner</surname><given-names>JA</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Tapia</surname><given-names>JC</given-names></name><name><surname>Sanes</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gamma protocadherins are required for synaptic development in the spinal cord</article-title><source>PNAS</source><volume>102</volume><fpage>8</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1073/pnas.0407931101</pub-id><pub-id pub-id-type="pmid">15574493</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winkler</surname><given-names>DG</given-names></name><name><surname>Faia</surname><given-names>KL</given-names></name><name><surname>DiNitto</surname><given-names>JP</given-names></name><name><surname>Ali</surname><given-names>JA</given-names></name><name><surname>White</surname><given-names>KF</given-names></name><name><surname>Brophy</surname><given-names>EE</given-names></name><name><surname>Pink</surname><given-names>MM</given-names></name><name><surname>Proctor</surname><given-names>JL</given-names></name><name><surname>Lussier</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>CM</given-names></name><name><surname>Hoyt</surname><given-names>JG</given-names></name><name><surname>Tillotson</surname><given-names>B</given-names></name><name><surname>Murphy</surname><given-names>EL</given-names></name><name><surname>Lim</surname><given-names>AR</given-names></name><name><surname>Thomas</surname><given-names>BD</given-names></name><name><surname>Macdougall</surname><given-names>JR</given-names></name><name><surname>Ren</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>L-S</given-names></name><name><surname>Jessen</surname><given-names>KA</given-names></name><name><surname>Fritz</surname><given-names>CC</given-names></name><name><surname>Dunbar</surname><given-names>JL</given-names></name><name><surname>Porter</surname><given-names>JR</given-names></name><name><surname>Rommel</surname><given-names>C</given-names></name><name><surname>Palombella</surname><given-names>VJ</given-names></name><name><surname>Changelian</surname><given-names>PS</given-names></name><name><surname>Kutok</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models</article-title><source>Chemistry &amp; Biology</source><volume>20</volume><fpage>1364</fpage><lpage>1374</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2013.09.017</pub-id><pub-id pub-id-type="pmid">24211136</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamagata</surname><given-names>M</given-names></name><name><surname>Duan</surname><given-names>X</given-names></name><name><surname>Sanes</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cadherins interact with synaptic organizers to promote synaptic differentiation</article-title><source>Frontiers in Molecular Neuroscience</source><volume>11</volume><elocation-id>142</elocation-id><pub-id pub-id-type="doi">10.3389/fnmol.2018.00142</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>F</given-names></name><name><surname>Danko</surname><given-names>T</given-names></name><name><surname>Botelho</surname><given-names>SC</given-names></name><name><surname>Patzke</surname><given-names>C</given-names></name><name><surname>Pak</surname><given-names>C</given-names></name><name><surname>Wernig</surname><given-names>M</given-names></name><name><surname>Südhof</surname><given-names>TC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Autism-associated SHANK3 haploinsufficiency causes ih channelopathy in human neurons</article-title><source>Science</source><volume>352</volume><elocation-id>aaf2669</elocation-id><pub-id pub-id-type="doi">10.1126/science.aaf2669</pub-id><pub-id pub-id-type="pmid">26966193</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>K-J</given-names></name><name><surname>Nguyen</surname><given-names>HN</given-names></name><name><surname>Ursini</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Kim</surname><given-names>N-S</given-names></name><name><surname>Wen</surname><given-names>Z</given-names></name><name><surname>Makri</surname><given-names>G</given-names></name><name><surname>Nauen</surname><given-names>D</given-names></name><name><surname>Shin</surname><given-names>JH</given-names></name><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Chung</surname><given-names>R</given-names></name><name><surname>Pekle</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Towe</surname><given-names>M</given-names></name><name><surname>Hussaini</surname><given-names>SMQ</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Rujescu</surname><given-names>D</given-names></name><name><surname>St Clair</surname><given-names>D</given-names></name><name><surname>Kleinman</surname><given-names>JE</given-names></name><name><surname>Hyde</surname><given-names>TM</given-names></name><name><surname>Krauss</surname><given-names>G</given-names></name><name><surname>Christian</surname><given-names>KM</given-names></name><name><surname>Rapoport</surname><given-names>JL</given-names></name><name><surname>Weinberger</surname><given-names>DR</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Ming</surname><given-names>G-L</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Modeling a genetic risk for schizophrenia in ipscs and mice reveals neural stem cell deficits associated with adherens junctions and polarity</article-title><source>Cell Stem Cell</source><volume>15</volume><fpage>79</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2014.05.003</pub-id><pub-id pub-id-type="pmid">24996170</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Shen</surname><given-names>EH</given-names></name><name><surname>Hohmann</surname><given-names>JG</given-names></name><name><surname>Oh</surname><given-names>SW</given-names></name><name><surname>Bernard</surname><given-names>A</given-names></name><name><surname>Royall</surname><given-names>JJ</given-names></name><name><surname>Glattfelder</surname><given-names>KJ</given-names></name><name><surname>Sunkin</surname><given-names>SM</given-names></name><name><surname>Morris</surname><given-names>JA</given-names></name><name><surname>Guillozet-Bongaarts</surname><given-names>AL</given-names></name><name><surname>Smith</surname><given-names>KA</given-names></name><name><surname>Ebbert</surname><given-names>AJ</given-names></name><name><surname>Swanson</surname><given-names>B</given-names></name><name><surname>Kuan</surname><given-names>L</given-names></name><name><surname>Page</surname><given-names>DT</given-names></name><name><surname>Overly</surname><given-names>CC</given-names></name><name><surname>Lein</surname><given-names>ES</given-names></name><name><surname>Hawrylycz</surname><given-names>MJ</given-names></name><name><surname>Hof</surname><given-names>PR</given-names></name><name><surname>Hyde</surname><given-names>TM</given-names></name><name><surname>Kleinman</surname><given-names>JE</given-names></name><name><surname>Jones</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Large-scale cellular-resolution gene profiling in human neocortex reveals species-specific molecular signatures</article-title><source>Cell</source><volume>149</volume><fpage>483</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.02.052</pub-id><pub-id pub-id-type="pmid">22500809</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>JH</given-names></name><name><surname>Chung</surname><given-names>TD</given-names></name><name><surname>Oldenburg</surname><given-names>KR</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>A simple statistical parameter for use in evaluation and validation of high throughput screening assays</article-title><source>Journal of Biomolecular Screening</source><volume>4</volume><fpage>67</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1177/108705719900400206</pub-id><pub-id pub-id-type="pmid">10838414</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Pak</surname><given-names>C</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Ahlenius</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Chanda</surname><given-names>S</given-names></name><name><surname>Marro</surname><given-names>S</given-names></name><name><surname>Patzke</surname><given-names>C</given-names></name><name><surname>Acuna</surname><given-names>C</given-names></name><name><surname>Covy</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>N</given-names></name><name><surname>Danko</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Wernig</surname><given-names>M</given-names></name><name><surname>Südhof</surname><given-names>TC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Rapid single-step induction of functional neurons from human pluripotent stem cells</article-title><source>Neuron</source><volume>78</volume><fpage>785</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2013.05.029</pub-id><pub-id pub-id-type="pmid">23764284</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Sloan</surname><given-names>SA</given-names></name><name><surname>Clarke</surname><given-names>LE</given-names></name><name><surname>Caneda</surname><given-names>C</given-names></name><name><surname>Plaza</surname><given-names>CA</given-names></name><name><surname>Blumenthal</surname><given-names>PD</given-names></name><name><surname>Vogel</surname><given-names>H</given-names></name><name><surname>Steinberg</surname><given-names>GK</given-names></name><name><surname>Edwards</surname><given-names>MSB</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Duncan</surname><given-names>JA</given-names></name><name><surname>Cheshier</surname><given-names>SH</given-names></name><name><surname>Shuer</surname><given-names>LM</given-names></name><name><surname>Chang</surname><given-names>EF</given-names></name><name><surname>Grant</surname><given-names>GA</given-names></name><name><surname>Gephart</surname><given-names>MGH</given-names></name><name><surname>Barres</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse</article-title><source>Neuron</source><volume>89</volume><fpage>37</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2015.11.013</pub-id><pub-id pub-id-type="pmid">26687838</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Marro</surname><given-names>SG</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Arendt</surname><given-names>KL</given-names></name><name><surname>Patzke</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Fair</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>N</given-names></name><name><surname>Südhof</surname><given-names>TC</given-names></name><name><surname>Wernig</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The fragile X mutation impairs homeostatic plasticity in human neurons by blocking synaptic retinoic acid signaling</article-title><source>Science Translational Medicine</source><volume>10</volume><elocation-id>eaar4338</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aar4338</pub-id><pub-id pub-id-type="pmid">30068571</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Brd4 suppression alleviates cerebral ischemia-induced brain injury by blocking glial activation via the inhibition of inflammatory response and pyroptosis</article-title><source>Biochemical and Biophysical Research Communications</source><volume>519</volume><fpage>481</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2019.07.097</pub-id><pub-id pub-id-type="pmid">31530390</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80168.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Goda</surname><given-names>Yukiko</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02qg15b79</institution-id><institution>Okinawa Institute of Science and Technology</institution></institution-wrap><country>Japan</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.05.17.492322" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.05.17.492322"/></front-stub><body><p>Berryer et al. report on an automated and quantitative platform to study the number of synaptic inputs formed in networks of human excitatory neurons and astrocytes in vitro. The utility of the platform was tested by screening a large collection of small molecules; several modulators of synapse density were identified and validated in follow-up experiments. The automated platform substantially extends what is currently available, particularly with respect to the automation of the initial analysis steps. The positive hits identified here, the inhibitors of bromodomain and extraterminal (BET) family of gene expression regulators, are important, and will likely contribute to the understanding of the mechanisms of human synapse assembly.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80168.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Goda</surname><given-names>Yukiko</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02qg15b79</institution-id><institution>Okinawa Institute of Science and Technology</institution></institution-wrap><country>Japan</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Verhage</surname><given-names>Matthijs</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/008xxew50</institution-id><institution>VU Amsterdam</institution></institution-wrap><country>Netherlands</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Sala</surname><given-names>Carlo</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04zaypm56</institution-id><institution>CNR Neuroscience Institute</institution></institution-wrap><country>Italy</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.05.17.492322">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.05.17.492322v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;An automated high-content synaptic phenotyping platform in human neurons and astrocytes reveals a role for BET proteins in synapse assembly&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Lu Chen as the Senior Editor. The following individuals involved in the review of your submission have agreed to reveal their identity: Matthijs Verhage (Reviewer #2); Carlo Sala (Reviewer #3).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>All three reviewers have acknowledged the high potential of the automated platform in drug screening and related studies that target human synapses and the novelty of identifying BET inhibitors in affecting synapse density. Some shortcomings of the study have been raised, however. These relate to the limitations of using synapsin I as the sole synaptic marker and the fact that the manuscript could be considerably strengthened by providing further evidence in support of the synaptic actions of BET inhibitors and including statistical analysis to clarify and place limits on the power of the phenotyping platform in detecting small effects. To this end, the following essential revisions are requested, the first two of which require additional experiments. Furthermore, the authors are also requested to address all the points raised by each reviewer.</p><p>1) The use of synapsin1 as a sole synapse marker should be experimentally validated in two ways:</p><p>(a) In a sample set of experiments, demonstrate the extent to which postsynaptic markers are found apposed to synapsin I and that the distribution of postsynaptic markers match that of synapsin I.</p><p>(b) In a sample set of experiments, demonstrate the extent to which other presynaptic vesicle marker and/or active zone markers colocalize with synapsin I and that the distribution of other presynaptic markers match that of synapsin I.</p><p>2) The effects of BET inhibitor treatment on the expression of synaptic proteins should be confirmed by Western blots.</p><p>3) The synaptic gene expression programs boosted by BET inhibitors should be further characterized with respect to their pre/post expression loci or function (cf. Reviewer 2, major point 3).</p><p>4) Further statistical analysis should be performed to clarify the power of the platform in detecting the effects of a certain size (cf. Reviewer 2, major point 1).</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>Here the synaptic phenotyping involves three parameters: (i) density of a synapse marker protein, (ii) dendrite area, and (iii) number of viable cells. In particular, the key parameter, synapse density, is reliant on the density of a presynaptic phosphoprotein, synapsin I, whose synaptic function, at least in rodents, might be limited and whose confinement at presynaptic boutons is activity-dependent. Therefore, it is possible that the use of another synaptic marker (presynaptic or postsynaptic) may give different outcomes. In other words, the robustness of a platform based on synapsin 1 as the only synaptic marker is not entirely clear. Providing some experimental support to this end would make the manuscript more convincing (cf. specific points 1, 5).</p><p>1) What percentage of Synapsin puncta present on MAP2 are bona fide synapses in that they contain postsynaptic markers? While it may not be necessary to perform the double labelling each time, it would be helpful to know how accurately the readout of presynaptic maker density corresponds to the actual synapse density.</p><p>2) Figure 1e, f, and Lines 196-197: The claimed consistency of plating across batches of differentiation needs to be better substantiated. For instance, in panel e, there is a big difference between batches 3 and 4. What is the permissible range for the said consistency and the basis for choosing such criteria warrants an explanation?</p><p>3) Figure 3. In order to facilitate a direct comparison of the dosage effects of the drugs on synapsin I density, MAP2 neurite area, and cell survival, the x-axis should be the same across the three parameters.</p><p>4) Figures4, 5. The presence of astrocytes in promoting synapsin 1 density on MAP2 neurites is far more potent than the effects of small molecule inhibitors in facilitating synapsin 1 density. Moreover, the presence of astrocytes actually seems to reduce the MAP2 positive neurite area, which will further boost the synapsin 1 density measurement that is made relative to MAP2 neurite area. Could one exclude the possibility that an apparent lack of an increase by the small molecule inhibitors in the absence of astrocytes was because of sensitivity issue?</p><p>5) Figure 6. A direct demonstration of an increase in neurexin 3 and/or homer 1 protein levels by immunofluorescence labelling and western blots in the co-culture system used here following BET inhibitor incubation would further strengthen the conclusion of a role played by BET proteins in attenuating synapse formation.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1. The authors claim they &quot;established a novel, automated, high-content synaptic platform&quot; (line 402). While the extent of automation certainly reaches beyond what has been published, other aspects are not 'novel', especially the central concept of evaluating the density of synapsin1 puncta over MAP2 positive dendrites. It would be good to define a bit more precise the exact step beyond the state of the art, which lies mostly in the automation of plating etc, and to give credit to previous studies that have delivered open-source methods for automated synapse quantifications:</p><p>SynQuant https://doi.org/10.1093/bioinformatics/btz760,</p><p>SynapseJ https://doi.org/10.3389/fncir.2021.731333,</p><p>SynPAnal https://doi.org/10.1371/journal.pone.0115298,</p><p>SynD https://doi.org/10.1016/j.jneumeth.2010.12.011</p><p>2. For Figures2 and 5, it is more informative to present the real images instead of the binary masks.</p><p>3. In line 192 the authors explained one of their quality control tests, it would be good to mention that it is performed 6 days post-plating. As for now, the only indication is in Fig1d.</p><p>4. In Figure 1: it is not clear that the staining is performed at DIV21. Swapping panels c and d would probably improve readability? Why panel g shows the dispersions of the data points, while panel e does not? The data are plotted as mean {plus minus} SEM, were the data tested for normality? It is not clear from the method section.</p><p>5. Please clarify: In line 267 there are listed 17 small molecules. However, in Figure 2 there are 20 molecules labeled, and the number of labeled molecules for the inhibitors family does not match with the text (e.g., 3 BET inhibitors in the text, but only two labeled).</p><p>6. It is not clear from the figures, nor the text in lines 305-320 that the experiments with and without astrocytes are done in parallel.</p><p>7. What is the size of the Speckles filter used for the synapse thresholding? The range of 1 to 6 pixels per synapse seems a bit broad, especially in the low-end (1-2 pxs) it might be prone to detect scatter noise. Did the authors try to evaluate how changing those parameters affects detection, and if so, please explain the choice of the declared parameters?</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>The present study provides a quantitative platform to count synapses in cultured human neurons derived from iPSCs. This platform was used to identify novel signaling pathways important for synapse formation.</p><p>To strengthen the impact of these findings the author should address the following points:</p><p>1) All the methodology was used to quantify a presynaptic marker and indeed the effect of BET was measured on presynaptic synapsin1. So it will be nice to show if BET treatment is able to increase the staining of a postsynaptic marker (Homer1 for example), if feasible.</p><p>2) The mRNA-seq analysis indicates that BET treatment increases the expression of some synaptic and non synaptic proteins. However, these specific genetic modifications should be confirmed also by WB analysis of some of the identified major proteins.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80168.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>All three reviewers have acknowledged the high potential of the automated platform in drug screening and related studies that target human synapses and the novelty of identifying BET inhibitors in affecting synapse density. Some shortcomings of the study have been raised, however. These relate to the limitations of using synapsin I as the sole synaptic marker and the fact that the manuscript could be considerably strengthened by providing further evidence in support of the synaptic actions of BET inhibitors and including statistical analysis to clarify and place limits on the power of the phenotyping platform in detecting small effects. To this end, the following essential revisions are requested, the first two of which require additional experiments. Furthermore, the authors are also requested to address all the points raised by each reviewer.</p><p>1) The use of synapsin1 as a sole synapse marker should be experimentally validated in two ways:</p><p>(a) In a sample set of experiments, demonstrate the extent to which postsynaptic markers are found apposed to synapsin I and that the distribution of postsynaptic markers match that of synapsin I.</p><p>(b) In a sample set of experiments, demonstrate the extent to which other presynaptic vesicle marker and/or active zone markers colocalize with synapsin I and that the distribution of other presynaptic markers match that of synapsin I.</p></disp-quote><p>We tested conditions for a set of two additional presynaptic and four additional post-synaptic antibodies to assess their distribution and colocalization with Synapsin1 on MAP2. Of these antibodies, we obtained quantifiable signal for one additional presynaptic marker (synaptophysin) and one additional postsynaptic marker (PSD-95). Co-localization analyses between synaptophysin and syanapsin1 on MAP2, as well as PSD-95 and synapsin1 on MAP2 are now presented in Figure 1—figure supplement 1 and discussed in detail below (Reviewer #1 point #1 and Reviewer #2 point #2)</p><disp-quote content-type="editor-comment"><p>2) The effects of BET inhibitor treatment on the expression of synaptic proteins should be confirmed by Western blots.</p></disp-quote><p>We have now confirmed that BETi treatment increases protein expression levels of postsynaptic proteins by Western blot analysis, including BAIAP2 and Homer1. Specifically, we show that both JQ1 treatment and Birabresib treatment significantly increase the expression of both postsynaptic scaffolding proteins compared to DMSO treated control. These data are now shown in Figure 6 and discussed in detail below (Reviewer #1 point #5).</p><disp-quote content-type="editor-comment"><p>3) The synaptic gene expression programs boosted by BET inhibitors should be further characterized with respect to their pre/post expression loci or function (cf. Reviewer 2, major point 3).</p></disp-quote><p>As discussed in detail below (Reviewer #2, point 3), we have now added SynGO analysis to Figure 6 and Supplementary File 5 to further characterize synaptic gene expression enhanced by BETi.</p><disp-quote content-type="editor-comment"><p>4) Further statistical analysis should be performed to clarify the power of the platform in detecting the effects of a certain size (cf. Reviewer 2, major point 1).</p></disp-quote><p>To clarify the power of the platform in detecting various effect sizes, we have now calculated Cohen’s d for: (1) the primary screen overall as well as for each small molecule included in the primary screen, (2) validation experiments performed in neuron monocultures and (3) validation experiments performed in neuron + astrocyte co-cultures, and these data have been added to Figure 5, Figure 5—figure supplement 1 and Supplementary File 2. We have also added a discussion of how this informs on study design. These analyses are discussed in detail below (Reviewer #2, point #1).</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>Here the synaptic phenotyping involves three parameters: (i) density of a synapse marker protein, (ii) dendrite area, and (iii) number of viable cells. In particular, the key parameter, synapse density, is reliant on the density of a presynaptic phosphoprotein, synapsin I, whose synaptic function, at least in rodents, might be limited and whose confinement at presynaptic boutons is activity-dependent. Therefore, it is possible that the use of another synaptic marker (presynaptic or postsynaptic) may give different outcomes. In other words, the robustness of a platform based on synapsin 1 as the only synaptic marker is not entirely clear. Providing some experimental support to this end would make the manuscript more convincing (cf. specific points 1, 5).</p><p>1) What percentage of Synapsin puncta present on MAP2 are bona fide synapses in that they contain postsynaptic markers? While it may not be necessary to perform the double labelling each time, it would be helpful to know how accurately the readout of presynaptic maker density corresponds to the actual synapse density.</p></disp-quote><p>As mentioned above, we tested conditions for four additional post-synaptic antibodies, drawing from those used in published studies of human cellular models (and species that would not cross-react with the antibodies used for Synapsin1 and MAP2). Specifically, we tested antibodies against PSD-95, NLGN4, Homer1 and BAIAP2 at a range of concentrations in co-cultures generated from two independent cell lines. Of these antibodies, we obtained quantifiable signal for PSD-95, while NLGN4, Homer1 and BAIAP2 appeared to be of poor quality in our cellular systems (e.g., nonspecific signal, high signal in astrocytes, etc.).</p><p>As shown in Figure 1—figure supplement 1, analysis of PSD-95 revealed that 43.1% of PSD-95 puncta on MAP2 also colocalized with synapsin1, and 28.8% of synapsin1 puncta on MAP2 also colocalized with PSD-95. Discussions of these data and limitations have been significantly elaborated upon on pages 10-11 of the Results section in the PDF and pages 24-25 and 29 of the Discussion section in the PDF. For example, we discuss how the partial colocalization could be due both to the relative immaturity of the synapses (presynaptic assembly preceding postsynaptic assembly at this early stage of neuronal development) as well as the overall poorer quality of the PSD-95 signal in human cellular material (PSD-95 signal was of insufficient quality and consistency for screening applications and was generally quite difficult to resolve as compared to Synapsin1). We include the reliance on Synapsin1 on MAP2 as an explicit limitation. We also add additional references on the use of Synapsin1 to label cortical glutamatergic synapses in rodent (e.g., Micheva 2010) and the use of Synapsin1 on MAP2 as a pan-synaptic marker in human cellular material (e.g., Chanda et al. 2019, Pak et al. 2015, Yi et al. 2016).</p><disp-quote content-type="editor-comment"><p>2) Figure 1e, f, and Lines 196-197: The claimed consistency of plating across batches of differentiation needs to be better substantiated. For instance, in panel e, there is a big difference between batches 3 and 4. What is the permissible range for the said consistency and the basis for choosing such criteria warrants an explanation?</p></disp-quote><p>In brief, we tested a range of hN plating densities based on the published literature of synaptic screens made with rodent neurons. We found that 4,000 hNs/well (as assessed by the number of surviving hNs from a plate randomly selected one day after co-culture) was a minimum for forming a synaptic network and 12,000 hNs/well was a maximum after which point, the hNs began to clump. This information is now indicated in the Figure 1e and in the corresponding text and figure legend. For reference, rodent screens typically plate down between 10,000 – 20,000 neurons/well (surviving number not assessed). It’s important to note the consistency of plating is critical within each batch so that approximately the same number of hNs are treated to allow for comparison. The consistency of plating is based on the standard error to the mean of each batch (Figure 1e) and on the intra-plate co-variance within each batch (Figure 1f). Each compound treatment condition is compared to controls contained within the same plate and the same batch; different batches are considered different experimental replicates where compound treatment is again compared to intra-plate / intra-batch controls. In other words, we are not comparing conditions across batches that have different absolute numbers of neurons. These points have now been elaborated upon in the text (please see pages 12 of the Results section in the PDF).</p><disp-quote content-type="editor-comment"><p>3) Figure 3. In order to facilitate a direct comparison of the dosage effects of the drugs on synapsin I density, MAP2 neurite area, and cell survival, the x-axis should be the same across the three parameters.</p></disp-quote><p>Figure 3 has now been changed to show the same x-axis for Synapsin1 density, MAP2 neurite area and cell survival using histogram format. The dose response curves for each of the 17 compounds have been moved to Figure 3—figure supplement 1. All data on dosage effects are now included both as dose response curves and histogram format (Figure 3, Figure 3—figure supplements 1-2) to facilitate comparison with area covered by MAP2 (histograms in Figure 3—figure supplement 3) and number of DAPI positive nuclei (histograms in Figure 3—figure supplement 4).</p><disp-quote content-type="editor-comment"><p>4) Figures4, 5. The presence of astrocytes in promoting synapsin 1 density on MAP2 neurites is far more potent than the effects of small molecule inhibitors in facilitating synapsin 1 density. Moreover, the presence of astrocytes actually seems to reduce the MAP2 positive neurite area, which will further boost the synapsin 1 density measurement that is made relative to MAP2 neurite area. Could one exclude the possibility that an apparent lack of an increase by the small molecule inhibitors in the absence of astrocytes was because of sensitivity issue?</p></disp-quote><p>As discussed below, to address the issue of sensitivity of our validation assays, we have now performed power calculations for both the neuron monoculture condition and the co-culture condition. These analyses indicate that we are sufficiently powered to detect changes in both assays, given the predicted effect sizes (Figure 5, Figure 5—figure supplement 1 and Supplementary File 2). For example, effect sizes in the co-culture condition were sufficiently large that we could scale down the number of fields (n = 47-80) and wells (n = 6-9) analyzed in future experiments. For the monoculture condition, effect sizes were much smaller; we scaled up the number of fields (n = 404-417) and wells (n = 52) analyzed which was sufficient to achieve 95% power for detecting changes due to Birabresib and I-BET151. While we are unable to exclude a technical limitation in detecting differences in the absence of astrocytes, the point we make in the text is that screens carried out in the absence of astrocytes are likely to miss hits, for either technical or biological reasons. We have now expanded on this point in the text (please see pages 19-20 of the Results section and page 26 of the Discussion section in the PDF).</p><disp-quote content-type="editor-comment"><p>5) Figure 6. A direct demonstration of an increase in neurexin 3 and/or homer 1 protein levels by immunofluorescence labelling and western blots in the co-culture system used here following BET inhibitor incubation would further strengthen the conclusion of a role played by BET proteins in attenuating synapse formation.</p></disp-quote><p>We have now performed western blot analyses for two postsynaptic proteins, Homer1 and BAIAP2, following both JQ1 treatment and birabresib treatment, compared to DMSO treated control. These experiments, which are now included in Figure 6, confirm upregulation of both Homer1 and BAIAP2 protein expression following BETi, supporting our transcript results and strengthening the conclusion that BET proteins can attenuate synapse formation. We also tested additional antibodies for genes increased at the transcript level such as AMPH but did not obtain specific signal in western blot analysis (data not shown). These data are also discussed on page 23 of the text in the PDF. As discussed above, we also tested Homer1 and BAIAP2 for immunofluorescence labeling, but did not obtain specific signal in our cultures for this application.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>1. The authors claim they &quot;established a novel, automated, high-content synaptic platform&quot; (line 402). While the extent of automation certainly reaches beyond what has been published, other aspects are not 'novel', especially the central concept of evaluating the density of synapsin1 puncta over MAP2 positive dendrites. It would be good to define a bit more precise the exact step beyond the state of the art, which lies mostly in the automation of plating etc, and to give credit to previous studies that have delivered open-source methods for automated synapse quantifications:</p><p>SynQuant https://doi.org/10.1093/bioinformatics/btz760,</p><p>SynapseJ https://doi.org/10.3389/fncir.2021.731333,</p><p>SynPAnal https://doi.org/10.1371/journal.pone.0115298,</p><p>SynD https://doi.org/10.1016/j.jneumeth.2010.12.011</p></disp-quote><p>We thank the reviewer for this comment and have now added the above references and more clearly defined aspects of novelty presented in the current study (please see page 25 of the Discussion section in the PDF).</p><disp-quote content-type="editor-comment"><p>2. For Figures2 and 5, it is more informative to present the real images instead of the binary masks.</p></disp-quote><p>We have now included raw images for Figures 2 and 5, and we have also kept the binary masks. We wanted to show individual zoomed in examples (which we agree, look much better with the real images) but also panning out to give a sense of the overall co-culture and MAP2 distribution (which was easier to show clearly with the binary masks).</p><disp-quote content-type="editor-comment"><p>3. In line 192 the authors explained one of their quality control tests, it would be good to mention that it is performed 6 days post-plating. As for now, the only indication is in Fig1d.</p></disp-quote><p>This information has now been specified in the text.</p><disp-quote content-type="editor-comment"><p>4. In Figure 1: it is not clear that the staining is performed at DIV21. Swapping panels c and d would probably improve readability? Why panel g shows the dispersions of the data points, while panel e does not? The data are plotted as mean {plus minus} SEM, were the data tested for normality? It is not clear from the method section.</p></disp-quote><p>We appreciate this comment on readability and have now swapped Figure 1c and Figure 1d, and included the day 21 time-point next to the staining examples and on page 12 of the text. We also now show the dispersion of the individual datapoints in Figure 1e (this includes 60 wells per plate and 60 points per bar). We also tested the data for normality which was confirmed using the Kolmogorov-Smirnov test; this information is included in the Methods section.</p><disp-quote content-type="editor-comment"><p>5. Please clarify: In line 267 there are listed 17 small molecules. However, in Figure 2 there are 20 molecules labeled, and the number of labeled molecules for the inhibitors family does not match with the text (e.g., 3 BET inhibitors in the text, but only two labeled).</p></disp-quote><p>This information has now been clarified in the text (please see pages 15-16 in the PDF). In particular, we followed-up on 17 small molecules but Figure 2 also shows anticarcinogens that decreased synaptic density (as well as viability) and were thus not followed up on with a dose response. We have separated the anticarcinogens in the legend in Figure 2 from the rest of the selected compounds and added these details to the corresponding figure legend. Birabresib was also not in the original compound library but we chose to add it for validation; BETi was an unexpected but particularly interesting hit class so we wanted additional validation of this result using a third independent BETi.</p><disp-quote content-type="editor-comment"><p>6. It is not clear from the figures, nor the text in lines 305-320 that the experiments with and without astrocytes are done in parallel.</p></disp-quote><p>Experiments performed with and without astrocytes were indeed done in parallel and this information has now been clarified in the text (please see page 18 in the PDF).</p><disp-quote content-type="editor-comment"><p>7. What is the size of the Speckles filter used for the synapse thresholding? The range of 1 to 6 pixels per synapse seems a bit broad, especially in the low-end (1-2 pxs) it might be prone to detect scatter noise. Did the authors try to evaluate how changing those parameters affects detection, and if so, please explain the choice of the declared parameters?</p></disp-quote><p>We had previously performed a cumulative distribution of Synapsin1 puncta diameter in pixels, which we have now included in Figure 1—figure supplement 4 and discussed in the text (please see pages 13-14 in the PDF). Of note, while estimates of Synapsin1 puncta diameters vary considerably, several recent studies have focused on diameters at the lower end (in the 1-3 pixel range in our assay). We used a broader distribution to capture Synapsin1 puncta which can be modified by end users in the platform for project specific goals.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>The present study provides a quantitative platform to count synapses in cultured human neurons derived from iPSCs. This platform was used to identify novel signaling pathways important for synapse formation.</p><p>To strengthen the impact of these findings the author should address the following points:</p><p>1) All the methodology was used to quantify a presynaptic marker and indeed the effect of BET was measured on presynaptic synapsin1. So it will be nice to show if BET treatment is able to increase the staining of a postsynaptic marker (Homer1 for example), if feasible.</p></disp-quote><p>As discussed above, we have now shown that BETi significantly increases the expression of the postsynaptic markers Homer1 and BAIAP2 compared to DMSO treated control by western blot analysis (please see Figure 6). We tested these same antibodies for immunofluorescence labeling in our cultures but unfortunately did not obtain specific signal for that application.</p><disp-quote content-type="editor-comment"><p>2) The mRNA-seq analysis indicates that BET treatment increases the expression of some synaptic and non synaptic proteins. However, these specific genetic modifications should be confirmed also by WB analysis of some of the identified major proteins.</p></disp-quote><p>As discussed above, we have now shown that BETi significantly increases the expression of the postsynaptic markers Homer1 and BAIAP2 compared to DMSO treated control, by western blot analysis. We focused on postsynaptic markers, as these were more challenging to capture in our assay by immunofluorescence but could more readily be captured by western blot analysis; postsynaptic genes were also a category which emerged from our SynGO analyses and thus seemed most relevant to confirm in the RNAseq dataset. We did test antibodies for other genes altered at the RNAseq level (e.g., AMPH) but did not obtain specific signal for western blot analysis.</p></body></sub-article></article>